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Abstract 
Studies over the last few decades provided supportive evidence for further research on the use of 
intravenous administration of high-dose ascorbate (0.5 – 1.5 grams per kilogram of body weight) in 
cancer treatment. Although intravenous ascorbate showed limited anticancer activity in the recent 
clinical trials, its potential beneficial effects were noted, such as improvement in quality of life, 
reduction of chemotherapy-associated toxicity, reduction of inflammation and stabilization of cancer 
progression. These observations were in agreement with the outcomes of three cancer patients who 
declined chemotherapy and received intravenous ascorbate as an alternative in a preliminary clinical 
case study (Chapter 4). It was commonly accepted that the cytotoxicity of ascorbate was mediated 
by hydrogen peroxide (H2O2). However, our analysis and interpretation of the published results were 
not consistent with this being the sole mechanism of cytotoxicity, and an additional 
dehydroascorbate-mediated mechanism was proposed in this thesis (Chapter 1). 
 
In order to have a holistic understanding of the differential effects of ascorbate treatment in in vitro, 
animal and human studies, the treatment-induced changes in the intracellular H2O2 concentrations of 
the targeted cells should be compared. However, precise measurement of intracellular H2O2 
concentrations in vivo is difficult. In Chapter 2, a mathematical model was established for estimating 
the extracellular and intracellular H2O2 concentrations in a biological system that was challenged with 
H2O2 and/or an agent that could induce H2O2 production (such as ascorbate). Simulation of the 
mathematical model was carried out with the values of variables estimated from the published 
scientific literature and the experimental data obtained from this study. Several predictions were made 
and validated with the experimental results. One simulation predicted a limited increase of 
intracellular H2O2 concentration in a typical intravenous ascorbate treatment, which should be 
insufficient to induce cell death in tumours. The mathematical model also provided methods for 
estimating intrinsic intracellular H2O2 production rate and intracellular H2O2 concentration based on 
extracellular H2O2 concentration and other cell-dependent parameters, which were easier to be 
obtained with the current experimental methods. 
 
In Chapter 3, it was demonstrated in vitro that the cytotoxicity of ascorbate was mediated by both 
H2O2 and dehydroascorbate (DHA). The associations between the responses of cells to ascorbate (0 
– 30 mM) and some extracellular, cellular and molecular variables, such as cell culture medium, 
serum, glucose, pyruvate, cell cycle, cell volume and the expression and activities of H2O2 
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decomposing enzymes catalase and glutathione peroxidase, were investigated. Pyruvate but not 
glucose showed protective effect on cells in DHA treatment. Increased oxygen reactive species (ROS) 
levels in the DHA-treated cells was observed. These results supported our hypothesis that DHA might 
be able to antagonize glucose uptake and modulate the cellular H2O2 decomposing capability, which 
could allow higher concentrations of intracellular H2O2 to be accumulated. Thus DHA could be 
potentially used as an adjuvant anticancer molecule in a ROS-mediated treatment of cancer, which 
was supported with our results that demonstrated synergistic cytotoxicity of DHA and arsenic trioxide 
on the leukaemia cell line HL-60. 
 
Transforming growth factor beta (TGFβ) signalling is a participant in both tumour suppression and 
tumour progression, and its involvement in regulating H2O2 production and removal has been 
demonstrated. In Chapter 5, the mRNA expression levels of TGFB1, TGFB2, TGFB3, TGFBR1 and 
TGFBR2 in primary breast tumours and adjacent normal breast tissues were analysed; and the 
associations with tumour characteristics and patients’ overall and relapse-free survival time were 
evaluated, using the public gene expression microarray data and our quantitative real-time PCR 
validation data. The results indicated a reduced responsiveness of breast tumour cells to TGFβ, a 
preferential up-regulation of TGFB1 in malignant tumours and a preferential up-regulation of TGFB3 
in premalignant tumours. High TGFB2, TGFB3 and TGFBR2 mRNA levels in tumours were 
generally associated with better prognosis for patients, especially those diagnosed with lymph node-
negative diseases. High TGFB1 and TGFBR1 mRNA levels in tumours were associated with poorer 
prognosis for patients diagnosed with small (diameter ≤ 2 cm) tumours. The results might not only 
provide prognostic value for patients but also assist in classifying tumours according to their potential 
responses to TGFβ and selecting patients for TGFβ signalling pathway targeted therapies. With the 
possibility to modulate H2O2 production and removal by TGFβ signalling pathway targeted therapies 
in the targeted tumours, it might allow us to develop strategies to improve the efficacy of intravenous 
ascorbate in selected patients in the future.  
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Chapter 1 
1 Introduction 
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1.1 Ascorbate in cancer care 
According to the definition by the United States National Cancer Institute, “Cancer is a term used for 
a family of diseases in which abnormal cells divide without control and are able to invade other 
tissues.” About 12.7 million cancer cases and 7.6 million cancer deaths were estimated to have 
occurred globally in 2008 [1]. Although advances in prevention, early detection and treatment have 
been made in reducing incidence and mortality rates and improving survival, cancer is still the leading 
cause of death in economically developed countries and the second leading cause of death in 
developing countries [1, 2].  
 
The conventional treatments for cancer include surgery, chemotherapy, radiotherapy and their 
combinations. The goal of the treatments is to “cure” or control the cancer to prolong survival in 
patients, while preserving the highest possible quality of life in both the long and short term [3]. 
Unfortunately, acute and/or chronic side effects can occur during and/or after the treatment, including 
pain, fatigue, distress, cognitive deficits, cardiotoxicity, reduction in bone density, pulmonary 
dysfunction, infertility and sexual dysfunction [3]. Patients diagnosed with a malignancy sometimes 
decline conventional treatment due to predisposing factors, such as having a close relative or friend 
who has died from cancer when receiving conventional treatment; experiences around the diagnosis; 
and factors relevant after the diagnosis, such as beliefs, need for control, side effects of conventional 
cancer treatment, and communication with physicians [4]. Some of these patients may participate in 
clinical trials for new treatments or try complementary and alternative medicine in order to have 
greater control over their illnesses [4, 5].  
 
Intravenous (IV) infusion of high-dose (0.5 – 1.5 grams per kilogram (g/kg) of body weight) ascorbate 
is one of the readily available options for the cancer patients who seek complementary and alternative 
medicine [6]. Ascorbate, or vitamin C, is a well-known essential micronutrient for humans. It has had 
a long and controversial history in cancer care [7]. Recently, intravenous infusion of high-dose 
ascorbate (IVA) as a cancer therapy has been reconsidered and reinvestigated by some researchers, 
yet it still remains a contentious intervention by the conventional medicine [7-9].  
 
The idea of using ascorbate to treat cancer can be traced back to the 1950s, when William J. 
McCormick hypothesized that cancer metastases spread through weakened collagen cellular 
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structures and that the maintenance of collagen synthesis at optimal levels by ascorbate could block 
cancer metastases [10]. In 1970s, Ewan Cameron, Douglas Rotman and Linus Pauling further 
hypothesized that cancer cells could be restrained from proliferating by the highly viscous nature of 
intercellular glycosaminoglycans and that ascorbate might be able to suppress cancer as it could 
inhibit hyaluronidase, which otherwise depolymerised the glycosaminoglycans [11, 12]. 
 
Based on these theories, Cameron and Pauling advocated using supplemental ascorbate in the 
supportive treatment of cancer [13]. They conducted an uncontrolled clinical trial of high-dose 
ascorbate supplementing 55 patients diagnosed with advanced cancer, and reported some beneficial 
clinical responses to the ascorbate treatment, including longer survival times than clinical expectation, 
symptomatic relief, control of ascites and tumour regressions, and one case of double complete 
regression of reticulum cell sarcoma [14, 15]. The majority of patients received oral ascorbate 10 
grams per day; for some patients, the treatment was initiated by intravenous administration of 
ascorbate for up to 10 days, 10 grams per day [14]. Subsequently, the trial was expanded to 100 
terminal cancer patients treated with ascorbate. The survival times of the 100 patients were reported 
largely increased compared with 1000 historically matched controls receiving the same treatments 
except for the ascorbate [16, 17]. Another trial conducted in Japan also showed that terminal cancer 
patients who received large doses of ascorbate had significant prolongation of survival times [18]. 
 
These clinical trials were subsequently criticised because they were not based on randomized, double-
blind principles, and the results were not reproduced in two follow-up randomized, double-blind and 
placebo-controlled trials conducted by Creagan et al. and Moertel et al. using oral administration with 
the same dose (10 grams per day) that Cameron and Pauling had previously recommended [19, 20]. 
No beneficial effect of the ascorbate treatment was observed in either of the two follow-up clinic 
trials, irrespective of the patients receiving chemotherapy (n = 150) [20] or not (n = 100) [19]. Many 
years of debate ensued with the majority of the medical community accepting the two more 
scientifically rigorous trials, and concluding that ascorbate was of no value in cancer treatment. Thus 
peer review made it difficult to disseminate Cameron’s subsequent positive observation that incurable 
cancer patients that received supplemental ascorbate had a significant increased survival time (343 
days) compared with the controls (180 days) [21]. 
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In the same period, many in vitro studies showed that ascorbate at millimolar concentrations could 
induce cell death in cancer cells, while normal cells were not suppressed [22-24]. One case study 
showed apparent positive effects of IVA on metastatic kidney adenocarcinoma [25]. Based on these 
information, Riordan et al. realized that the discrepancy between the findings of the previous clinical 
trials might reflect differences in the route of ascorbate administration: Cameron’s patients had 
received both oral and intravenous ascorbate, whereas, Creagan and Moertel’s patients had received 
only oral ascorbate [26]. They further proposed that intravenous ascorbate, administered in sufficient 
doses to achieve plasma concentrations that had demonstrable cytotoxic effects on tumour cells in 
vitro, be investigated as a chemotherapeutic agent [26]. 
 
Riordan et al.’s hypothesis was later supported by Padayatty et al.’s clinical pharmacokinetic study 
of ascorbate in healthy adults [27]. At their highest dose of 1.25 grams, the mean peak plasma 
ascorbate concentration from intravenous administration (885 µM) was 6.6 folds higher (P < 0.001) 
than that from oral administration (134.8 µM) [27]. When all doses (0.015 – 1.25 grams) were 
considered, the peak plasma ascorbate concentrations increased with increasing intravenous doses 
but seemed to plateau with increasing oral doses. For the maximum tolerated doses, the peak plasma 
ascorbate concentrations predicted using pharmacokinetic modelling were 220 µM for an oral dose 
of 3 grams every 4 hours and 15 mM for a 100-gram intravenous dose, almost 70 folds higher. With 
these pharmacokinetic data as background, Padayatty et al. revisited the earlier work and came to the 
same realization that Riordan et al. had addressed, namely, that intravenous ascorbate should be 
investigated as a cancer treatment [27].  
 
Several independent clinical case reports have shown that at least 11 patients with terminal cancers 
who received IVA had later enjoyed complete regressions of tumours, improved symptoms and/or 
prolonged life. Campbell et al. reported a case of a 42-year-old man with histologically proven widely 
disseminated reticulum cell sarcoma who had two complete spontaneous regressions of his fatal 
illness after IVA administration [28]. Riordan et al. reviewed seven cases of patients diagnosed with 
cancer, including renal cell carcinoma, colorectal cancer, pancreatic cancer, non-Hodgkin’s 
lymphoma and breast cancer, who had positive outcomes after receiving IVA treatment alone or in 
combination with conventional therapy [29]. Padayatty et al. reported three well-documented cases 
of advanced cancers, confirmed by histopathological review, where patients had unexpectedly long 
survival times after receiving IVA therapy [30]. These authors concluded that the IVA therapy should 
 5 
 
have been responsible for the patients’ excellent responses. Whereas, Assouline and Miller 
commented that in each case there was a possible alternative explanation, and they also pointed out 
that these case reports omitted the number of patients who received IVA therapy with no effect [31]. 
Because these cases were collected over many years from several institutions, this number might be 
quite large and the overall response rate might be quite low [31].  
 
IVA is essentially safe. For decades, IVA has been extensively used by practitioners of 
complementary and alternative medicine to treat diverse conditions including infections, autoimmune 
diseases, cancer and illnesses of uncertain origin [6]. The risks of serious side effects accompanied 
with IVA, such as acute oliguric renal failure [32], bone oxalate deposition [33] and calcium oxalate 
stone formation [34] are rare and can be prevented when adhering to proper screening of patients to 
exclude: pre-existing renal disease, renal insufficiency or failure, glucose 6-phosphate dehydrogenase 
deficiency, a history of oxalatenephrolithiasis, or paroxysmal nocturnal hemoglobinuria [6]. A Phase 
I clinical trial of IVA conducted in 24 patients diagnosed with a variety of late stage terminal cancers 
demonstrated that continuous infusions of ascorbate at 0.15 – 0.71 g/kg of body weight daily for up 
to eight weeks were well tolerated [35]. Another Phase I clinical trial of IVA involving 24 
appropriately screened patients with advanced untreatable malignancies had shown that up to 1.5 g/kg 
of body weight ascorbate infused within 90 – 120 minutes three times weekly could produce a peak 
plasma concentration of 26.2 ± 4.9 mM and was essentially free of risk [36]. The side effects that 
occurred were consistent with the side effects attending rapid infusion of any high-osmolarity solution, 
and the symptoms were preventable by encouraging patients to drink fluids before and during infusion 
[36]. A more recent Phase I clinical trial of IVA reported that plasma concentration of ascorbate could 
be maintained at 10 – 20 mM for 5 – 6 hours, and a peak concentration of 49 mM could be safely 
achieved [37]. However, only limited antitumor activities of IVA was reported in these Phase I 
clinical trials [35-37], which also became one of the reasons for the debates on the use of IVA alone 
as a cancer therapy [38].  
 
Although there exists controversy on its anticancer effect, IVA has shown promising beneficial 
effects in terminal cancer patients who received it as an alone treatment or in combination with other 
therapies [39]. Yeom et al. assessed the quality of life of 39 terminal cancer patients who had been 
given 10-gram IVA twice with a 3-day interval and an oral intake of 4-gram ascorbate daily for a 
week [40]. They reported that after receiving the IVA treatment, the patients’ health-related quality 
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of life were significantly improved in the global health scale, function scales and some symptom 
scales as assessed using the Korean version of the European Organization for Research and Treatment 
of cancer core quality-of-life questionnaire [40]. Vollbracht et al. reported that 7.5-gram IVA once a 
week during adjuvant therapies, for a minimum of 4 weeks significantly reduced the side effects in 
breast cancer patients during chemo-/radiotherapy and aftercare, in particular of nausea, loss of 
appetite, fatigue, depression, sleep disorders, dizziness and haemorrhagic diathesis [41]. Reduction 
of chemotherapy-associated toxicity was also reported in patients diagnosed with ovarian cancer who 
received the conventional chemotherapeutic agents carboplatin and paclitaxel in combination with 
IVA at a dose of 75 or 100 grams twice per week for 12 months [42]. Kiziltan  et al. reported that 
IVA at a dose of 2.5 grams with 3 – 10 applications following at 1-week intervals produced a 55% 
reduction in pain in 11 cancer patients with bone metastases who experienced poor quality of life, 
including intensifying pain, after receiving a total of 3000 cGy of radiotherapy [43]. The possibility 
of using IVA as an adjuvant therapy has also emerged for preventing and treating cancer-associated 
sepsis [44] and modulating inflammation in cancer patients [45]. Stabilized cancer progression is not 
a negligible result of IVA treatments, which may help patients live with rather than curing the cancer. 
Riordan et al. reported one stable disease [35], and Hoffer et al. reported two stable diseases [36] after 
IVA treatment in the Phase I clinical trials. However, in all these studies, there was no control group 
or available reference for a statistical analysis to be made to exclude a placebo effect.  
 
1.2 Supportive in vitro and animal studies 
Rigorous research studies have shown that ascorbate at pharmacologic concentrations (0.2 – 20 mM), 
can selectively kill a number of cancer cell lines and primary cancer types in vitro, while 
nontumorigenic cells remain unaffected (Table 1-1). Bram et al. reported that ascorbate was 
preferentially toxic to several malignant melanoma cell lines and copper ions could greatly increase 
this preferential toxicity [24]. Park et al. reported that leukemic cells from 7 patients with acute non-
lymphocytic leukaemia grown in culture were far more sensitive to pharmacologic ascorbate than 
normal myeloid cells [22]. Pavelic reported that high concentrations of ascorbate reduced the DNA, 
RNA and protein synthesis and mitosis of human neuroblastoma cells, without affecting normal 
neuronal cells [46]. Chen et al. tested the cytotoxicity of ascorbate on 43 cancer cell lines and 5 normal 
cell lines, and reported that only 7 of the cancer cells were resistant to ascorbate treatment of up to 
20 mM for two hours, while all the 5 normal cells were resistant [47].   
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Table 1-1. Human cancer cell lines and primary cancer types that are sensitive to 
pharmacologic ascorbate in vitro. 
Cancer cell types References 
Ehrlich ascites carcinoma cells [23] 
Melanoma: FO-1, Be1, Va1, Na11, Ma11 and DOR [24] 
Bone marrow cells from patients with acute non-lymphocytic leukaemia [22] 
Neuroblastoma: N56831 [46] 
Prostate: LNCap and DU145 [48] 
Leukaemia: HL-60, NB4, NB40R1, K562 and cells containing over 90% blasts 
from patients with acute myeloid leukaemia 
[49] 
Lymphoma: JLP119 
Glioblastoma: S635 
Ovarian:OVCAR5, OVCAR8 and SHIN3 
Bladder: 5637 
Glioblastoma: A172, LN229, SF295, U251, D54 and T98G 
Breast: MCF7, T47 and MB231 
Lung: A549 
Renal: 769P 
Cervical: HeLa 
[47] 
Mesothelioma: ACC-MESO, Y-MESO, EHMES-1 and EHMES-10 [50] 
Pancreatic cancer: MIA PaCa-2, AsPC-1 and BxPC-3 [51] 
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Many animal studies have shown that high-dose ascorbate administered via intraperitoneal (IP) or 
intravenous injection has inhibitory effects on the growth of xenografted tumours and metastases. It 
was reported that in rats, the baseline plasma ascorbate concentrations were approximately 50 – 100 
µM; IV administration of pharmacologic ascorbate (0.5 g/kg of body weight) could achieve peak 
plasma and extracellular fluid concentrations of ascorbate to over 8 mM, while IP administration 
could achieve these concentrations to around 3 mM [52]. Kimoto et al. reported that injection of 
ascorbate (0.2 mL, 4%; equivalent to 0.3 g/kg of body weight) for 12 days prolonged the survival 
rates of mice inoculated IP with Ehrlich tumour cells from 0 to 24% at the 30th day [53]. Pavelic 
reported that ascorbate given IP (0.5 g/kg of body weight, daily) for the first 10 days significantly 
reduced the volume of inoculated human neuroblastoma tumours in mice and prolonged the survival 
by 55% [46]. Chen et al. showed that IP injection of ascorbate (4 g/kg of body weight, twice a day 
for over a week) significantly reduced the growth and weight of ovarian, pancreatic and glioblastoma 
xenografted tumours in athymic nude mice by 41% – 53% (P = 0.04 – 0.001), and reduced the 
incidence of metastasis (present in ~30% of glioblastoma controls) to zero [47]. Yeom et al. reported 
IP injection of ascorbate (5.5 – 30 mg per mouse; equivalent to 0.2 – 1.2 g/kg of body weight, every 
two days for 28 days) increased the survival rates of mice inoculated IP with sarcoma S-180 cells 
from 0 to 20% at the 28th day[54]. Takemura et al. reported that even a single IV injection of ascorbate 
(50 µL, 1 M; equivalent to 0.35 g/kg of body weight) into tail vein could significantly decrease the 
growth rate of mesothelioma tumour inoculated in mice by around 50% for the first 20 days [50]. 
 
Pollard et al. reported that IP ascorbate (4 g/kg of body weight, daily for 30 days) reduced the growth 
of implanted PAIII prostate cancer adenocarcinoma cells (derived from a germfree LW rat) in 
syngeneic, immune-competent LW rats by around 22% (P = 0.026) and reduced the incidence of 
metastasis by 50% (P = 0.009) [55]. Their results were consistent with the results of the studies using 
athymic nude mice as summarized above. They also reported that ascorbate treatment changed the 
quantitative relationship between the primary tumour weight and the number of lung metastases. In 
the control rats, the distribution of tumour weights and cognate metastatic number appeared to be 
somewhat random. In the rats treated with ascorbate, there was a proportional and objectively linear 
relationship and a discrete and mathematically defined lag between the growth of the primary tumour 
and eventual occurrence of detectable metastases [55]. The explanation given by the authors were 
that in the presence of ascorbate there could be a critical mass of primary tumour that must be reached 
before metastases could occur.  
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Pharmacologic ascorbate could also enhance the anticancer effect of radiation [56] and some 
chemotherapy drugs such as cisplatin [57], carboplatin and paclitaxel [42] in in vitro and animal 
models. However, the effects of ascorbate treatment reported from the studies using in vitro and 
animal models should not be equally expected in humans. Firstly, there obviously exist differences 
in the genetics and microenvironment between the cancer cell lines used in cell culture and animal 
models and the tumour cells in humans. Secondly, the pharmacology of IP and IV injection in animals 
is quite different from that of IV administration in humans [36, 58]. Thirdly, tumours xenografted in 
rodents appeared to be much more sensitive to ascorbate. Orally administered ascorbate could also 
reduce the growth of tumours in xenograft animal models [59-61], however, it was disproved in 
human studies [19, 20].  
 
1.3 Proposed mechanisms of action and common misinterpretation of 
results 
Ascorbate is normally considered as a reducing agent in biological systems, whereas it can also 
behave as a pro-oxidant under certain conditions [62, 63]. The biological effects of ascorbate depend 
on concentration, route of administration, and duration of exposure. Most plants and animals 
synthesize ascorbate for their own requirement, however, humans cannot due to a lack of L-
gulonolactone oxidase and need to acquire ascorbate from food [64]. The recommended dietary 
allowance (RDA) for ascorbate varies between different countries. In the United States, the RDA for 
ascorbate is 100 – 120 mg/day for adults [64]. The normal steady state for plasma concentration of 
ascorbate in humans is around 70 – 85 µM (physiological concentrations) [27]. By intake of ascorbate 
rich foods (fruits and vegetables), the plasma ascorbate concentration can increase to the order of 0.1 
mM, however, it cannot exceed 0.22 mM even by administration of high oral doses because of the 
limited intestinal absorption [7]. In contrast, via intravenous administration, ascorbate plasma 
concentration can reach up to 49 mM and maintain at 10 – 20 mM (pharmacologic concentrations) 
for 5 – 6 hours [37]. 
 
The flux of ascorbate in and out of the cell is controlled by active transport and facilitated diffusion, 
while simple diffusion is small and negligible [65, 66]. Ascorbate can be transported by sodium-
dependent vitamin C transporters (SVCTs) in an ATP-dependent manner. The expression of SVCT1 
and SVCT2 can be inhibited by substrate feedback [67]. The oxidized form of ascorbate, 
 10 
 
dehydroascorbate (DHA) can be transported by glucose transporters (GLUTs; GLUT1, GLUT3 and 
GLUT4) in a gradient-driven energy-independent mechanism followed by intracellular reduction to 
ascorbate [67]. Based on Km values, GLUTs have lower affinity for DHA than do SVCTs for 
ascorbate, and glucose has competitive inhibition effect on DHA transport through GLUTs [67]. 
Cancer cells usually have increased number of facilitative GLUTs to intake enough glucose for their 
growth [68]. Since DHA have similar molecular structures as glucose, cellular intake of DHA is 
favoured in malignant cells [63, 69]. 
 
It was first proposed by Benade et al. that hydrogen peroxide (H2O2) was the intermediate of the 
cytotoxicity of ascorbate [23]. They reported that ascorbate was highly toxic to Ehrlich ascites 
carcinoma cells in vitro, and the toxicity could be inhibited by glucose, low oxygen pressure and 
catalase but synergistically enhanced by 3-amino- 1,2,4-triazole (3-AT), a catalase inhibitor [23]. The 
growth inhibitory effect of ascorbate appeared to be dependent on its concentration in culture medium 
rather than its intracellular concentration as whether or not intracellular ascorbate was preloaded, 
extracellular ascorbate induced the same amount and type of death [70]. It was later demonstrated 
that H2O2 (micromolar level) could be dose-dependently produced by ascorbate at millimolar 
concentrations in cell culture medium and extracellular fluid in vitro [52, 71], and the induced 
production of H2O2 was almost linearly correlated to ascorbate concentration and incubation time 
[52]. The types and amounts of cell death induced by 0 – 250 μM H2O2 and 0 – 5 mM ascorbate in 
Burkitt’s lymphoma cells were similar [72]. Both catalase, a membrane-impermeant H2O2-scavenger 
and tetrakis (4-benzoic acid) meso-substituted manganoporphyrin, a membrane-permeant H2O2-
scavenger could inhibit the cytotoxicity of ascorbate, while superoxide dismutase, an enzyme capable 
of scavenging superoxide and generating H2O2, could not [48, 72]. Overexpression of cytosolic 
catalase in pancreatic cancer cells by transfection could help the cells tolerate higher-dose ascorbate 
treatment, while catalase expressed in mitochondria could not [51].  
 
Two electrons can be transferred from one ascorbate molecule during its oxidation process to form 
one H2O2 molecule, and removal of the two electrons from ascorbate results in the generation of DHA 
[73]. However, the variables determining the oxidation of ascorbate in vitro and in vivo are still not 
fully understood [52]. It was reported that in the absence of catalytic metals, ascorbate in an air-
saturated solution was stable at pH 7.0 with a first-order rate constant for the oxidation of ascorbate 
less than 6×10-7 /s [74]. The addition of metal ions, such as Cu+, Cu2+, Fe2+, Fe3+, Mn2+ and Zn2+, 
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dose-dependently increased the ascorbyl radical concentration and accelerated the degradation of 
ascorbate whereas Na+, K+, Ca2+ and Mg2+ were totally inactive [75]. Elevating temperature and 
increasing pH could also enhance the oxidation process of ascorbate [76]. However, these studies 
were based on in vitro conditions, the in vivo significance of the relevant modulating factors need to 
be further elucidated.  
 
The cytotoxicity of ascorbate may involve the regulation of metal ions in cells. It was demonstrated 
that high-dose ascorbate could increase the intracellular Ca2+ [77-79]. Removal of Ca2+ ions from the 
culture medium significantly reduced the cytotoxic activity of ascorbate but not the cytotoxic activity 
of H2O2 [80]. Pharmacologic ascorbate treatment could inhibit the intracellular iron intake by 
reducing transferrin receptor expression in cells [81, 82], and mobilize iron from intracellular ferritin 
[83-85], which, as a result, might enhance the toxicity of ascorbate by increasing H2O2 production. 
In addition, cancer cells were more likely to discharge ferritin into the medium during cell culture 
[86], which might make them more vulnerable to ascorbate treatment. The in vitro anticancer activity 
of ascorbate could be enhanced by non-cytotoxic concentrations of cupric ion [53, 87, 88]. It was 
reported that the tissue, cellular and serum copper levels were considerably elevated in various 
malignancies, and cancer cells with elevated copper levels might thus become more sensitive to 
ascorbate treatment [88, 89]. However, membrane-impermeant metal chelator diethylenetriamine-
pentaacetic acid (DTPA) and membrane-permeant chelator N,N’-bis (2-hydroxybenzyl) 
ethylenediamine-N,N’-diacetic acid (HBED) had shown only minor protection against ascorbate-
induced death in human Burkitt’s lymphoma cells, which indicated that the effect of ascorbate was 
unlikely due to chelatable, trace redox-active metals [72].  
 
The in vitro cellular responses to pharmacologic concentrations of ascorbate can range from cell cycle 
arrest at G1/S phase [79, 90] to cell death via apoptosis [72], autophagy [51, 91] and autoschizis [92], 
owing to the variety of lesions that it can produce in combination with the diversity of cellular repair 
mechanisms and responding pathways that can be elicited on the damage. Pharmacologic 
concentrations of ascorbate can cause oxidative DNA breakage [93-95], induce lipid peroxidation of 
membranous organelles [96, 97], impair the respiratory chain and decrease membrane potential in 
mitochondria [50, 79, 98, 99], reduce ATP level [51] and reduce intracellular glutathione [100]. 
Ascorbate treatment can modulate the expression/activation of a range of genes/proteins that regulate 
inflammation, angiogenesis, cell proliferation and programmed cell death (Table 1-2).   
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Table 1-2. Examples of pharmacologic ascorbate-induced alteration of gene expression and 
protein activation. 
Inflammation-related genes 
> Inhibited the activation of transcription factor NF-kB [101, 102]. 
> Down-regulated the expression of cyclooxygenase-2 (COX-2) [102, 103].  
> Down-regulated the expression of interleukin-18 (IL-18) [104].  
> Down-regulated the expression of tumour necrosis factor TNF-α, IL-6 and IL-2 [105]. 
Angiogenesis-related genes 
> Down-regulated the expression of basic fibroblast growth factor (bFGF), vascular endothelial 
growth factor (VEGF) and matrix metalloproteinase-2 (MMP2) [54, 106, 107]. 
> Down-regulated the expression of hypoxia-inducible factor-1α (HIF-1α) [108]. 
Cell proliferation-related genes 
> Up-regulated the expression of tumour suppressor p53 and cyclin-dependent kinase inhibitor 
p21; Down-regulated the expression of cyclin A, cyclin E, cyclin-dependent kinases CDK2 and 
CDK4 [79, 109]. 
> Inhibited the activation of mitosis-inducing phosphatase [90]. 
> Induced the phosphorylation of extracellular signal-regulated kinases (ERK), and activated small 
G protein Raf1 and mitogen-activated protein kinases (MAPK) kinase 2 [110].  
> Induced the activation of phospholipase D [111].  
Programmed cell death-related genes 
> Up-regulated the expression of apoptosis regulator Bax, released cytochrome C from 
mitochondria to cytosol, activated caspase 9 and caspase 3, and cleaved Poly ADP-ribose 
polymerase (PARP) [49]. 
> Caused the translocation of apoptosis-inducing factor (AIF) from mitochondria to nucleus [112].  
 
Chen et al. have made a series of investigations on the mechanisms of the cytotoxicity of ascorbate 
using in vitro and animal models [47, 52, 72], which have been widely cited. They reported that high 
micromolar concentrations of H2O2 (up to ~200 µM) could be detected during and after millimolar 
ascorbate treatment in cell culture media and rats’ extracellular fluids (ECFs) but not in rats’ blood 
[47, 52, 72]. They concluded that ascorbate could selectively sustain H2O2 formation within the 
interstitial fluids of tumours but not in blood and thus ascorbate could be a pro-drug for delivering 
H2O2 to cancer [47]. However, their interpretation was incorrect and misleading. Cells can decompose 
H2O2 [113]. Thus the more cells in a system that contains a limited source of H2O2 production, the 
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lower maximum H2O2 concentration it can reach. The ECFs of rats were collected using micro-
dialysis over a period of 30 minutes [52]. Under the in vitro conditions, the ECF contained hardly any 
cells, while the blood still contained blood cells. Ascorbate could produce H2O2 continuously, as a 
result, in the period of 30 minutes, H2O2 should be easily accumulated in the ECF but not in the blood. 
However, under the in vivo conditions, there were obviously many cells, which could decompose 
H2O2 continuously. As a result, the actual H2O2 concentrations in ECF in vivo might be much lower 
or even undetectable as it was in blood. Therefore, Chen et al.’s experiments demonstrated that H2O2 
could be generated by ascorbate in ECF, however, their results were insufficient to demonstrate that 
the same toxic concentrations of H2O2 could be accumulated in ECF under in vivo conditions.  
 
1.4 Hypotheses and aims 
To conclude the above literature review, the current rationale for the proposed use of IVA in cancer 
treatment has its roots in cell and animal experiments, where millimolar concentrations of ascorbate 
(achievable via intravenous infusion in humans [37]) can kill a number of cancer cells but not normal 
cells in vitro [72], and suppress the growth of tumour xenografts in rodents [47, 55]. The clinical data 
obtained several decades ago described a significant increase in the survival time of terminal cancer 
patients who received 10 grams of sodium ascorbate daily compared with the retrospective controls 
[17]. At least three case reports have shown that IVA should be linked to the regression of tumours 
in 11 patients who received IVA [28-30]. Moreover, the phase I clinical trials of IVA in patients 
diagnosed with a variety of advanced cancers demonstrated no adverse effects for maintaining the 
plasma ascorbate concentrations at 10 – 20 mM for several hours, and the researchers concluded that 
IVA was generally safe when simple precautions were taken [35-37]. Although the overall anticancer 
efficacy of IVA appeared to be low as suggested by the published scientific literature [31], the 
reported beneficial effects of IVA are promising, which include improving patient’s quality of life 
[40], reducing chemotherapy-associated toxicity [42], reducing radiotherapy induced pain  [43], 
reducing inflammation [45] and stabilizing cancer progression [35, 36].  
 
Biological systems are usually very complex and the black box theory is often adapted to predict an 
output from an input (Figure 1-1). Unfortunately, sometimes the differences between the black boxes 
for comparison are ignored, and the seemly same input levels may not be really the same. It is 
generally accepted that the cytotoxic effect of ascorbate on cancer cells is due to the generation of 
H2O2, which have been demonstrated in in vitro studies [51, 72]. The cellular responses to H2O2 are 
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concentration dependent, ranging from proliferation, regulation and adaptation to apoptosis and 
necrosis [114]. Cytotoxic high micromolar concentrations of H2O2 could be detected in the 
extracellular fluids collected from rats that were administrated with parenteral ascorbate [52, 72], 
however, as commented in the previous section, its occurrence in vivo is still uncertain. The 
contentiousness between the promising in vitro anticancer activity of pharmacologic ascorbate and 
the seemly low efficacy of IVA reported in the human studies was probably due to the fact that the 
cell density under the cell culture conditions was far lower than the cell density in vivo (Figure 1-1). 
Human cells all have H2O2 decomposing enzymes, such as catalase and glutathione peroxidase (GPx) 
[113], so each cell is a H2O2 sink. Therefore during ascorbate treatment, the cells at higher density 
should have lower accumulation of intracellular H2O2. Furthermore, ascorbate may produce H2O2 at 
different rates in cell culture media and extracellular fluids, and the cancer cells used in the in vitro 
and animal studies may have genetic variations from the cancer cells in humans (Figure 1-1). Thus 
the evidence obtained from the in vitro and animal models should be interpreted with care.  
 
For a chemotherapeutic agent to effectively kill cancer cells in vivo, it must reach an effective 
concentration in the plasma/extracellular fluid for a long enough period of time. In the clinical studies, 
researchers used gram per kilogram of body weight or plasma concentrations of ascorbate as a 
predictor of drug dosage, however, it poorly represented the cytotoxic effect of ascorbate that was 
shown in the in vitro studies. Based on the H2O2-mediated mechanism, the accumulation of 
intracellular H2O2 should be the better estimator of the cytotoxic effect of ascorbate treatment when 
it is compared between different biological/experimental systems (Hypothesis 1). To ensure an 
effective anticancer effect, the intracellular H2O2 concentration induced by IVA should reach a level 
that is sufficient to have an inhibitory effect on the cancer cells as demonstrated in vitro. However, 
intracellular H2O2 concentrations under in vivo conditions cannot be accurately measured due to the 
limitation of the current technology. In order to provide a holistic understanding of the differential 
effects of ascorbate treatment in different biological/experimental systems, a mathematical model 
was designed. The mathematical model aimed to describe the relationships of the key variables and 
processes that determine the intracellular H2O2 concentrations in an system challenged with H2O2 
and/or an agent capable of producing H2O2 (such as ascorbate), and to predict/simulate the dynamic 
changes of the intracellular concentrations of H2O2 under in vivo conditions based on the relevant in 
vitro experimental data (Aim 1, Chapter 2).  
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Figure 1-1. Comparison of the cell culture, animal and human models for ascorbate treatment. 
The arrows at the left side represent the inputs, i.e. the ascorbate treatment. The middle square boxes 
represent the study models, i.e. the cells cultured in vitro, the animals bearing tumour xenografts and 
the cancer patients. The arrows at the right side represent the typical outputs reported in the published 
literature. The ovals in the middle square boxes represent the cells, and the number of them represents 
the density of cells in the systems. The different colours of the ovals indicate that the cells are 
genetically different. The blue space in the square boxes represent the cell culture medium or the 
extracellular fluid in the systems.  
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One hypothesis of this thesis is that the cytotoxicity of ascorbate to cancer cells is not only mediated 
by H2O2, but also by DHA, the oxidized form of ascorbate (Hypothesis 2, Figure 1-2). Ascorbate can 
be oxidized to DHA [73], and produce H2O2 [72]. H2O2 that is diffused into a cell can be decomposed 
by the cell’s redox regulatory system [115]. However, excess intracellular H2O2 that cannot be 
scavenged in time can damage cellular components and interrupt cellular signalling, and if the repair 
system is overwhelmed, the cell will eventually undergo cell death [114, 115]. DHA can be 
transported into the cells via certain glucose transporters and may compete with glucose uptake [67]. 
It may cause further glucose starvation by inhibiting hexokinase activity [116]. In a cell, DHA can be 
reduced to ascorbate [67, 73], via a process that consume glutathione (GSH), a cofactor for the H2O2 
decomposing enzyme glutathione peroxidase [117, 118]. Cancer cells have much higher expression 
of glucose transporters than normal cells due to a much larger demand for glucose [68]. Thus DHA 
that is produced by the oxidation of pharmacologic ascorbate may be preferentially transported into 
cancer cells, and as a result antagonize the glucose uptake and reduce the cell’s capability to remove 
H2O2, which may allow higher levels of intracellular H2O2 to be accumulated. 
 
In this study, the mechanisms of the cytotoxicity of ascorbate to cancer cells were further elucidated 
by demonstrating that the cytotoxicity of ascorbate was mediated by both H2O2 and DHA (Aim 2, 
Chapter 3). The possible extracellular, cellular and molecular variables that might be associated with 
the differential responses of cells to ascorbate treatment (Aim 3, Chapter 3) and the two proposed 
mechanisms of the DHA-mediated cytotoxicity (Aim 4, Chapter 3) were also investigated. In order 
to evaluate the safety of an optimised IVA protocol for the treatment of cancer and assess the roles 
of H2O2 and DHA in the treatment, a Phase I clinical trial of IVA was proposed (Aim 5, Chapter 4). 
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Figure 1-2. Schematic mechanisms of the cytotoxicity of ascorbate to cancer cells. 
Ascorbate can be oxidized to DHA and produce H2O2 in cell culture media and extracellular fluids. 
Ascorbate can be transported into the cells via SVCTs, while DHA can be transported into the cells 
via GLUTs, and thus may antagonise glucose uptake. When DHA is reduced to ascorbate in the cells, 
GSH is consumed, which may reduce the H2O2 decomposing capacity of glutathione peroxidase. 
H2O2 can be channelled into the cells via AQPs. If excess intracellular H2O2 is not removed by the 
redox regulatory system, it will disrupt, alter and/or damage the cellular components and processes. 
If cell’s repair system cannot cope with the damages, cells may eventually undergo programed cell 
death.  
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The research plan changed as the understanding of the mechanism was updated. One of the strategies 
for this study was to investigate the expression of the genes that might determine the differential 
responses of tumour cells to ascorbate treatment, which could be used to select patients who would 
benefit from an IVA treatment (Hypothesis 3). Ideally, this could start by evaluating the changes in 
the gene expression of the tumour cells before and after ascorbate treatment in vitro. However, due 
to the recognition that the increase of intracellular H2O2 by IVA in humans would be much lower 
compared with that under the in vitro conditions based on the simulation of the mathematical model 
(Chapter 2), the in vitro research plan was not progressed, as it would provide limited even misleading 
perspectives. Instead, one pathway known to be involved in regulating H2O2 production and removal, 
transforming growth factor beta (TGFβ), was investigated [119]. TGFβ1 has been shown to simulate 
H2O2 production in a variety of cell types and suppress the expression of antioxidant enzymes such 
as catalase in some cells [119]. By determining the associations between the tumour TGFβ pathway 
gene expression and tumour characteristics and patients’ clinical outcomes, we may be able to identify 
the patients where TGFβ pathway targeted therapies can improve the efficacy of IVA treatment for 
cancer (Aim 6, Chapter 5). 
 
By better understanding the mechanisms of the cytotoxicity of ascorbate to cancer cells from an in 
vitro aspect, we may learn why the in vitro and in vivo results were conflicting and determine as to 
whether the use of IVA in cancer treatment should be abandoned or whether strategies can be 
developed to improve its clinical efficacy or to use it in an alternative way. If an objective anticancer 
response of IVA or a beneficial effect in cancer treatment can be conclusively demonstrated, IVA 
may become an economically viable chemotherapeutic option or an annexed therapy to the 
conventional cancer treatments with minimum side effects for cancer patients. 
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Chapter 2 
2 Mathematical modelling of extracellular and intracellular 
hydrogen peroxide concentrations 
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2.1 Background 
Hydrogen peroxide belongs to reactive oxygen species (ROS) [120], and it has been proposed to be 
the effective intermediate for many cytotoxic agents, including ascorbate [72, 121]. In biological 
systems, H2O2 forms as a natural by-product of metabolism and functions as a signalling molecule in 
the regulation of a variety of biological processes [113]. H2O2 can be channelled across membranes 
by some aquaporins, while simple diffusion is limited [122]. Peroxidases, such as catalase (mainly 
located in peroxisome), glutathione peroxidases (mainly located in cytosol) and peroxiredoxins can 
decompose H2O2 to water and oxygen [115]. The excess intracellular H2O2 that cannot be 
decomposed by enzymes in time may disrupt cellular redox homeostasis and signalling, oxidize 
proteins, lipids or nucleic acids and increase protein synthesis error rate, and thereby dysfunction vital 
cellular process and cause general cellular damage and eventually induce cell cycle arrest and cell 
death [120, 121].  
 
It has been demonstrated that millimolar ascorbate has cytotoxic effects on cancer cells in in vitro 
and animal studies, however, IVA only shows limited anticancer efficacy in human clinical trials [7]. 
The use of discrete descriptions of evidence to explain the differential effects of ascorbate treatment 
among different biological/experimental systems is insufficient and sometimes contradictory due to 
the complex nature of the biological mechanism. Until now, the mechanisms by which cells exhibit 
different responses to ascorbate treatment and how the extracellular, cellular and molecular variables 
and ascorbate are coordinated to induce cytotoxicity are still poorly understood. As proposed in the 
previous chapter, the intracellular H2O2 concentration should be a better estimator of the ascorbate-
induced cytotoxicity. When being challenged with the same dose of ascorbate, cells in different 
systems certainly experience different intracellular H2O2 concentrations that cause different extent of 
interruption or damage to the cellular processes. Due to the limitation of the current methods for 
accurate measurement of intracellular H2O2 concentrations under in vivo conditions, a mathematical 
model was established to study how the key variables and processes determine intracellular 
concentrations of H2O2. By using the data from the published literatures [72, 123] and our in vitro 
experiments, we were able to make in silico simulation of the dynamic changes of extracellular and 
intracellular H2O2 concentrations during H2O2 or ascorbate treatment under many different 
circumstances including in vivo conditions. 
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2.2 Determining the key variables and establishing the relationships between 
them 
Assuming that there is an in vitro or in vivo system in which the human cells are challenged with 
H2O2 or an agent that can induce the production of H2O2 such as ascorbate, the variables and processes 
determining the H2O2 concentrations in the extracellular, cytosol and organelle compartments are 
schematically shown in Figure 2-1 and defined in Table 2-1. Basically, it is assumed that H2O2 can 
be introduced or produced from a source in any of the three compartments, and transport freely 
through the membranes and be decomposed by the relevant enzymes and consumed by the reactions 
with other molecules in each compartment. The relationships between the variables can be described 
by the three differential equations (a1), (a2) and (a3). 
 
  
Figure 2-1. Schematic diagram of the variables and processes determining the hydrogen 
peroxide concentrations in the extracellular, cytosol and organelle compartments. 
The blue background represents the extracellular compartment, the orange oval shape represents a 
cell, and the green round shape represents an organelle. The first letters H, P, M, E, X and V denote 
H2O2 concentration, production rate, membrane permeability rate constant, enzyme decomposition 
rate constant, unspecified decomposition rate constant and volume, respectively. The second letters 
E, C and O denote extracellular, cytosol and organelle, respectively. The third letter i denotes the ith 
cell. The 4th letter j denotes the jth organelle. The letters n and m denote the cell number and the 
organelle number, respectively. For example, VCi denotes the cytosol volume of the ith cell. 
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Table 2-1 Definition of the variables used in the mathematical model. 
Symbols Variables Units 
HE Extracellular H2O2 concentration  M 
HCi H2O2 concentration in the cytosol of the ith cell M 
HOij H2O2 concentration in the jth organelle of the ith cell M 
PE Extracellular H2O2 production rate M/s 
PCi H2O2 production rate in the cytosol of the ith cell M/s 
POij H2O2 production rate in the jth organelle of the ith cell M/s 
MEi H2O2 permeability rate constant of the outer membrane of the ith cell /s 
MCi H2O2 permeability rate constant of the inner membrane of the ith cell /s 
MCij H2O2 permeability rate constant of the outer membrane of the jth organelle in 
the ith cell 
/s 
MOij H2O2 permeability rate constant of the inner membrane of the jth organelle in 
the ith cell 
/s 
EE Extracellular H2O2 enzyme decomposition rate constant /s 
ECi H2O2 enzyme decomposition rate constant in the cytosol of the ith cell /s 
EOij H2O2 enzyme decomposition rate constant in the jth organelle of the ith cell /s 
XE Unspecified extracellular H2O2 decomposition rate constant /s 
XCi Unspecified H2O2 decomposition rate constant in the cytosol of the ith cell /s 
XOij Unspecified H2O2 decomposition rate constant in the jth organelle of the ith cell /s 
VE Extracellular volume L 
VCi Volume of the cytosol in the ith cell L 
VOij Volume of the jth organelle in the ith cell L 
n Number of cells count 
m Number of organelles count 
HE[ss] Steady-state extracellular H2O2 concentration M 
HCi[ss] Steady-state H2O2 concentration in the cytosol of the ith cell M 
HOij[ss] Steady-state H2O2 concentration in the jth organelle of the ith cell M 
PIi Intracellular H2O2 production rate of the ith cell M/s 
EIi Intracellular H2O2 enzyme decomposition rate of the ith cell /s 
M: molar; L: litre; s: second. 
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dHE
dt
= PE − (EE + XE) × HE +
1
VE
× ∑ (MCi × HCi − MEi × HE) × VCi 
n
i=1
 (a1) 
 
Equation (a1) states that the instantaneous rate of change of the extracellular H2O2 concentration (
dHE
dt
) 
is equal to the average rate of change of extracellular H2O2 concentration that is due to the H2O2 
production in the extracellular medium (PE), the enzyme and unspecified decomposition (−(EE +
XE) × HE)  in the extracellular medium and the motion of H2O2 into and out of the cells(
1
VE
×
∑ (MCi × HCi − MEi × HE) × VCi )ni=1 . 
 
dHCi
dt
= PCi − (ECi + XCi) × HCi + MEi × HE − MCi × HCi +
1
VCi
× ∑ (MOij × HOij − MCij × HCi) × VOij
m
j=1
 
(a2) 
 
Equation (a2) states that the instantaneous rate of change of the H2O2 concentration in the cytosol of 
the ith cell (
dHCi
dt
) is equal to the average rate of change of cytosol H2O2 concentration that is due to 
the H2O2 production in the cytosol of the ith cell (PCi), the enzyme and unspecified decomposition 
(−(ECi + XCi) × HCi) in the cytosol of the ith cell, the motion of H2O2 into and out of the ith 
cell  (MEi × HE − MCi × HCi) and the motion of H2O2 into and out of the organelles of the ith 
cell (
1
VCi
× ∑ (MOij × HOij − MCij × HCi) × VOij)mj=1 .  
 
dHOij
dt
= POij − (EOij + XOij) × HOij + MCij × HCi − MOij × HOij (a3) 
 
Equation (a3) states that the instantaneous rate of change of the H2O2 concentration in the jth organelle 
of the ith cell (
dHOij
dt
) is equal to the average rate of change of organelle H2O2 concentration that is due 
to the H2O2 production in the jth organelle of the ith cell (POij), the enzyme and unspecified 
decomposition (−(EOij + XOij) × HOij) in the jth organelle of the ith cell and the motion of H2O2 
into and out of the jth organelle of the ith cell (MCij × HCi − MOij × HOij). 
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In order to make the mathematical model easier to compute, its complexity needs to be reduced by 
stripping away as much non-essential variables and processes as possible. Here, the cytosol and 
organelle H2O2 together are considered as the intracellular H2O2. At steady state, 
dHE
dt
, 
dHCi
dt
 and 
dHOij
dt
 
should all be equal to 0. The steady-state H2O2 concentration in the jth organelle of the ith cell, 
HOij[ss], can be obtained as in equation (a4) based on equation (a3), where Hci[ss] is the steady-state 
H2O2 concentration in the cytosol of the ith cell. Equation (a5) can be obtained from equation (a2) by 
substituting the HOij using equation (a4), where HE[ss] is the steady-state extracellular H2O2 
concentration. Two new variables can thus be defined from equation (a5), PIi for the intracellular 
H2O2 production rate of the ith cell (a6) and EIi for the intracellular H2O2 enzyme decomposition rate 
of the ith cell (a7). As a result, a relationship between HCi and HE at steady state can be obtained as 
in equation (a8), based on equation (a5). Equations (a4) and (a8) implicate that at steady state, 
gradients of H2O2 concentrations form in the extracellular, cytosol and organelle compartments, 
which are only dependent on the cell-dependent parameters.  
 
HOij[ss] =
POij + MCij × HCi[ss]
MOij + EOij + XOij
 (a4) 
 
PCi − (ECi + XCi) × HCi[ss] + MEi × HE[ss] − MCi × HCi[ss] +
1
VCi
× ∑
VOij × MOij × POij
MOij + EOij + XOij
m
j=1
−
Hci[ss]
VCi
× ∑
VOij × MCij × (EOij + XOij)
MOij + EOij + XOij
= 0
m
j=1
 
(a5) 
 
PIi = PCi +
1
VCi
× ∑
VOij × MOij × POij
MOij + EOij + XOij
m
j=1
 (a6) 
 
EIi = ECi +
1
VCi
× ∑
VOij × MCij × (EOij + XOij)
MOij + EOij + XOij
m
j=1
 (a7) 
 
HCi[ss] =
PIi + MEi × HE[ss]
MCi + EIi + XCi
 (a8) 
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Equation (a9) defines the H2O2 permeability rate constant across the membrane (M), where Ps is the 
membrane permeability constant for H2O2, A is the surface area of cell, and V is the volume of cell 
[123]. It indicates when Ps is the same, the smaller cells should have higher membrane permeability 
rate constant for H2O2 due to their larger surface to volume ratios. 
 
M =
Ps × A
V
 (a9) 
 
To further simplify the mathematical model, the average values of all variables are used instead of 
the individual values, and the possible consumption of H2O2 by unspecified reactions with other 
molecules is ignored, which should be trivial compared with the decomposition by enzymes.       
Figure 2-2 shows the simplified processes and variables that determine the dynamic changes of 
extracellular and intracellular H2O2 concentrations, in a system that contains viable cells. The 
relationships between the variables can be described by the two differential equations (b1) and (b2), 
with the definition of the variables provided in Table 2-2.  
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VO: Volume of extracellular medium, L
VI: Volume of cell, L
HO
Extracellular H2O2
concentration, M
HI
Intracellular H2O2
concentration2, M
MI
H2O2 permeability rate constant
of the inner membrane, /s
MO
H2O2 permeability rate constant
of the outer membrane, /s
n: Number of cells
EO
Extracellular
H2O2 enzyme
decomposition
rate constant, /s
EI
Intracellular
H2O2 enzyme
decomposition
rate constant, /s
PO
Extracellular
H2O2 production 
rate, M/s
PI
Intracellular
H2O2 production 
rate, M/s
 
Figure 2-2. Schematic diagram of the mathematical model of the extracellular and intracellular 
H2O2 concentrations. 
The blue background represents the extracellular medium and the purple square shape represents a 
cell. HO denotes the extracellular H2O2 concentration. HI denotes the intracellular H2O2 
concentration. PO and PI denote the extracellular and intracellular H2O2 production rates, respectively. 
MO and MI denote the H2O2 permeability rate constants of the outer and inner membranes, 
respectively. The two black arrows denote the motion of H2O2 into and out of the cell. EO denotes 
the extracellular H2O2 enzyme decomposition rate constant. EI denotes the intracellular H2O2 enzyme 
decomposition rate constant, which is the sum of the activities of all the enzymes that are capable of 
decomposing H2O2. n denotes the number of cells in the system. VI denotes the average volume of 
the cells. VO denotes the volume of the extracellular medium.  
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Table 2-2. Definition of the variables used in the simplified mathematical model. 
Symbols Variables Units 
HO Extracellular H2O2 concentration M 
HI Intracellular H2O2 concentration M 
PO Extracellular H2O2 production rate M/s 
PI Intracellular H2O2 production rate M/s 
MO H2O2 permeability rate constant of the outer membrane /s 
MI H2O2 permeability rate constant of the inner membrane /s 
EO Extracellular H2O2 enzyme decomposition rate constant /s 
EI Intracellular H2O2 enzyme decomposition rate constant /s 
VI Average volume of the cells L 
VO Volume of the extracellular medium L 
n Number of the cells count 
HO[ss] Steady-state extracellular H2O2 concentration M 
HI[ss] Steady-state intracellular H2O2 concentration M 
Kcell An assumed kinetic constant of decomposing H2O2 by the cells /s 
HO0 A bolus addition of H2O2 to the extracellular medium M 
PO0 Added extracellular H2O2 production rate M/s 
PI0 Added intracellular H2O2 production rate M/s 
HO[0] Extracellular H2O2 concentration at time 0 M 
HI[0] Intracellular H2O2 concentration at time 0 M 
HO[t] Extracellular H2O2 concentration as a function of time M 
HI[t] Intracellular H2O2 concentration as a function of time M 
SShi[t] An estimation of intracellular H2O2 concentration from the extracellular H2O2 
concentration 
M 
Kvc First-order reaction constant for the oxidation of ascorbate /s 
VC[t] Ascorbate concentration as a function of time M 
VC0 Initial concentration of ascorbate M 
VCPO[t] H2O2 production rate by ascorbate as a function of time M/s 
M: molar; L: litre; s: second. 
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dHO
dt
= PO − EO × HO +
n × VI
VO
× (MI × HI − MO × HO) (b1) 
 
Equation (b1) states that the instantaneous rate of change of the extracellular H2O2 concentration (
dHO
dt
) 
is equal to the average rate of change of extracellular H2O2 concentration that is due to the 
extracellular H2O2 production (PO), extracellular H2O2 enzyme decomposition (−EO × HO) and the 
motion of H2O2 into (−
n×VI
VO
× MO × HO) and out (
n×VI
VO
× MI × HI) of the cells. 
 
dHI
dt
= PI − EI × HI + MO × HO − MI × HI (b2) 
 
Equation (b2) states that the instantaneous rate of change of the intracellular H2O2 concentration (
dHI
dt
) 
is equal to the average rate of change of intracellular H2O2 concentration that is due to the intracellular 
H2O2 production (PI), intracellular enzyme decomposition (−EI × HI) and the motion of H2O2 into 
(MO × HO) and out (−MI × HI) of the cell. 
 
The pair of the two-dimensional differential equations (b1) and (b2) can be simplified to a pair of 
one-dimensional, second-order differential equations (b7) and (b8). Allowing a = PO, b =
n×VI×MI
VO
, 
c = EO +
n×VI×MO
VO
, d = PI, e = MO and f = MI + EI, equations (b1) and (b2) can be converted to 
equations (b3) and (b4), respectively. Equations (b5) and (b6) can be obtained by taking derivative 
on both sides of equations (b3) and (b4), respectively. Equation (b7) can be obtained by substituting 
equations (b3) and (b5) to equation (b4). Equation (b8) can be obtained by substituting equations (b4) 
and (b6) to equation (b3). 
 
HI =
1
b
(
dHO
dt
+ c × HO − a) (b3) 
 
HO =
1
e
(
dHI
dt
+ f × HI − d) (b4) 
 29 
 
dHI
dt
=
1
b
(
d2HO
dt2
+ c ×
dHO
dt
) (b5) 
 
dHO
dt
=
1
e
(
d2HI
dt2
+ f ×
dHI
dt
) (b6) 
 
d2HO
dt2
+ (c + f) ×
dHO
dt
+ (c × f − b × e) × HO − (b × d + a × f) = 0 (b7) 
 
d2HI
dt2
+ (c + f) ×
dHI
dt
+ (c × f − b × e) × HI − (c × d + a × e) = 0 (b8) 
 
2.3 Estimating the values of variables at steady state 
At steady state, 
dHO
dt
= 0 and 
dHI
dt
= 0, so the steady-state extracellular H2O2 concentration (HO[ss]) 
and the steady-state intracellular H2O2 concentration (HI[ss]) can be obtained as in equations (c1) and 
(c2) from equations (b1) and (b2), respectively. The ratio of the two steady-state concentrations can 
be obtained as in equation (c3). A simple relationship (c4) between HO[ss] and HI[ss] can be obtained 
from equation (b2), which only depends on the cell’s intrinsic parameters. 
 
HO[ss] =
n × VI × MI × PI + (EI + MI) × VO × PO
n × VI × MO × EI + (EI + MI) × VO × EO
 (c1) 
 
HI[ss] =
n × VI × MO × PI + EO × VO × PI + MO × VO × PO
n × VI × MO × EI + (EI + MI) × VO × EO
 (c2) 
 
HO[ss]
HI[ss]
=
n × VI × MI × PI + (EI + MI) × VO × PO
n × VI × MO × PI + EO × VO × PI + MO × VO × PO
 (c3) 
 
HI[ss] =
PI + MO × HO[ss]
MI + EI
 (c4) 
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Antunes and Cadenas proposed a mathematical model estimating the steady-state gradients of H2O2 
across the bio-membranes based on further simplified scenarios [123]. They proposed that the 
relationship between the extracellular and intracellular H2O2 concentrations at steady state was as 
shown in equation (d1), which can also be obtained by setting  MI = MO , PI = 0 and EO = 0 in 
equations (c3) or (c4). Their experimental data showed that in a cell culture system, the decrease of 
the extracellular H2O2 after a bolus addition of H2O2 was approximately following a first-order kinetic 
process. They thus proposed that the decrease of extracellular H2O2 due to removal of H2O2 by cells 
followed first-order kinetics. It can be formulated as shown in equation (d2), where Kcell is an 
assumed kinetic constant of decomposing H2O2 by the cells. They also proposed the relationship 
between Kcell and EI as shown in equation (d3). 
 
HI[ss]
HO[ss]
=
MI
MI + EI
 (d1) 
 
dHO
dt
= Kcell × HO (d2) 
 
Kcell
EI
=
HI[ss]
HO[ss]
=
MI
MI + EI
 (d3) 
 
However, there is a problem of the definition of Kcell. As at steady state, 
dHO
dt
  should be equal to 0, 
if Kcell is a constant unequal to 0, it will force HO to be equal to 0, which means there are no gradients 
of H2O2 formed in different cellular compartments at steady state. According to equation (b7), the 
change of extracellular H2O2 is obviously not a first-order kinetic process. However, it approximates 
to a first-order kinetic process at certain scenarios, especially when cell density is low, where Kcell 
can be used to estimate other variables. 
 
The default values of the variables used in our mathematical model were estimated from Antunes and 
Cadenas’ study on Jurkat T-cells [123]. Jurkat T-cells were spheres with an average surface area of 
627 ± 21 μm2, so the average volume of Jurkat T-cells was 1.48×10-12 L. The cell density used for 
the in vitro experiment was 1×106 cells/mL. The Kcell was measured to be 0.001 /s per 1×106 cells. 
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The EI of glutathione peroxidase and catalase was determined to be 0.0066 /s per 1.0×106 cells, which 
was equivalent to 4.5 /s for an average Jurkat T-cell. The MI of an average Jurkat T-cell could be 
determined to be 0.8 /s based on equation (d1).  
 
Antunes and Cadenas did not include a PI in their model. However, cells do have H2O2 production, 
which is not negligible. It was reported that human cancer cell lines could produce H2O2 at rates up 
to 0.5 nmol/10000 cells/h [124], which was equivalent to around 10 μM/s if the volume of cells was 
1.5×10-12 L. Escherichia coli could generate H2O2 at a rate of about 14 μM/s when it grew 
exponentially in glucose medium [125]. Using our mathematical model, PI can be estimated based 
on equation (c1) when the system is at steady state. Given MI = MO  and EO = 0, PI can be estimated 
from the equation: PI = EI × HO[ss] . In the Figure 2 of Antunes and Cadenas’ paper, the 
extracellular H2O2 concentration (HO) reduced to around 4.5 μM at around 80 minutes after a bolus 
addition of 100 μM H2O2 [123]. Although it could not be determined how close it was to the HO[ss], 
the PI for Jurkat T-cells could be estimated to be equal or less than 2.0×10-5 M/s. Later, by matching 
the Figure 2 of Antunes and Cadenas’ paper and the simulation of the extracellular H2O2 
concentration using the conditions as described in their paper, the PI for Jurkat T-cells was calibrated 
to be around 1.0×10-5 M/s.  
 
2.4 Simulation of the mathematical model 
Assuming that in a steady-state system, the extracellular H2O2 concentration can be immediately 
changed by a bolus addition of H2O2 to the extracellular medium (HO0), the extracellular H2O2 
production rate can be immediately changed by an agent that can produce H2O2 at a rate of PO0, 
and/or the intracellular H2O2 production rate can be immediately changed by PI0, then the steady state 
of the system will be disrupted, and a new steady state will be reached over time. The extracellular 
and intracellular H2O2 concentrations at time 0 (HO[0] and HI[0], respectively) when HO0, PO0 and 
PI0 are introduced, can be determined as shown in equations (e1) and (e2) based on equations (c1) 
and (c2). At steady state, 
dHO
dt
= 0  and 
dHI
dt
= 0, however, due to the immediate input of HO0, PO0 
and PI0, the  
dHO
dt
  and 
dHI
dt
 at time 0 (HO′[0] and HI′[0], respectively) should be determined as shown 
in equations (e3) and (e4) based on equations (b1) and (b2).  
 
 32 
 
HO[0] = HO0 +
n × VI × MI × PI + (EI + MI) × VO × PO
n × VI × MO × EI + (EI + MI) × VO × EO
 (e1) 
 
HI[0] = HI[ss] =
n × VI × MO × PI + EO × VO × PI + MO × VO × PO
n × VI × MO × EI + (EI + MI) × VO × EO
 (e2) 
 
HO′[0] = PO0 − EO × HO0 −
n × VI × MO × HO0
VO
 (e3) 
 
HI′[0] = PI0 + MO × HO0 (e4) 
 
Equation (b7) can be symbolically solved using Mathematica (version 9.0, Wolfram Research, Inc.) 
by applying equations (e1) and (e3) as the boundary conditions, and equation (b8) can be also solved 
by applying equations (e2) and (e4) as the boundary conditions. Due to the introduction of HO0, PO0 
and PI0, a = PO + PO0  and d = PI + PI0  should be updated in equations (b7) and (b8) for the 
calculation. As a results, the equations of the extracellular and intracellular H2O2 concentrations as a 
function of time (HO[t] and HI[t], respectively) can be obtained. Taking the derivative on the both 
side of equations (b7) and (b8), the exact forms of the third-order differential equations can be 
obtained, which indicate the rates of change for HO[t] and HI[t] are the same. Based on equation (c4), 
an estimation of the intracellular H2O2 concentration based on the extracellular H2O2 concentration 
is proposed and described as in equation (f1), where d = PI + PI0. Using the default values of 
variables as shown in Figure 2-3, the dynamic changes of extracellular and intracellular H2O2 
concentrations responding to different conditions can be plotted based on the equations of HO[t] and 
HI[t] (Figure 2-4).  
 
SShi[t] =
d + MO × HO[t]
MI + EI
 (f1) 
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Figure 2-3. The relevant variables with default values. 
The default values of the variables were estimated from Antunes and Cadenas’ paper [123]. The 
definition and unit of each variable were shown in the parentheses. 
 
 
Figure 2-4. Simulation of the mathematical model with manipulable values of variables. 
(A) Simulation of the extracellular (HO[t]) and intracellular (HI[t]) H2O2 concentrations when a bolus 
100 μM H2O2 is added to a steady state cell culture system containing Jurkat T-cells (1.0×106 cells/mL) 
for 1.5 hours. (B) Same data as (A) shown in log scale. (C) Ratios of the extracellular H2O2 
concentrations to the intracellular H2O2 concentrations. (D) Ratios of the intracellular H2O2 
concentrations to the intracellular H2O2 concentration at time 0 (HI[0]). (E) Ratios between the 
estimated intracellular H2O2 concentrations from the extracellular H2O2 concentrations (SShi[t]) and 
HI[t]. HO[t] is in blue and HI[t] is in red. The y-axis is the H2O2 concentration and the x-axis is the 
time in seconds. 
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The simulation of the mathematical model shows that after the addition of 100 μM H2O2, the 
intracellular H2O2 reaches its peak concentration within a second (Figure 2-4). Due to the 
consumption of H2O2 by the cells, both extracellular and intracellular H2O2 concentrations fall over 
time towards a steady state (Figure 2-4 A). The decrease of the extracellular H2O2concentrations 
approximates to but not exactly follows a first-order dynamic process (Figure 2-4 B). SShi[t] appears 
to become a very good approximation of the intracellular H2O2 concentration (HI[t]), almost 
immediately after the intracellular H2O2 concentration reaches its peak (Figure 2-4 E). 
 
2.5 Production of hydrogen peroxide by ascorbate 
It has been demonstrated that the production of H2O2 by ascorbate in cell culture medium and rat’s 
extracellular fluid and plasma in vitro was almost linearly correlated to ascorbate concentration and 
incubation time [52, 72]. Assuming that the oxidization of ascorbate is a first-order process (g1), 
where Kvc is the first-order reaction constant and VC0 is the initial concentration of ascorbate, the 
change of the ascorbate concentrations over time (VC[t]) can be obtained as in equation (g2). 
Assuming that every ascorbate molecule contributes to the formation of H2O2, the production rate of 
H2O2 by ascorbate can be determined as in equation (g3), and the accumulation of H2O2 can be 
determined as in equation (g4). It was observed that ascorbate could be fully oxidized to DHA in 
around 30 hours in RPMI 1640 medium when catalase was present (details in Chapter 3). Thus Kvc 
can be determined to be approximately 2.0×10-5 /s, i.e. 20 in a million of ascorbate molecules generate 
H2O2 per second.  
 
dVC
dt
= Kvc × VC (g1) 
 
VC[t] = VC0 × e−Kvc×t (g2) 
 
VCPO[t] = Kvc × VC0 × e−Kvc×t (g3) 
 
∫ Kvc × VC0 × e−Kvc×t
t
0
= VC0 − e−Kvc×t × VC0 (g4) 
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The change of ascorbate and H2O2 concentrations in a cell culture medium over time can be simulated 
based on the equations (g2), (g3) and (g4), given Kvc = 2.0×10-5 /s (Figure 2-5).  Chen et al. measured 
the concentrations of H2O2 that was produced by ascorbate in the cell culture medium for 1 hour [72]. 
Their results were consistent with the simulation (Figure 2-5 C), which confirmed the value of Kvc 
as estimated. Hoffer et al. reported that when the plasma concentration of ascorbate reached a peak 
after the intravenous infusion of ascorbate, it would gradually reduce by 80% after the first 6 hours 
due to renal filtration and excretion [36]. If the clearance of ascorbate in vivo also followed a first-
order reaction process, then the clearance rate constant could be determined to be around 6.0×10-5 /s, 
which indicated that only around 1/3 of the ascorbate contributed to the production of H2O2 in vivo. 
 
 
Figure 2-5. Simulation of the production of hydrogen peroxide by ascorbate. 
(A) Simulation of the decrease of ascorbate concentrations due to oxidation for 24 hours. The y-axis 
is the ascorbate concentration, and the x-axis is the time in hours. (B) Simulation of the H2O2 
production rate by ascorbate for the first 2 hours. The y-axis is the H2O2 production rate, and the x-
axis is the time in minutes. (C) Simulation of the accumulation of H2O2 produced by ascorbate in the 
medium for the first 1 hour. The simulations were based on VC0 = 2 mM and Kvc = 2.0×10-5 /s. The 
y-axis is the extracellular H2O2 concentration, and the x-axis is the time in minutes.  
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2.6 Prediction and validation of the mathematical model 
(Refer to section 3.2 of Chapter 3 for the relevant materials and experimental methods used here).  
 
In this section, the mathematical model and the estimated Jurkat T-cell’s parameters were used to 
simulate the extracellular and intracellular H2O2 concentrations in a system with different cell 
densities being challenged with H2O2 or ascorbate at a serials of concentrations. The predictions were 
validated with the cell viability data obtained from the HL-60 cells (human leukaemia cell line) that 
were treated with H2O2 or ascorbate. Ascorbate could produce H2O2 in cell culture medium, thus an 
ascorbate treatment was equivalent to adding a PO0 that would fall following a first-order process 
over time due to the consumption of ascorbate. Here, ascorbate uptake by cells was not accounted. 
During the first 1.5 hours in an ascorbate treatment, less than 10% of ascorbate was estimated to be 
oxidized, and H2O2 produced by ascorbate almost linearly accumulated in the cell culture medium 
over time (Figure 2-5). To make the calculation in the following predictions simpler, the production 
rate of H2O2 by ascorbate was let remain to be its maximum as at time 0 for 1.5 hours. For example, 
a 20 mM ascorbate treatment was considered as equivalent to adding a PO of 4.0×10-7 M/s. 
 
The results showed that the intracellular and extracellular levels of H2O2 could be used as estimators 
for the effect of ascorbate treatment (Figure 2-6). HL-60 cells were very sensitive to both H2O2 and 
ascorbate treatment (Figure 2-6 A). Ascorbate at a concentration of 0.3 mM could induce death in 
over 80% HL-60 cells in 1 hour (Figure 2-6 A). HL-60 cells were resistant to 1-hour 5 μM H2O2 
treatment, however, when H2O2 was increased to 10 μM, a dramatic fall of cell viability was observed 
(Figure 2-6 A). According to the prediction based on Jurkat T-cell’s parameters, 5 μM H2O2 could 
increase the intracellular levels of H2O2 in Jurkat T-cells by around 20% – 30%, while 10 μM H2O2 
could increase that by around 50% – 60% (Figure 2-6 D and E). In a 1-hour 0.3 mM ascorbate 
treatment, the extracellular H2O2 was predicted to reach to around 20 μM (Figure 2-6 B), which 
indicated that it might have a similar effect as a 1-hour 20 μM H2O2 treatment. This was validated by 
the observation that the HL-60 cells exposed to 20 μM H2O2 for 1 hour had similar cell viability as 
that was treated with 1-hour 0.3 mM ascorbate (Figure 2-6 A). The mathematical model also predicted 
that cells would experience an average higher level of intracellular H2O2 when they were treated with 
50 μM H2O2 than those were treated with 0.6 mM ascorbate (Figure 2-6 C and G). This was validated 
by the results that lower cell viability was observed in the cells treated with 50 μM H2O2 compared 
with those treated with 0.6 mM ascorbate (P < 0.001).  
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Figure 2-6. Simulation of the extracellular and intracellular hydrogen peroxide concentrations 
in a cell culture system challenged with ascorbate and hydrogen peroxide. 
(A) Comparison of the cytotoxic effect of ascorbate and H2O2. HL-60 cells at a density of 2.0×105 
cells/mL in complete RPMI 1640 medium were treated with either ascorbate or H2O2 at different 
concentrations for 1 hour followed by 3 times washes. The cells were then incubated in fresh complete 
RPMI 1640 medium for additional 24 hours before alamarBlue viability assay. Data represented were 
the mean ± SD of six repeats. (B-G) Simulation of the extracellular (HO[t]) and intracellular (HI[t]) 
H2O2 concentrations (in log scale) and the ratios of the intracellular H2O2 concentrations to the 
intracellular H2O2 concentration at time 0 when a bolus (B) 0.3 mM ascorbate, (C) 0.6 mM ascorbate, 
(D) 5 μM H2O2, (E) 10 μM H2O2, (F) 20 μM H2O2, or (G) 50 μM H2O2 is added to a steady-state cell 
culture system containing Jurkat T-cells (1.0×105 cells/mL) for 1.5 hours. HO[t] is in blue and HI[t] 
is in red. The x-axis is the time in seconds. 
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Assuming in an in vitro experiment, Jurkat T-cells at a wide range of cell densities were treated with 
0.2 – 20 mM ascorbate for 1.5 hours, the extracellular and intracellular concentrations of H2O2 could 
be simulated as shown in Figure 2-7. In the published studies, the cell density used for ascorbate 
treatment was usually 1.0×105 cells/mL. At this density, Jurkat T-cells treated with 2 – 20 mM of 
ascorbate should experience dramatically increased intracellular concentrations of H2O2 (Figure 2-7 
B and C). Whereas, the increase of intracellular H2O2 concentrations in the cells treated with 200 μM 
of ascorbate would be limited (Figure 2-7 A). These predictions were consistent with the findings that 
cancer cells could be killed by millimolar concentration of ascorbate but not physiological ascorbate 
(≤ 200 μM).  
 
When cell density was increased, the estimated increase of intracellular H2O2 concentration due to a 
20 mM ascorbate treatment was dramatically decreased (Figure 2-7 C - G). For the cells at a density 
over 1.0×108 cells/mL, the estimated maximum increase of intracellular H2O2 concentration was less 
than 30% during a 20 mM ascorbate treatment (Figure 2-7 F), which was much smaller than the 
estimated increase of intracellular H2O2 concentration in the cells at a density of 1.0×105 cells/mL 
that would be treated with 200 μM ascorbate (Figure 2-7 A). The level was also equivalent to that 
was induced by 1-hour 5 μM H2O2 treatment (Figure 2-6 D), which did not show any cytotoxicity 
effect on HL-60 cells (Figure 2-6 A), one of the most sensitive cancer cell lines to ascorbate treatment 
that were used in this study (Figure 3-1). At 1.0×108 cells/mL, the volume ratio of cells to medium 
was around 0.15, which was much less than the ratio under in vivo conditions [126]. Although, the 
simulation was based on the values of variables that were estimated form the Jurkat T-cells, these 
predictions provided the scale of increase of intracellular H2O2 concentrations during an IVA 
treatment in humans, which should be very limited.  
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Figure 2-7. Simulation of the extracellular and intracellular hydrogen peroxide concentrations 
in biological systems with different cell densities during ascorbate treatment. 
The extracellular (HO[t], blue lines) and intracellular (HI[t], red lines) H2O2 concentrations (y axis, 
in log scale) and the ratios of intracellular H2O2 concentrations to the intracellular H2O2 concentration 
at time 0 (HI[0]) were simulated in the biological systems with different cell densities that were 
treated different concentrations of ascorbate. The simulation was based on the Jurkat T-cell’s 
parameters. The x-axis is the time in seconds.  
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To verify the predictions, HL-60 cells at two different cell densities were treated with ascorbate at a 
serial of concentrations (Figure 2-8). The cells at higher density were significantly more tolerant to 
the ascorbate treatment. According to the simulation of the mathematical model (Figure 2-7 B and 
D), the cells that were treated with 20 mM ascorbate at 1.0×106 cells/mL should experience higher 
intracellular levels of H2O2 than those were treated with 2 mM ascorbate at 1.0×105 cells/mL. 
However, the HL-60 cells at 2.0×106 cells/mL that were treated with 19.2 mM ascorbate were more 
resistant than the cells at 2.0×105 cells/mL that were treated with 1.2 mM (P < 0.001, Figure 2-8 A).  
 
A premise of the mathematical model was that cells should be evenly distributed in medium. HL-60 
is a suspension cell line. However, during cell culture, it was observed that the HL-60 cells tended to 
be floating at the bottom, and visually observable layers of cells were formed at the bottom during 
the experiment with the higher cell density. Moreover, it was observed that MSTO-211 cells (human 
mesothelioma cell line) could easily form multiple cell layers during cell culture. When MSTO-211 
cells were challenged with 1-hour ascorbate treatment, only the cells on the upper surface of the 
multiple layers were killed, while those at the bottom were still alive as indicated by their normal 
morphology (Figure S 1). These observations indicated that the cells in the higher density group were 
not equally exposed to the ascorbate treatment as the cells in the outer layers could protect the inside 
cells against the treatment, which might explain the minor inconstancy between the prediction from 
the mathematical model and the experimental data. 
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Figure 2-8. Comparison of the cytotoxic effect of ascorbate on HL-60 cells at two different cell 
densities. 
(A) The HL-60 cells in logarithmic growth phase (2.0×105 cells/mL for HL-60, 1× and 2.0×106 
cells/mL for HL-60, 10×) were placed in RPMI 1640 medium supplemented with 10% FBS and 1× 
PSG in 1.7 mL Eppendorf tubes. The cells were exposed to ascorbate at different concentrations for 
1 hour at 37 ˚C in 5% CO2 / 95% air with the caps loosely closed. After the treatment, the cells were 
washed three times with RPMI 1640 medium. Then the cells were diluted to 2.0×105 cells/mL and 
cultured in complete RPMI 1640 medium in a 96-well plate for another 24 hours. The viability of the 
cells was determined by alamarBlue. Data represented were the mean ± SD of six repeats. (B) 
Representative morphology of HL-60 cells 24-hour post-treatment (phase contrast microscopy; 
magnification: 200×; red scale bar: 50 μm). 
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2.7 Discussion 
Our mathematical model provided a rigorous means of thinking about, holistic understanding and 
describing the relationship of the important variables and processes that determine the extracellular 
and intracellular H2O2 concentrations in an in vitro or in vivo system that is challenged with H2O2. 
Using the estimated values of variables from experimental data, the mathematical model can simulate 
the dynamic changes of extracellular and intracellular H2O2 concentrations when H2O2 or an agent 
that can produce H2O2 (such as ascorbate) is added and/or a change in one or more values of variables 
is made in the system. Based on the estimated parameters of Jurkat T-cells [123] and the estimation 
of the kinetics of oxidation of ascorbate (details in Chapter 3), a few simulations were made under 
certain circumstance. Although the data of the extracellular and intracellular H2O2 concentrations for 
validation were lack for the HL-60 cells that was tested, the results of cell viability assay were 
consistent with the predictions of the mathematical model.  
 
In the development of the mathematical model, it has been shown that at steady state, gradients of 
H2O2 concentrations can form among extracellular medium, cytosol and membranous organelles, 
which should be dependent on the cell’s intrinsic parameters: H2O2 membrane permeability rate 
constant, H2O2 enzyme decomposition rate constant and intracellular H2O2 production rate. The 
mathematical model provided a novel and simple method to estimate the intracellular H2O2 
production rate at steady state conditions, i.e. PI = EI × HO[ss], by measuring the intracellular H2O2 
enzyme decomposition rate constant and the steady-state extracellular H2O2 concentration. Under in 
vitro conditions, HO[ss] can be measured in the medium where cells are seeded at a very high density 
for a period of a few hours.  
 
H2O2 has important roles as a signalling molecule in the regulation of a variety of biological processes, 
however, if the intracellular H2O2 is too high above a cell’s normal steady-state concentration, it 
becomes harmful to the cell [113]. The dramatic differential responses between the HL-60 cells 
(2.0×105 cells/mL) treated with 5 μM and 10 μM H2O2 implicated a cellular tolerability threshold to 
H2O2 damage, for which the accumulation of damage should exceed before inducing cell death. 
According to our prediction, the two different treatments could increase the intracellular H2O2 
concentration in the Jurkat T-cells at the same cell density by 20% – 30% and 50% – 60% above their 
normal stead-state concentrations, respectively. Although, it could not be confirmed in this study 
whether HL-60 cells also experienced the similar scale of increases of intracellular levels of H2O2, 
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further study with specific parameters obtained for HL-60 cells may prove and provide the cellular 
tolerability threshold to H2O2 damage. Based on the mathematical model, we could further propose 
that the level of H2O2-induced cytotoxicity should be correlated with the integral of the excess 
intracellular H2O2 concentration with respect to the exposure time, i.e. ∫ HI[t] × dt − HI[ss]
t
0
× t, and 
the rate of accumulation might participate in the determination of the types of cell death. 
 
Without a justification and understanding of the differences between in vitro and in vivo studies, the 
in vitro studies may provide little useful implications for any application in humans. The most 
significant discrepancy between the in vitro and in vivo studies of ascorbate treatment is that the ratio 
of the volume of medium to the volume of cells in the cell culture system is far greater than that is 
under in vivo conditions (Figure 1-1). In our in vitro cell viability assay, ascorbate was usually 
administrated to the cells at a density of 1.0×105 cells/mL (also commonly used by other researchers), 
and the cells were roughly 10 µm in each dimension. At this cell density, cells usually formed a 
monolayer in the cell culture plates, and the volume ratio of medium to cells was around 10000:1. 
For an average man of 60 kg, extracellular fluid accounts for approximately 15% of the body weight, 
while solid, intracellular water and fat account for approximately 20%, 40% and 25% of the body 
weight, respectively [126]. The relative volume of medium to cell ratio should be in the scale of 1:4.  
 
As every cell is a sink of H2O2, the huge differences in the volume ratio of medium to cells can result 
in huge differences in the kinetics of H2O2 that is produced by the same concentration of ascorbate. 
The same amount of H2O2 can be consumed or detoxified in vivo at a much greater rate than it is in 
vitro, and the amount of intracellular H2O2 that cells are exposed to in an in vivo system is thus far 
less than that in an in vitro system. Our results showed that even an increase of cell density by 10 
times (from 2.0×105 cells/mL to 2.0×106 cells/mL) could dramatically reduce the cytotoxic effect of 
1-hour ascorbate treatment on Hl-60 cells, one of the most sensitive cancer cell lines to ascorbate 
treatment that had been used in the study. Based on the simulation of the mathematical model, the 
increase of intracellular H2O2 due to IVA in humans should be limited and unlikely to induce cell 
death. Muhlhofer et al.’s study might provide some evidence for this, which showed that there was 
no increase in the plasma concentrations of α-tocopherol and thiobarbituric acid-reactive substances, 
a well-established parameter for lipid peroxidation, in six healthy males who received daily infusions 
of up to 7.5 grams ascorbate for six consecutive days [127], though the dose used  was only around 
1/10 of that was usually used in a IVA treatment for cancer [36]. 
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It is difficult to measure and monitor intracellular H2O2 in humans during IVA. The simulation of the 
mathematical model showed that SShi[t] could be a very good approximation of HI[t], the 
intracellular H2O2 concentrations as a function of time. Based on equation (f1), the levels of 
intracellular H2O2 can be estimated by measuring extracellular H2O2 concentrations when the relevant 
cell-dependent parameters are given. Because of the circulation system, although different cells have 
different capacity to decompose the H2O2 that are generated by ascorbate in the microenvironment, 
regional high H2O2 concentration should not be accumulated, and different cells should be exposed 
to roughly the same extracellular concentrations of H2O2. Since SShi[t] only depends on the cell’s 
intrinsic parameters. It implicates that if the measured highest possible H2O2 concentration in the 
extracellular fluid during IVA is lower than the minimum extracellular H2O2 that is required to induce 
cell death or to be cytotoxic to cancer cells under the in vitro conditions, then it can be deduced that 
the H2O2-mediated mechanism is not sufficient to support the proposed anticancer effect of IVA 
(reviewed in Chapter 1). 
 
In conclusion, the mathematical model provided an in silico tool to simulate the changes of 
extracellular and intracellular H2O2 concentrations in a system that is challenged with H2O2 or an 
agent capable of producing H2O2. It also provided novel and simple methods for estimating the 
intracellular H2O2 concentration and production rate using the relevant cell-dependent parameters and 
extracellular H2O2 concentration, which are easier to be measured by the current experimental 
methods. The mathematical model further improved our understanding of the differences in the 
anticancer efficacy of ascorbate treatments among the results reported from the in vitro, animal and 
human studies. In the future, when systems biology provides enough proteomics and 
morphylogimatics information, this model may be integrated to high throughput H2O2-mediated 
anticancer drug discovering programs. 
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Chapter 3 
3 Cytotoxicity of ascorbate to cancer cells is due to the 
production of hydrogen peroxide and dehydroascorbate 
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3.1 Background 
Ascorbate can be oxidized to DHA and produce H2O2 in cell culture medium and extracellular fluid 
[52, 72]; hence the effects of ascorbate treatment on cells should also be contributed by the two 
molecules. As reviewed in Chapter 1, the H2O2-mediated mechanism of the cytotoxicity of 
pharmacologic ascorbate was mostly based on the observations in the in vitro and animal studies that, 
1) ascorbate was toxic to the cancer cells and xenograft tumours, 2) micromolar concentrations of 
H2O2 could be probed in the cell culture medium and extracellular fluid, and 3) the cytotoxic effect 
of ascorbate could be blocked by catalase in the in vitro ascorbate treatment in a period of 1 – 2 hours. 
For the same duration of treatment, DHA at millimolar concentrations appeared to be non-toxic to 
cancer cells [72]. As a result, H2O2 was generally accepted as the intermediate of the cytotoxicity of 
ascorbate both in vitro and in vivo, while the possible involvement of DHA was not further 
investigated. 
 
However, as discussed in Chapter 1, the results obtained from the animal studies that were used to 
back up the H2O2-mediated mechanism in vivo was misinterpreted [52], and thus the occurrence of 
micromolar H2O2 in vivo is still uncertain. In Chapter 2, a simulation of the mathematical model 
predicted a limited increase of intracellular H2O2 concentration in a typical IVA treatment based on 
the sole H2O2-mediated mechanism, which was unlikely to be sufficient to induce cell death in the 
tumours. 
 
In Chapter 1, a DHA-mediated mechanism of the cytotoxicity of ascorbate was proposed. DHA has 
a similar structure to glucose, and can be transported into the cells via certain glucose transporters 
[67]. By intravenous infusion of ascorbate, the plasma ascorbate concentration can be maintained at 
10 – 20 mM for several hours [37]. This may allow sufficient amount of ascorbate to be oxidized to 
DHA, which may compete with glucose uptake, since the normal fasting plasma glucose level is less 
than 5.6 mM [128]. After DHA is transported into the cells, it may cause further glucose starvation 
by inhibiting the hexokinase activity [116]. Intracellular DHA can be reduced to ascorbate by the 
glutathione-dependent mechanism [117, 118], which may reduce the cellular H2O2 decomposing 
capacity. Cancer cells usually have more glucose transporters than normal cells due to Warburg effect 
[68], and as a result DHA may preferentially antagonize glucose uptake in cancer cells and reduce 
the cells’ capability to remove H2O2 and as a result allow higher intracellular H2O2 to be built up. 
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In this Chapter, the H2O2-mediated and the possible DHA-mediated mechanisms of the cytotoxicity 
of ascorbate were investigated. The cytotoxicity of ascorbate was confirmed on a range of normal 
cell types and cancer cell lines. The oxidation of ascorbate to DHA in cell culture medium was 
investigated under a few different conditions. The possible extracellular, cellular and molecular 
variables that might be associated with the differential responses of cells to ascorbate treatment were 
also investigated. Since DHA may be able to sensitize cancer cells for a ROS-mediated treatment via 
the modulation of the redox regulation system of cell, here, the synergistic cytotoxicity of DHA and 
arsenic trioxide (As2O3) was evaluated as an example. 
 
3.2 Materials and methods 
3.2.1 Materials 
A stock solution of 1 M sodium ascorbate was made by dissolving the appropriate amount of ascorbic 
acid (Sigma-Aldrich: 95209-50G) in ultrapure distilled water (Life Technologies: 10977-015), and 
the pH was adjusted to 7.0 with 10 M sodium hydroxide (NaOH, Sigma-Aldrich: S8045). The freshly 
prepared stock solution was always filtered (0.22 µm), and stored in small aliquots at -80 ºC, which 
could prevent oxidation of ascorbate for months [129]. At room temperature, it was observed that the 
stock solution stored even in tightly capped Eppendorf tubes could gradually turn from transparent to 
light yellowish in a few days, indicating the oxidation of ascorbate. Thus, the aliquots of ascorbate 
were always used immediately and never reused for different experiments.  
 
Dehydroascorbic acid is less soluble in water compared with ascorbic acid. A stock solution of 500 
mM sodium dehydroascorbate was made by adding appropriate amount of dehydroascorbic acid 
(Sigma-Aldrich: 261556-5G) in ultrapure distilled water and then slowly adding 10 M NaOH with 
stir until fully dissolved. The pH of the stock solution was adjusted to 7.0 with 10 M NaOH. The 
stock solution was then filtered (0.22 µm) and stored in small aliquots at -80 ºC. It was noted that the 
pH of the stock solution dropped over time during the adjustment, which might be due to partial 
dissolution of dehydroascorbic acid. So when the pH reached 7.0, the solution was left for at least 30 
minutes before the final adjustment.  
 
The H2O2 used in the cell treatment was purchased from Sigma-Aldrich (323381-500ML), and was 
stored in small aliquots at -20 ºC before use. A 10 mM stock solution of As2O3 was made by 
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dissolving the appropriate amount of As2O3 in 60 mM NaOH, and it was filtered (0.2 μm) and stored 
at 4 ºC. The catalase (Sigma-Aldrich: C9322-10G) used in the cell treatment was derived bovine liver.  
 
3.2.2 Cell culture, cryopreservation and recovery 
The cells used in this study were obtained from the American Type Culture Collection (ATCC), the 
European Collection of Cell Cultures (ECACC) and our collaborative labs (Table 3-1). The fibroblast 
cells and keratinocytes were originated from a young donor’s foreskin. The keratinocytes were 
cultured in Keratinocyte-SFM (Life Technologies: 17005-042). The fibroblast cells and cancer cell 
lines were cultured in either Roswell Park Memorial Institute (RPMI) 1640 medium (Life 
Technologies: 21870-076) or Dulbecco's modification of Eagle's medium (DMEM, Life 
Technologies: 11960-044) as recommended by ATCC and ECACC, with supplement of 10% fetal 
bovine serum (FBS, Sigma-Aldrich: 12003C-500ML) and 1× Penicillin-Streptomycin-Glutamine 
(PSG, Life Technologies: 15140-122). The cells were cultured in tissue culture flasks or plates at 37 
˚C in 5% CO2 / 95% air unless otherwise stated. Cell morphology was observed and photographed 
by phase contrast microscopy. Cell number was counted using a haemocytometer. Trypan blue (Life 
Technologies: 15250-061) was used to distinguish live and dead cells.  
 
Cells in logarithmic growth phase were collected for cryopreservation by centrifugation at 150 – 300 
×g for 5 – 10 minutes. Pelleted cells were resuspended to at least 1.0×106 cells/mL in pre-chilled 
cryopreservation medium, which was composed of 70% basal medium, 20% FBS and 10% dimethyl 
sulfoxide (DMSO, Sigma-Aldrich: D8418-100ML). The cryovials which contained the cells were 
placed at 4 ˚C for 20 min, -20 ˚C for 30 minutes, and then -80 ˚C for 6 – 24 hours. For long term 
storage, the cryovials were transferred to a liquid nitrogen tank. For cell recovery, the cryovials were 
removed from the storage, and immediately placed in a 37 ˚C water bath with gentle shaking to allow 
the cell solution to thaw in 1 – 2 minutes. The cryopreservation media were then removed by 
centrifugation, and replaced with fresh complete medium.  
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Table 3-1. Human and mouse cells used in this study. 
Cells Cell types Cell culture media Sources 
HL-60 Leukaemia RPMI 1640 medium ATCC 
HL-60M Leukaemia RPMI 1640 medium mutation 
EL4 Lymphoma (mouse) DMEM ECACC 
EL4M Lymphoma (mouse) DMEM mutation 
HCC1954 Breast cancer RPMI 1640 medium ATCC 
MCF7 Breast cancer DMEM ATCC 
MDA-MB-231 Breast cancer DMEM ATCC 
T-47D Breast cancer RPMI 1640 medium ATCC 
PC-3 Prostate cancer RPMI 1640 medium Collaborative lab 
Hep G2 Hepatocellular carcinoma DMEM Collaborative lab 
Hep 3B Hepatocellular carcinoma DMEM Collaborative lab 
NCI-H2052 Mesothelioma RPMI 1640 medium ATCC 
NCI-H2452 Mesothelioma RPMI 1640 medium ATCC 
MSTO-211 Mesothelioma RPMI 1640 medium ATCC 
Fibroblast cells Normal DMEM Collaborative lab 
Keratinocytes Normal Keratinocyte-SFM Collaborative lab 
 
3.2.3 Cell treatment and collection 
In cell treatments, tissue culture plates/tubes were shaken gently for around 30 seconds to allow the 
cell culture media/solutions and treatment agents to be well mixed before returning to incubator. The 
presented concentrations of treatment agents were always the finial concentrations, unless otherwise 
stated. It was observed that crystals could form in DMEM with high-dose ascorbate over time, so 
only RPMI 1640 medium was used for ascorbate treatment. The variables of a cell model included 
cell type, density and culture medium. The variables of a cell treatment included concentration and 
combination of treatment agents and treatment duration.  
 
Cells grown in adhere cultures were dissociated from surface by 0.25% trypsin with 
ethylenediaminetetraacetic acid (EDTA) (Life Technologies: 25200-072) or TrypLE Express (Life 
Technologies: 12605-028) for 2 – 5 minutes. The old cell culture medium was removed and 2 – 3 mL 
per 25 cm2 surface area of trypsin was added. Cells could be washed once before trypsinization by 
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serum-free medium if necessary. Trypsinization of cells was monitored under an inverted phase 
contrast microscope to avoid over-trypsinization. Cells grown in suspension and those were 
dissociated by trypsin were collected by centrifugation at 300 – 500 ×g for 3 – 5 minutes.  
 
3.2.4 Cell viability assay 
AlamarBlue (Life Technologies: DAL1025) was used to measure metabolic cell viability. Ascorbate 
is a strong reductant, and can reduce alamarBlue, while H2O2 cannot (data not shown). To avoid the 
interference with ascorbate, cells were washed thoroughly with serum-free medium for at least twice 
before conducting an alamarBlue assay. Procedures were taken very gently to minimize washing off 
cells. As suggested by the manufacturer's instruction, 10 µL alamarBlue was added to each well of a 
96-well plate that contained 100 μL cell samples. After 30 seconds gentle shaking to mix the solutions, 
the plate was return to the cell culture incubator for 3 hours before measurement at excitation: 544 
nm and emission: 590 – 610 nm. The fluorescence intensity was linear to the number of viable cells 
(Figure S 2). In all the viability assays, the alamarBlue assay values were within the range that were 
linear to the viable cells, unless otherwise stated.  
 
3.2.5 Cell cycle analysis by flow cytometry 
HL-60 and HL-60M cells (5.0×105 cells/mL) were treated with ascorbate for 1 hour in 12-well plates 
(1 mL per well), and washed twice with RPMI 1640 medium (centrifugation at 300 ×g for 5 minutes). 
After cultured in the complete RPMI 1640 medium for another 20 hours, 1.0×106 cells were harvested 
and placed in a 15 mL tube. The cells were pipetted a few times to make a single-cell suspension, and 
pelleted by centrifugation at 300 ×g for 5 minutes. The cell culture medium was removed, and the 
cells was washed with 3 mL cold (4 °C) Dulbecco's phosphate-buffered saline (D-PBS; 2.67 mM 
KCl, 1.47 mM KH2PO4, 137.93 mM NaCl, 8.06 mM Na2HPO4-7H2O) twice. For the second wash, 
0.5 mL D-PBS was left in the tube and the cells were resuspended by brief vortex. Pre-chilled 90% 
ethanol (-20 °C) was added at a volume of 3.5 mL drop by drop with gentle vortexing. The cells were 
fixed at 4 °C overnight. The fixed cells were pelleted by centrifugation at 300 ×g for 5 minutes. After 
removing most of the ethanol, the cell pellets with the remaining ~0.2 mL ethanol were gently 
vortexed to avoid clumping. The cells were then washed twice with D-PBS + 1% FBS at a volume of 
3 mL, with centrifugation at 1000 ×g for 5 minutes. During the washes, ~0.2 mL D-PBS was left and 
then the cells were vortexed gently to avoid clumping. RNaseA (200 µg/mL, 0.3 mL) was added to 
make a final concentration of 120 µg/mL and incubated at room temperature for 10 minutes. Then 
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0.5 mL of 100 µg/mL propidium iodide (PI, final concentration: 50 µg/mL) in D-PBS was added and 
incubated at room temperature for 20 minutes. The cells were kept at 4 °C in dark before transferring 
to a Becton Dickinson tube (FALCON: 352054), and analysed on a Becton Dickinson FACS Canto 
flow cytometer machine. The cells should be filtered (35 µm) before loading to the machine if obvious 
clump was observed. The forward scatter (FSC) voltage was set to 49, the side scatter (SSC) voltage 
was set to 325 and the PI voltage was set to 419. The PI was excited at 488 nm by the argon-ion laser. 
The flow speed was set to low and acquired data for 10000 events. The flow cytometry data was 
analysed using FlowJo 7.6 and Becton Dickinson FACSDiva software. An example of analysis was 
shown in Figure S 3. 
 
3.2.6 Cell death analysis by flow cytometry 
Cell death type was determined using the Dead Cell Apoptosis Kit with Annexin V Alexa Fluor 488 
& Propidium Iodide (PI) - for Flow Cytometry (Life Technologies: V13241) following the 
manufacturer’s instruction. Briefly, the cells were collected after the treatment by centrifugation at 
300 ×g for 3 minutes. The cells were washed once with D-PBS, and then resuspended in 100 µL 1× 
annexin-binding buffer to 1.0×106 cells/mL. Alexa Fluor 488 annexin V (5 µL) and PI working 
solutions (100 µg/mL, 1 µL) were added to the cells and incubated at room temperature for 15 minutes. 
After the incubation, 400 µL 1× annexin-binding buffer was added and mixed gently. The samples 
were kept on ice until analysis. The analysis was carried out on a Becton Dickinson LSR II flow 
cytometry machine by measuring the fluorescence emission at 530 nm and 575 nm using 488 nm 
excitation. The flow cytometry data was analysed using Kaluza 1.2 (Beckman Coulter, Inc.).  
 
3.2.7 Intracellular hydrogen peroxide detection by flow cytometry 
The cell-permeable 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) is a commonly used 
indicator of endogenous reactive oxygen species level, though its intensity is not linear to the ROS 
level [130]. In this study, H2DCFDA (Sigma-Aldrich: D6883-50MG) was used as an indicator of the 
intracellular H2O2 levels. A 10 mM H2DCFDA stock solution was prepared by adding 10 mL DMSO 
to 50 mg H2DCFDA, and stored at -20 °C. The cells (2.0×105 cells/mL) in complete RPMI 1640 
medium were pre-treated with 10 μM H2DCFDA + 0.1% DMSO for 30 minutes in the cell culture 
incubator before any treatment. After the treatment, the cells were washed twice in RPMI 1640 
medium and placed in cold D-PBS and analysed on a Becton Dickinson LSR II flow cytometry 
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machine by measuring the fluorescence emission at 530 nm using 488 nm excitation. The flow 
cytometry data was analysed using Kaluza 1.2. 
 
3.2.8 Western blotting 
Cell lysates were prepared by adding Radioimmunoprecipitation assay (RIPA) buffer (25 mM Tris-
HCl pH 7.6, 150 mM sodium chloride (NaCl), 1% NP-40, 1% sodium deoxycholate, 0.1% sodium 
dodecyl sulphate) to cell pellets followed by 30 seconds of ultrasonication on ice. The protein 
concentration was determined using Pierce bicinchoninic acid (BCA) assay kit (Thermo Scientific: 
23227) following the manufacturer’s manual. The cell lysates were diluted in ultrapure distilled water 
at different concentrations for measurement e.g. from 1;10 to 1:100. Bovine serum albumin (BSA) 
standards was prepared in ultrapure distilled water (0, 25, 125, 250, 500, 750, 1000, 1500 and 2000 
µg/mL). Appropriate amount of RIPA buffer was added to the BSA standards to compensate the 
amount of RIPA buffer in the cell lysates. The prepared cell lysates and BSA standards were added 
at a volume of 20 μL to a 96-well plate. Reagent A and B (provided by the Pierce BCA assay) were 
mixed at a proportion of 1:50 to make a working solution and loaded to each well at a volume of 180 
μL. The plate was incubated at 37˚C in dark for 30 minutes and the absorbance was measured at 544 
nm. 
 
Proteins in cell lysates were separated using sodium dodecyl sulphate (SDS) polyacrylamide gel 
electrophoresis (SDS-PAGE). Cell lysates (containing 5 – 30 μg protein for each gel lane) were mixed 
with 4× loading buffer, and heated at 95˚C for 4 minutes. Then the samples were loaded on a 12% 
PAGE resolving gel with a 5% stacking gel, and run in SDS running buffer (25 mM Tris, 192 mM 
glycine, 0.1% SDS) at 90 V for 30 minutes and then 200 V for around 60 – 90 minutes. A Millipore 
Immobilon FL PVDF membrane (LI-COR, Millennium Science: 926-31098) was pre-treated in 
methanol for 5 minutes, and then it was used to transfer proteins from the gel in ice cold transfer 
buffer (25 mM Tris, 192 mM glycine, 20% methanol) at 90 V for 1 hour.  
 
The western blotting was done using simultaneous incubation with two antibodies using LI-COR 
Odyssey technology, following the manufacturer’s instruction. The membrane was blocked by 
odyssey blocking buffer (LI-COR: 927-40003) at 4 ˚C with continuous gentle shaking for overnight. 
The blocking reagent was in phosphate-buffered saline (PBS) containing 0.1% sodium azide, 
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however, the blocking reagent of the odyssey blocking buffer was not disclosed by the manufacturer. 
The primary antibodies, catalase (Santa Cruz: sc-271242), glutathione peroxidase 1 and 2 (Santa Cruz: 
sc-133160) and actin (Sigma-Aldrich: A2066-.2ML), were diluted 1:800 in odyssey blocking buffer 
with 0.1% Tween-20. The membrane was incubated with the primary antibody solution for 1.5 hours, 
and then washed for 5 minutes for 4 times in appropriate amount of D-PBS plus 0.1% Tween-20 with 
gentle shaking. Secondary antibodies, IRDye 800CW Donkey anti-Mouse IgG (LI-COR: 926-32212) 
and IRDye 680 Donkey anti-Rabbit IgG (LI-COR: 926-32223) were diluted 1:10000 in the odyssey 
blocking buffer with 0.1% Tween-20. The membrane was incubated with the secondary antibody 
solution for 30 minutes, protected from light with gentle shaking. Then the membrane was washed 
for 5 minutes for 4 times in appropriate amount of D-PBS plus 0.1% Tween-20 with gentle shaking. 
The membrane was rinsed in D-PBS and scanned on an LI-COR Odyssey scanner. The data was 
analysed using the Odyssey program (version 3.0). According to LI-COR, Odyssey western blotting 
is quantitative, given that pipetting error is minimized. The signal intensity is linear to the amount of 
2nd antibody. 
 
3.2.9 Catalase activity assay 
The catalase activity of cell lysate was measured using Amplex Red Catalase Assay Kit (Life 
Technologies: A22180) following the manufacturer’s manual. One unit (U) of catalase is defined as 
the amount of enzyme that will decompose 1.0 μmole of H2O2 per minute at pH 7.0 at 25 °C. The cell 
lysate was prepared by adding RIPA buffer to the cell pellets followed by 30 seconds of 
ultrasonication on ice. The experimental samples were cell lysates rather than purified catalase. Thus 
the activity measured might not be solely contributed by catalase. It was observed that RIPA buffer 
had inhibitory effect on catalase activity, however, it did not affect the relative catalase activities 
between different cell lines when compared at the same dilution. To avoid underestimation of the 
actual activity, RIPA buffer was also added to the standards.  
 
3.2.10 Total RNA extraction 
The total RNA was extracted using TRIzol (Life Technologies: 15596-018) following the 
manufacturer’s protocol. The tumour specimens were cut into small pieces (approximately 2 mm × 2 
mm × 2 mm) on dry ice using a surgical blade and tweezers. The cut pieces were immediately placed 
into a sterile 2 mL tube with 50 µL of TRIzol reagent, and homogenized using a small pestle until 
fine grinding, following an addition of 1 mL TRIzol. The cultured cells were pelleted by 
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centrifugation and washed with D-PBS once, following an addition of 1 mL TRIzol. The tubes 
containing cells and TRIzol were shaken vigorously for 15 seconds, and then left at room temperature 
for 10 minutes to permit complete dissociation of nucleoprotein complexes. Chloroform was added 
at a volume of 0.2 mL. The tubes were shaken vigorously for 15 seconds, and then left at room 
temperature for 2 – 3 minutes, followed by centrifugation at 12000 ×g at 4 °C for 15 minutes. The 
colourless aqueous phase was transferred to a fresh tube, and 0.5 mL isopropyl alcohol was added to 
precipitate the RNA at room temperature. After 10 minutes, the tubes were centrifuged at 10000 ×g 
at 4 °C for 20 minutes. The supernatant was removed carefully with pipette. The RNA pellet was 
washed with 75% ethanol once by centrifugation at 7500 ×g at 4 °C for 5 minutes. After the removal 
of the supernatant, the pellet was air-dried for 20 minutes, and then dissolved in 10 – 50 µL RNase-
free water (according to the size of pellet) by passing the solution a few times through a pipette tip, 
and incubated at 55 – 60 °C for 10 minutes. The RNA samples were stored in small aliquots at -80 
ºC before use. 
 
3.2.11 Agarose gel electrophoresis 
Appropriate amount of agarose was added to 1× TAE buffer: 40 mM Tris-acetate, 2 mM EDTA, pH 
8, and microwaved to boiling for a few seconds to get fully dissolved. Ethidium bromide (final 
concentration of 0.5 µg/mL) was added until the solution was left cool to around 60 ºC. Then the gel 
was casted in an agarose gel making apparatus. The RNA or DNA samples were mixed with 6× gel-
loading buffer: bromophenol blue 0.3% (w/v), EDTA (0.1 M, pH 8.0), SDS (0.5% w/v), sucrose 40% 
(w/v) in ultrapure distilled water and loaded to the agarose gel. The electrophoresis was run at 5V/cm 
for around 60 minutes in 1× TAE buffer. The gel was photographed as soon as possible using an 
ultraviolet gel scanner. The general RNA quality in this study was assessed by agarose gel 
electrophoresis. Figure S 4 showed three distinct bright bands from top to bottom in each lane, which 
were 28S, 18S and 5S ribosomal RNA. It indicated that the RNA samples were of sufficient quality 
to progress to further tests. 
 
3.2.12 Reverse-transcription quantitative real-time polymerase chain reaction 
To ensure the reliability of the RT-qPCR results, the minimum information for publication of 
quantitative real-time PCR experiments (MIQE) guidelines were employed [131]. In gene expression 
studies, the appropriate reference genes for normalization of RT-qPCR data should exhibit stable 
expression among all specimens, and using more than one reference gene should obtain more reliable 
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results [132]. The details of the RT-qPCR method were described in Chapter 5. The qPCR primers 
for CAT were 5’-AGCGGTCAAGAACTTCACT-3’ (Forward) and 5’-
TCGCATTCTTAGGCTTCTCA-3’ (Reverse). The difference in the qPCR efficiency of the target 
genes and reference genes in this study was minimum, as demonstrated by the similar shapes of their 
amplification plots as shown in Figure S 5. 
 
3.2.13 Statistical analysis 
Statistical analyses were performed in R (version 3.1.0, R Development Core Team, 2014) and 
Microsoft Excel 2010. All the P values presented were two-sided, and were derived from testing the 
null hypothesis that the difference between treatment and control were equal to 0 or there was no 
correlation between the tested variables. P values < 0.05 were considered as significant in the study 
unless otherwise stated. 
 
3.3 Cancer cells are more sensitive to pharmacologic ascorbate compared 
with normal cells 
Pharmacologic ascorbate exhibited dose-dependent cytotoxicity on a range of cells in vitro (Figure 
3-1). Two normal cell types and eleven cancer cell lines were exposed to sodium ascorbate at a series 
of concentrations for 1 hour, and the cell viability was determined 24 hours after the treatments. The 
cancer cells were more sensitive to pharmacologic ascorbate treatments than the normal cells. The 
primary normal keratinocytes and fibroblast cells were almost resistant (> 90% survival) up to the 
highest concentration of ascorbate (19.2 mM), while the most resistant cancer cell line NCI-H2452 
had only about 50% viability and the most sensitive cancer cell lines HL-60, EL4 and EL4M had zero 
viability under the same condition. Sodium chloride at the same concentrations or higher (up to 60 
mM) had no observable effects on the cells (Figure S 6), indicating that both osmolality and sodium 
load were not contributing to the ascorbate-induced cytotoxicity. Ascorbate at the physiological 
concentrations of 0 – 200 µM had no observable effect on the proliferation of NCI-H2052 or NCI-
H2452 cells (Figure S 7). 
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Figure 3-1. Effects of pharmacologic ascorbate on cancer and normal cells. 
(A) The effect of 1-hour ascorbate treatment on cell viability. The cells in logarithmic growth phase 
were seeded in their recommended growth media (1.0×105 cells/mL). After 24 hours, the cell culture 
media were changed to RPMI 1640 medium supplemented with 10% FBS and 1× PSG. The cells 
were then exposed to sodium ascorbate (0 – 19.2 mM, pH 7.0) for 1 hour. After the treatment, the 
cells were washed three times with RPMI 1640 medium, and cultured in their recommended growth 
media for another 24 hours. The viability of the cells was determined by alamarBlue. Data represented 
were the mean ± SD of six repeats. (B) Representative 24-hour post-treatment morphology of MCF7 
cells (phase contrast microscopy; magnification: 200×; red scale bar: 50 μm).  
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3.4 Hydrogen peroxide is an intermediate of the cytotoxicity of ascorbate 
H2O2 has been proposed to be an intermediate of the cytotoxicity of ascorbate [72]. Here, we 
confirmed this by demonstrating that catalase, a specific membrane-impermeable H2O2 scavenger 
could completely block the cytotoxic effect of 1-hour 19.2 mM ascorbate treatment on HL-60 cells 
(Figure 3-2), one of the most sensitive cell lines to ascorbate treatment that was used in this study 
(Figure 3-1).  
 
 
Figure 3-2. Inhibitory effect of catalase on cytotoxicity of ascorbate. 
HL-60 cells (2.0×105 cells/mL) in complete RPMI1640 medium were exposed to 19.2 mM ascorbate 
with or without catalase (20, 100 and 500 U/mL) for 1 hour. After the treatment, the cells were washed 
three times with RPMI 1640 medium, and cultured in complete RPMI 1640 medium for another 24 
hours. Catalase was always added before the ascorbate treatment. The viability of the cells was 
determined by alamarBlue. Data represented were the mean ± SD of six repeats.  
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Two protocols of ascorbate treatments were designed and performed on two mesothelioma cell lines 
(Figure 3-3 A) to demonstrate that the cytotoxicity of ascorbate should be dependent on the 
accumulated exposure to H2O2 that were produced by ascorbate but not the accumulated exposure to 
ascorbate, which was proposed in the previous chapter. The 1,3,5h ascorbate treatment protocol could 
achieve the similar levels of cytotoxicity at much lower initial ascorbate concentrations than the 1h 
ascorbate treatment protocol (Figure 3-3 B). For example, the 1,3,5h ascorbate treatment could reduce 
the cell viability to below 20% in both cell lines at an initial ascorbate concentration of 2.4 mM, while 
in the 1h ascorbate treatment, cells still have over 40% viability after being treated with 19.2 mM 
ascorbate, which was 8 times as high (Figure 3-3 B). The accumulated exposure to ascorbate for the 
cells in the 19.2 mM (8×) ascorbate treatment of the 1h protocol and in the 2.4 mM (1×) ascorbate 
treatment of the 1,3,5h protocol were compared as in Figure 3-3 C. The product of ascorbate 
concentration and treatment duration were 8 and 2.5, respectively. This could not explain the 
difference in the induced cytotoxicity levels. According to the previous estimation (Figure 2-5), the 
accumulated exposure to the estimated concentrations of H2O2 produced by 19.2 mM (8×) ascorbate 
in the 1h protocol and 2.4 mM (1×) ascorbate in the 1,3,5h protocol could be plotted as in Figure 3-3 
D. The product of the estimated concentration of H2O2 and treatment duration were 4 and 4.5, 
respectively. It was more reasonable to explain the difference in the induced cytotoxicity levels. 
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Figure 3-3. Ascorbate-induced cytotoxicity depends on accumulation of hydrogen peroxides. 
(A) Schematic diagram for the two ascorbate treatment protocols. The cells (8.0×104 cells/mL) in 
logarithmic growth phase were cultured in RPMI 1640 medium with 10% FBS and 1× PSG for 24 
hours. For the 1h ascorbate treatment, the cells were exposed to serial concentrations of ascorbate (0 
- 19.2 mM, pH 7.0) for 1 hour. After the treatment, the cells were washed with RPMI 1640 medium 
for three times and cultured in complete RPMI 1640 medium for 24 hours before the cell viability 
assay was performed. For the 1,3,5h ascorbate treatment, the cells were exposed to the same serial 
concentrations of ascorbate for 1h, and then the ascorbate concentrations were reduced to 50% by 
replacing half of the media with fresh complete media at the end of the 1st hour and further reduced 
to 1/4 and 1/8 at the end of the 3rd and 5th hour. After the treatment, the cells were washed with 
RPMI 1640 medium for three times and cultured in complete RPMI 1640 medium for 20 hours before 
the cell viability assay was performed. (B) Viability of the cells after treated with the two different 
ascorbate treatments. The cell viability was determined using alamarBlue. Data represented were the 
mean ± SD of six repeats. (C) Comparison of the ascorbate concentrations and (D) the estimated 
H2O2 concentrations that the cells were exposed in the two ascorbate treatments, where the ascorbate 
concentration in the 1h ascorbate treatment was set to be 8 times as high as the initial ascorbate 
concentration in the 1,3,5h ascorbate treatment. 
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We hypothesized that the cells might become more sensitive to ascorbate treatment if the cellular 
catalase activity could be inhibited. It was reported that 3-amino-1,2,4 triazole (3-AT) could inhibit 
catalase activity irreversibly [133], and 3-AT pre-treatment could sensitise Ehrlich ascites carcinoma 
cells to ascorbate treatment [23]. In a catalase activity assay, 30 mM 3-AT could almost completely 
(> 99%) inhibit the activity of 4 U/mL catalase and the activity of catalase in 300 μg/mL EL4 and 
HL-60 cell lysates (data not shown). However, 3-AT pre-treatment could only slightly sensitise Hep 
G2 cells (hepatocellular carcinoma) to ascorbate treatment but not for the primary fibroblast (Figure 
3-4), NCI-H2052 or NCI-H2452 cells (data not shown). 
 
It was reported that 3-AT was permeable to liver cells but not blood cells [134], and the mechanism 
was unclear. Antunes and Cadenas reported that in the JurkatT-cells, the intracellular glutathione 
peroxidase activity was responsible for most of the H2O2 consumption in cytosol, while the catalase 
activity was only responsible for less than 10% of the removal of H2O2 in the cells [123]. The limited 
effect of 3-AT pre-treatment might be due to the possible inefficient permeability of 3-AT to the cell 
types that were used, and/or the possible limited contribution of catalase to the total H2O2 
decomposing capability of the cells. 
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Figure 3-4. Effects of ascorbate on 3-amino-1,2,4 triazole pre-treated cells. 
Primary fibroblast cells (8.0×104 cells/mL) and Hep G2 cells (1.5×105 cells/mL) in logarithmic 
growth phase were cultured in DMEM supplemented with 10% FBS and 1× PSG for 24 hours. The 
Hep G2 cells were pre-treated with 30 mM of 3-AT for 1 hour. The primary fibroblast cells were pre-
treated with 20 mM of 3-AT for 30 hours. Then the cells were exposed to ascorbate at a serials of 
concentrations (0 – 19.2 mM, pH 7.0) for 1 hour. After the treatment, the cells were washed with 
DMEM twice and cultured in complete DMEM for another 24 hours. The cell viability was measured 
using alamarBlue assay.  The data represented were the mean ± SEM of six repeats.  
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3.5 Associations between the cytotoxicity of ascorbate and some cellular and 
molecular variables 
Cells have differential responses to ascorbate treatment (Figure 3-1). Two pairs of cells that were 
derived from the same genetic lineage were used to assess the possible cellular and molecular 
variables that might be associated with the differential responses of cells to pharmacologic ascorbate 
(Table 3-2). EL4 cell line (mouse lymphoma) was newly purchased from ATCC, and EL4M was an 
EL4 cell line that was mutated during cell culture after many passages. HL-60 cell line (human 
leukaemia) was newly purchased from ECACC, and HL-60M was a HL-60 cell line that was mutated 
during cell culture after many passages. 
 
In order to compare the sensitiveness to ascorbate treatment, different cells are usually treated with 
ascorbate at the same density. However, the difference in the volume of cells is usually not considered. 
EL4M cells were much more sensitive to ascorbate treatment compared with EL4 cells (Figure 3-5 
C). EL4 is a suspension cell line. However, unknown mutations made EL4M cells significantly 
smaller and slightly adherent to the cell culture surface (Figure 3-5 A). The average volume of EL4 
cells was approximately twice as large as that of EL4M cells as indicated by the morphology and the 
amount of protein (as well as total RNA, data not shown) per cell (Figure 3-5 E). Interestingly, EL4 
and EL4M cells still proliferated at the similar speed (Figure 3-5 B). EL4 cells had similar protein 
expression and activity of catalase per μg of cell lysate (Figure 3-5 D). Since EL4 cells were twice as 
large as EL4M cells, the catalase activity in an average EL4 cell was also around twice as high as that 
in an average EL4M cell. Glutathione peroxidase 1 and 2 proteins were not detectable by western 
blotting in the two cell lines (data not shown), which implicated that catalase might be the major H2O2 
decomposing enzyme in the two cells. The larger amount of catalase in EL4 cells might thus help 
them experience lower intracellular H2O2, and as a result be more resistant to ascorbate treatment 
compared with EL4M cells at the same cell density. The surface to volume ratio of bigger cells are 
smaller, which implicates lower membrane permeability rate for H2O2 (details in Chapter 2). This 
might also add advantage to EL4 cells in the ascorbate treatment. 
 
HL-60 cells were more sensitive to ascorbate treatment compared with HL-60M cells (Figure 3-6 C). 
HL-60 cells had significantly higher glutathione peroxidase 1 and 2 protein expression levels but 
lower protein expression and activity of catalase per μg of cell lysate protein compared with HL-60M 
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cells (Figure 3-6 D). Since HL-60 cells were slightly larger than HL-60M cells (indicated by the 
morphology and the amount of protein per cell), the catalase activity of an average HL-60 cell was 
similar as that in an average HL-60M cell (Figure 3-6 E). Thus the overall H2O2 decomposing 
capability of HL-60 cells seemed to be higher than that of HL-60M cells, which could not explain 
why HL-60 cells were more sensitive to ascorbate treatment.  
 
Although HL-60 cells were slightly larger than HL-60M cells, they grew significantly faster than HL-
60M cells in the same complete RPMI medium (Figure 3-6 B). Cell cycle analysis revealed that HL-
60 cells had larger proportion of cells at S phase compared with HL-60M cells (Figure 3-7). The 
viability of the two cell lines could both be reduced in a 1-hour 0.3 mM ascorbate treatment. After 
the treatment, the distribution of cell cycle phases in the survived HL-60 cells was significantly 
altered (P = 1.6×10-11, Fisher's Exact Test). Especially, the proportion of cells at S phase was 
significantly reduced. The results implicated that cells at S phase were more vulnerable to H2O2 
damage. However, the distribution of cell cycle phases in the survived HL-60M cells was not affected 
by the same treatment.  
 
Table 3-2. Summary of the results from the study on the two pairs of cells. 
 HL-60, compared with HL-60M EL4 compared with EL4M 
Response to ascorbate 
treatment 
More sensitive Less sensitive 
Glutathione peroxidase 1 & 
2 protein expression per cell 
Significantly higher Both undetectable 
Catalase protein expression 
and activity per cell 
Similar Twice as high 
Average volume of cell Slightly larger Twice as large 
Growth rate Much faster Similar 
Cell cycle analysis More cells in S phase Not available 
Effect of ascorbate treatment 
on cell cycle distribution 
HL-60: proportion of cells at S and 
G2/M phases dramatically reduced 
after the treatment;  
HL-60M: No effect. 
Not available 
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Figure 3-5. Cell model of EL4 and EL4M. 
(A) Morphology of EL4 and EL4M cells (phase contrast microscopy; magnification: 200×; red scale 
bar: 50 μm). (B) Growth curve of EL4 and EL4M cells. The cells were seeded at 5.0×104 cells/mL in 
complete RPMI medium, and the number of cells was counted using a haemocytometer over five 
days. Data represented were the mean ± SD of four repeats. (C) The cells at a density of 2.0×105 
cells/mL were treated with ascorbate at different concentrations for 1 hour. After the treatment, the 
cells were washed with serum-free RPMI 1640 medium for three times, and cultured in complete 
RPMI media for another 24 hours. The viability of the cells was determined using alamarBlue assay. 
Data represented were the mean ± SEM of six repeats. (D) Representative western blots of catalase 
and actin from two independent experiments. Total protein lysates (30 μg total protein) of the two 
cells were separated by SDS-PAGE (12%). The protein expression of catalase and actin (as a 
reference) was measured using Odyssey western blotting technology. (E) The catalase activity of EL4 
and EL4M cells. The catalase activity was measured in the cell lysate using Amplex Red Catalase 
Assay. The average amount of protein for a cell was determined using BCA assay, and the average 
catalase activity per cell was thus calculated. Data represented were the mean ± SD of duplicate 
experiments.  
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Figure 3-6. Cell model of HL-60 and HL-60M. 
(A) Morphology of HL-60 and HL-60M cells (phase contrast microscopy; magnification: 200×; red 
scale bar: 50 μm). (B) Growth curve of HL-60 and HL-60M cells. The cells were seeded at 5.0×104 
cells/mL in complete RPMI medium, and the number of cells was counted using a haemocytometer 
over five days. Data represented were the mean ± SD of four repeats. (C) The cells at a density of 
2.0×105 cells/mL were treated with ascorbate at different concentrations for 1 hour. After the 
treatment, the cells were washed with serum-free RPMI 1640 medium for three times, and cultured 
in complete RPMI media for another 24 hours. The viability of the cells was determined using 
alamarBlue assay. Data represented were the mean ± SEM of six repeats. (D) Representative western 
blots of glutathione peroxidase 1 and 2 (GPx), catalase and actin from two independent experiments. 
Total protein lysates (30 μg total protein) of the two cells were separated by SDS-PAGE (12%). The 
protein expression of GPx, catalase and action (as a reference) was measured using Odyssey western 
blotting technology. (E) The catalase activity of HL-60 and HL-60M cells. The catalase activity was 
measured in the cell lysate using Amplex Red Catalase Assay. The average amount of protein for a 
cell was determined using BCA assay, and the average catalase activity per cell was thus calculated. 
Data represented were the mean ± SD of duplicate experiments.  
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Figure 3-7. Cell cycle analysis of HL-60 and HL-60M cells. 
Representative cell cycle analysis plots of (A) HL-60 cells (no treatment control), (B) HL-60 cells 
treated with 0.3 mM ascorbate for 1 hour, (D) HL-60M cells (no treatment control) and (E) HL-60M 
cells treated with 0.3 mM ascorbate for 1 hour. The cell cycle analysis was done 24-hour post-
treatment using propidium iodide staining. Single cells were gated using SSC-A and FSC-A. The x-
axis was the intensity of propidium iodide, which was in proportion to the amount of DNA per cell. 
The y-axis was the number of counted cells. (C) Comparison of the proportion of HL-60 cells in 
G1/G0, S and G2/M phases in panels (A) and (B). (D) Comparison of the proportion of HL-60M cells 
in G1/G0, S and G2/M phases in panels (D) and (E). Data represented were the mean ± SD of 
duplicate experiments. 
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3.6 Oxidation of ascorbate 
Ascorbate can be oxidized to DHA [73]. Sodium ascorbate is transparent in aqueous medium, while 
sodium dehydroascorbate is yellowish. It was observed that the freshly prepared 1M sodium ascorbate 
solution (pH 7.0, in ultrapure distilled water) could spontaneously turn from transparent to light 
yellowish in capped Eppendorf tubes within days at room temperature, and the same process could 
be completed within hours when the solution was exposed to the air, indicating the oxidation of 
ascorbate to DHA and the involvement of oxygen. The absorbance of sodium dehydroascorbate 
solution at 450 – 544 nm was linearly correlated with its concentration with an R2 of 0.9999 (Figure 
S 8). Here, the absorbance at 450 nm was used as an indicator of the oxidation of ascorbate in the cell 
culture medium.  
 
Oxidation of ascorbate in DMEM was faster than in RPMI 1640 medium (Figure 3-8), which was in 
consistency with our observation that ascorbate exhibited higher cytotoxicity to cancer cells cultured 
in DMEM than those cultured in RPMI 1640 medium (data not shown). The results were also in 
agreement with Clement’s study which showed that 1 mM ascorbate generated 161 ± 39 μM H2O2 in 
DMEM and induced apoptosis in 50% of HL-60 cells, whereas it produced only 83 ± 17 μM H2O2 
and 0 apoptosis in RPMI 1640 medium [135]. A possible explanation is that DMEM contains Fe3+, 
an enhancer of H2O2 production by ascorbate, while RMPI contains GSH, an inhibitor of H2O2 
production by ascorbate [100, 136].  
 
The removal of H2O2 by catalase could shift the reaction equilibrium towards DHA (Figure 3-8). In 
Figure 3-1, the viability of most cancer cells dropped sharply when the ascorbate concentrations were 
increased at its lower range. A possible explanation might be that when the cell density was low, the 
extracellular H2O2 could gradually accumulate to a certain concentration and slow down further 
oxidation of ascorbate. Thus the actual extracellular H2O2 might be maintained at a level and not be 
in proportion to the ascorbate concentrations, as noted in Chen et al.’s report [72]. 
 
The absorbance at 450 nm of the medium containing ascorbate increased over time (Figure 3-9 and 
Figure 3-10). In the first 3.5 hours, the spectrometry was not sensitive enough to identify any changes. 
In the first 10 hours, the log-transformed values of absorbance increased almost linearly with time. 
After that, the rate of increase slowed down and the values of absorbance appeared to increase linearly 
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with time and then started to reach a plateau at around the 30th hour (Figure 3-9). The absorbance of 
the medium containing DHA also increased over time, which was not expected (Figure 3-10). The 
absorbance curve of the medium containing ascorbate between the 10th and 30th hours was similar as 
the absorbance curve of the medium containing DHA during the first 20 hours, and the maximum 
absorbance of the medium containing ascorbate was significantly higher than the initial absorbance 
of the medium containing DHA (Figure 3-10). These results implicated that something contributing 
to the absorbance at 450 nm was formed in the medium containing DHA, which should be further 
investigated. The absorbance of the medium containing DHA started to fall after 20 hours. This might 
be due to the inevitable evaporation of the medium during the experiment. In Figure 3-9, the 
absorbance at 450 nm was lower in the medium that contained more cells, implicating a portion of 
ascorbate and/or DHA was absorbed by the cells. 
 
Fetal bovine serum might have inhibitory effect on the oxidation of ascorbate (Figure 3-10). It was 
reported that in RPMI medium supplemented with serum, ascorbate started to function as pro-oxidant 
at the concentration of around 200 μM, while in the serum-free medium it started to function as pro-
oxidant at the concentration of around 100 μM [137]. This could be supported by the results that the 
cells in the complete medium had higher cell viability than those in the serum-free medium after 1-
hour ascorbate treatment (Figure S 9), which  was also consistent with Sakagami et al.’s report that 
added serum could protect cells under ascorbate-induced cytotoxicity [138]. The differential 
ascorbate-induced cytotoxicity might also dependant on cell’s ability to use components (unknown) 
in serum that could afford protection thereby avoiding cell death. When serum was removed during 
the ascorbate treatment, the normal primary fibroblast cell lost its resistance to ascorbate treatment, 
and became even more sensitive to ascorbate treatment than the breast cancer cell line HCC1954 
(Figure S 9).  
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Figure 3-8. Oxidation of ascorbate in DMEM and RPMI 1640 medium with or without catalase. 
Sodium ascorbate was made to different concentrations with or without 500 U/mL catalase (CAT) in 
DMEM and RPMI 1640 medium supplemented with 10% FBS and 1× PSG. The media were put in 
a 96-well plate and incubated at 37 ˚C in 5% CO2 / 95% air until every measurement. The absorbance 
at 450 nm was measured at 13 intervals in 24 hours. The data presented were the absorbance values 
subtracted from those of relevant media which contained no ascorbate. Data represented were the 
mean ± SD of four repeats.  
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Figure 3-9. Comparison of oxidation of ascorbate in complete RPMI 1640 medium with cells. 
Fibroblast cells were seeded at different densities in RPMI 1640 medium with 10% FBS and 1× PSG 
in a 96-well plate. Ascorbate (20 mM) and catalase (500 U/mL) were added to the medium. The plate 
was incubated at 37 ˚C in 5% CO2 / 95% air until every measurement. The absorbance of the media 
at 450 nm was measured at 26 intervals over 30 hours. The data presented were the absorbance values 
subtracted from those of relevant media which contained no ascorbate. Data represented were the 
mean ± SD of four repeats. The insert was the log scale (y-axis) view of the same data.  
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Figure 3-10. Comparison of oxidation of ascorbate and dehydroascorbate in RPMI 1640 
medium with different FBS concentrations. 
Ascorbate and DHA in combination with 500 U/mL catalase (CAT) were added to RPMI 1640 
medium containing different concentrations of FBS. The absorbance of the media at 450 nm was 
measured at 26 intervals over 30 hours. The media were incubated at 37 ˚C in 5% CO2 / 95% air until 
every measurement. The data presented were the absorbance values subtracted from those of relevant 
media which contained no ascorbate or DHA. Data represented were the mean ± SD of four repeats. 
Negative values for the ascorbate media were obtained in the first 3.5 hours. 
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3.7 Dehydroascorbate is also an intermediate of the cytotoxicity of ascorbate 
Our preliminary data showed that large amount of catalase (640 U/mL) could block the cytotoxicity 
of 30 and 60 mM ascorbate on PC-3 cells in the first 8 hours but not for longer periods of time (Figure 
S 6). Here, it was shown that ascorbate could induce more cell death in MCF7 (Figure 3-11) and NCI-
H2452 cells (Figure 3-12) compared with DHA. However, in the presence of large amount of catalase, 
the cytotoxicity of ascorbate reduced more dramatically, and ascorbate became less cytotoxic 
compared with DHA, though both agents still exhibited dose- and time-dependent cytotoxicity 
(Figure 3-11 and Figure 3-12). Catalase is a very efficient membrane-impermeant H2O2 decomposing 
enzyme [72]. In the experiment, catalase was always added to the medium before ascorbate or DHA 
treatment. If H2O2 was the sole intermediate of the cytotoxicity of ascorbate, the removal of the 
produced extracellular H2O2 by large amount of catalase should entirely block the cytotoxicity of 
ascorbate. Thus the results indicated that the cytotoxicity of ascorbate in the presence of catalase 
should be due to or at least largely due to DHA instead of ascorbate itself or a potential build-up of 
extracellular H2O2 that was produced during the treatment; otherwise, ascorbate should be more toxic 
than DHA as it had higher capability to produce H2O2.  
 
In Chapter 1, we proposed that DHA at millimolar concentrations might antagonize the glucose 
uptake of cancer cells, and as a result reduce or inhibit glycolysis. Here, it was shown that pyruvate, 
a product of glycolysis, but not glucose showed some protective effect on the DHA-induced 
cytotoxicity in MCF7 (Figure 3-11 and Figure S 10) and NCI-H2452 cells (Figure 3-12). Although 
pyruvate could also slightly enhance the cell growth in the control cells, the protective effect on the 
cells treated with DHA did not seem to be simply a reflection of that. According to our observation 
under the microscope during the treatment, pyruvate treatment seemed to be able to delay the cell 
death for several hours, however, it could not inhibit cell death.  
 
The effect of DHA was not due to potential change of pH or loss of catalase activity during the 
treatment. Compared with the control, the pH of the media that were collected after the 24-hour 30 
mM DHA treatment only dropped less than 0.1, which was negligible. The amount of catalase (500 
U/mL, Sigma-Aldrich: C9322-10G) added in the treatment was calculated based on the 
manufacturer’s indicated activity per μg protein. After the 24-hour treatment, the activity of catalase 
in the cell culture medium surprisingly exceeded 1000 U/mL as measured using Amplex Red Catalase 
Assay Kit (Life Technologies: A22180). Although it was not possible to tell how much catalase 
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activity might be lost over 24 hours, if there was any, the remaining catalase should still be far in 
excess. This could be supported by the previous data which showed that 20 U/mL catalase could 
completely block the cytotoxic effect of a 1-hour 19.2 mM ascorbate treatment on HL-60 cells (Figure 
3-2). In addition, at concentrations of as low as 0.4 – 0.8 U/mL, catalase still showed protective effect 
on HL-60 cells in a 200 μM H2O2 treatment (Figure S 11). 
 
 
Figure 3-11. Comparison of cytotoxicity of ascorbate and dehydroascorbate on MCF7 cells. 
MCF7 cells were seeded at a density of 5.0×104 cells/mL in complete RPMI medium in a 96-well 
plate. After 24 hours, the cells were treated with ascorbate for (A) 24 hours or (C) 48 hours, or treated 
with DHA for (B) 24 hours or (D) 48 hours. Catalase (500 U/mL), glucose (20 mM) and/or pyruvate 
(4 mM) were added in the ascorbate and DHA treatment. Catalase was always added before other 
drugs. The cells were then washed twice and the viability was measured by alamarBlue. Data 
presented were the mean ± SD of three repeats. 
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Figure 3-12. Comparison of cytotoxicity of ascorbate and dehydroascorbate on NCI-H2452 cells. 
NCI-H2452 cells were seeded at a density of 5.0×104 cells/mL in complete RPMI medium in a 96-
well plate. After 24 hours, the cells were treated with ascorbate for (A) 24 hours or (C) 48 hours, or 
treated with DHA for (B) 24 hours or (D) 48 hours. Catalase (500 U/mL), glucose (20 mM) and/or 
pyruvate (4 mM) were added in the ascorbate and DHA treatment. Catalase was always added before 
other drugs. The cells were then washed twice and the viability was measured by alamarBlue. Data 
presented were the mean ± SD of three repeats.  
 
3.8 Synergistic cytotoxic effects of dehydroascorbate and arsenic trioxide on 
HL-60 cells 
HL-60 was one of the most sensitive cancer cell lines to ascorbate treatment that were used in this 
study (Figure 3-1). HL-60 is a leukaemia cell line that was derived from a 36-year-old woman with 
acute promyelocytic leukaemia (APL). Arsenic trioxide has been shown to be effective on APL in 
doses of 0.06 – 0.2 mg/kg body weight/day [139]. The United States Food and Drug Administration 
has approved arsenic trioxide injection to be used to treat APL in patients whose disease has not 
gotten better with other chemotherapy or has recurred [140]. Plasma concentration of As2O3 could 
reach a peak level of 5.54 – 7.30 μM after one dose of 10 mg in relapsed APL patients [141]. It was 
reported that the cytotoxic effect of 6 μM As2O3 could be significantly enhanced by 100 μM ascorbate 
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on HL-60 cells [142]. In this Chapter, the synergistic cytotoxicity of DHA and As2O3 was investigated 
on HL-60 cells. 
 
DHA and As2O3 both exhibited dose- and time-dependent cytotoxic effects on HL-60 cells (Figure 
3-13). The combination of the two agents showed synergistic cytotoxic effects on HL-60 cells (Figure 
3-13). Similar as ascorbate, the cytotoxic effects of both agents were also dependent on cell density 
(Figure 3-14 A). Catalase had no effect on the cytotoxicity of As2O3, which indicated that 
extracellular H2O2 was not a participant in the As2O3-induced cytotoxicity (Figure 3-14 A).   
 
HL-60 cells exposed to 5 μM As2O3 for 20 hours exhibited lower cell viability than those exposed to 
5 mM DHA for the same duration in the presence of catalase (Figure 3-14 A). Larger proportion of 
live cells and cells at the late stage of apoptosis but lower proportion of cells at the early stage 
apoptosis were observed in the cells treated with 5 μM As2O3 compared with the cells treated with 5 
mM DHA (Figure 3-14 B and C). Here, the alamarBlue assay measured the metabolic cell viability, 
while the cell death analysis measured the proportion of the types of cell death. The results indicated 
that the cells undergoing early stage of apoptosis should contribute more than those undergoing late 
stage of apoptosis to the reading of alamarBlue viability assay.  
 
In flow cytometry, the forward scatter and the side scatter signalling intensities are considered 
positively correlating with the volume of cell and the inner complexity of cell, respectively [143]. In 
this study, the area of FSC (FSC-A) and SSC (SSC-A) were recorded for the live cells after the 
treatment (Figure 3-14 D). It was noted that the median FSC-A of the cells that survived the 5 μM 
As2O3 treatment was slightly reduced, while the median FSC-A of the cells that survived the 5 mM 
DHA treatment and the combined 5 μM As2O3 and 5 mM DHA treatment was significantly increased. 
The medians of the SSC-A of the cells survived the three treatments were all significantly increased. 
 
Pre-treatment of H2DCFDA had no significant effect on the viability of HL-60 cells during the DHA 
and As2O3 treatments (Figure 3-14 A). After the treatments, higher levels of H2DCFDA signalling 
intensity was observed in all treatment groups, especially in the cells treated with the combination of 
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As2O3 and DHA (Figure 3-14 E). The results implicated the involvement of ROS in the induced 
cytotoxicity. 
 
 
Figure 3-13. Synergistic cytotoxicity of dehydroascorbate and arsenic trioxide on HL-60. 
(A) Cell viability of HL-60 cells (2.0×105 cells/mL, in complete RPMI 1640 medium) that were 
treated with different combinations of DHA (0, 5 and 10 mM) and As2O3 (0, 2 and 4 μM) in the 
presence of catalase (500 U/mL) for 12 hours. The cells were washed twice with RPMI 1640 medium 
and then cultured in complete RPMI 1640 medium for another 12 hours until the cell viability was 
measured by alamarBlue. (B) Cell viability of HL-60 cells (5.0×105 cells/mL, in complete RPMI 
1640 medium) that were treated with different combinations of DHA (0, 5 and 10 mM) and As2O3 (0, 
1, 2 and 4 μM) in the presence of catalase (200 U/mL) for 24 hours. The cells were washed three 
times with RPMI 1640 medium and the cell viability was measured by alamarBlue. (C) 
Representative morphology of HL-60 cells (same cells from panel B) after the treatments (phase 
contrast microscopy; magnification: 100×; red scale bar: 100 μm). Dead cells were stained with 
Trypan blue. Data presented were the mean ± SD of two repeats. 
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Figure 3-14. Cell death types and ROS levels in HL-60 cells treated with dehydroascorbate and 
arsenic trioxide. 
(A) Cell viability of HL-60 cells (1.0×106 cells/mL or 2.0×105 cells/mL) that were treated with 5 μM 
As2O3, 5 mM DHA alone or in combination with or without 500 U/mL catalase (CAT) in complete 
RPMI 1640 medium for 20 hours. Some cells (2.0×105 cells/mL) were pre-treated with 10 μM 
H2DCFDA + 0.1% DMSO for 30 minutes before the As2O3 and DHA treatments. The cell viability 
was measured by alamarBlue assay. (B) Representative plots of cell death analysis and (C) the 
proportion of the types of cell death in the HL-60 cells (2.0×105 cells/mL) after the As2O3 and DHA 
treatments. The death types induced by the treatment were determined using Dead Cell Apoptosis Kit 
with Annexin V Alexa Fluor® 488 & Propidium Iodide (PI). (D) The relative medians and SD of 
FSC-A and SSC-A for the live cells in panel (C). The number of live cells, N, was shown at the 
bottom. (E) The relative medians and SD of the H2DCFDA signal intensity in the H2DCFDA pre-
treated HL-60 cells (2.0×105 cells/mL) after the As2O3 and DHA treatments. The flow cytometry data 
presented in (B – E) were the mean ± SD of two repeats, and were obtained from 10000 events gated 
using FSC-A and SSC-A. *** P values < 0.0001, derived from t-test.  
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3.9 Expression of selected genes that may be associated with cell responses 
to ascorbate 
The in vitro studies above demonstrated that cancer cells were generally more sensitive to ascorbate 
compared with normal cells, and different cancer types and cell lines had differential responses to 
ascorbate. Here, the expression levels of the genes that might determine the differential sensitiveness 
of cells, such as catalase (CAT), glutathione peroxidases (GPXs) and glucose transporters (GLUTs), 
were investigated in breast tumours and matched normal tissues using The Cancer Genome Atlas 
(TCGA) microarray data (Table 3-3, details of the methods were described in Chapter 5). As reviewed 
in Chapter 1 and discussed in Chapter 2, catalase and glutathione peroxidases can decompose H2O2, 
thus cells with more of these proteins may experience lower levels of intracellular H2O2 during 
ascorbate treatment. Glucose transports, specifically GLUT1, GLUT3 and GLUT4, could transport 
DHA into the cells [67], thus cells with more of these glucose transporters may absorb DHA faster 
and as a result have a higher DHA-induced cytotoxicity. 
 
The results showed that the mRNA levels of CAT, GPX2 and GPX3 were significantly lower, while 
the mRNA levels of GLUT1 was significantly higher in primary breast tumours compared with the 
paired normal tissues (Table 3-3). The data were in agreement with the previous results that cancer 
cells were more sensitive to ascorbate compared with normal cells. Lower expression of GLUT4 was 
observed in the breast tumours compared with the normal tissues, however, its absolute level 
compared with GLUT1 could not be determined from these data. To further clarify the association of 
these genes with the differential sensitiveness of cells to ascorbate, further protein studies should be 
conducted. 
 
The mRNA expression of catalase was also measured by RT-qPCR in 71 breast cancer biopsies 
(details of the methods were described in Chapter 5). The grade 3 breast tumours had significantly 
the lowest mRNA expression of catalase (Figure 3-15). Ascorbate treatment was unlikely to change 
the expression of catalase in the breast cancer cells (Figure S 12), which implicated that the 
sensitiveness of cells might not be changed after ascorbate treatment and patients with grade 3 breast 
tumours might benefit more from IVA treatment.  
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Table 3-3. Comparison of the mRNA expression levels of the selected genes between breast 
tumours and matched normal tissues. 
Genes Cancer a Normal a Fold change b P value c 
CAT 0.46 1.94 0.36 5.5×10-14 
GPX1 0.37 0.52 0.90 0.14 
GPX2 -3.3 -2.0 0.41 1.7×10-06 
GPX3 -0.13 1.8 0.26 2.1×10-12 
GPX4 0.56 0.69 0.92 0.0014 
GPX5 0.21 0.105 1.07 0.024 
GPX6 0.34 0.22 1.09 0.021 
GPX7 -0.18 -0.092 0.94 0.24 
GLUT1 -0.81 -1.7 1.9 2.9×10-11 
GLUT3 -2.82 -2.69 0.91 0.32 
GLUT4 -0.57 1.8 0.19 5.6×10-15 
The data presented were a the median Lowess normalized and log2-transformed mRNA expression 
levels in 59 primary breast tumours and their adjacent normal tissues from the TCGA BRCA database. 
b The relative median mRNA expression levels in cancer versus normal tissues. c The Wilcoxon rank-
sum test was employed to test for differences in the mRNA expression levels between the primary 
breast tumours and their adjacent normal tissues. The P values highlighted in bold were statistically 
significant (< 2.8×10-06, adjusted by the total number of the genes measured, i.e. 0.05/17814).  
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Figure 3-15. The mRNA expression of catalase by tumour grade in breast tumours. 
The data presented were the log2-transformed mRNA expression levels of CAT (normalized by 
GAPDH and HPRT1) in 71 breast tumours, which were obtained using RT-qPCR. The number, N, of 
breast tumours in each group was displayed at the bottom. The P values were derived from Wilcoxon 
rank-sum test. 
 
3.10 Discussion 
Our results confirmed that cancer cells were more sensitive to pharmacologic ascorbate than normal 
cells, and H2O2 was an intermediate of the cytotoxicity of ascorbate [47]. The possible mechanisms 
by which cancer and normal cells had differential responses to ascorbate treatment might be due to 
but not limited to the following reasons. Firstly, cancer cells usually have defects in the DNA repair 
mechanisms and cell cycle checkpoint pathways (e.g. a mutated p53 gene) [144]. It was believed that 
H2O2 generated in ascorbate treatment could damage cells’ DNA [46]. At the same levels of DNA 
damages, normal cells may be arrested until the damages are repaired, however, cancer cells may 
either die or reproduce slowly [79]. Secondly, cancer cells generally have an increased rate of growth 
and metabolism and as a result produce more ROS than normal cells do [145], e.g. increased level of 
H2O2 was observed in cancer cells [121]. Cancer cells under sustained ROS stress tend to heavily 
utilize the adaptation mechanisms and may exhaust the cellular ROS-buffering capacity, thus may be 
more vulnerable to oxidative stress [146]. Thirdly, cancer cells may have lower capability of 
decomposing H2O2. It has been reviewed that normal cells have 10- to 100-fold greater content of 
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catalase than tumour cells do [63]. It was also reported that compared to normal hepatocytes, 
hepatoma cells had less than 10% of antioxidant enzyme activities, including catalase, superoxide 
dismutase and glutathione peroxidase and GSH content, which was correlated with its higher sensitive 
to ascorbate [147]. Our results were in agreement with these findings by showing that the mRNA 
levels of catalase and glutathione peroxidases 2 and 3 were significantly lower in breast tumours 
compared with their matched normal tissues.  
 
The extracellular, cellular and molecular variables, that might be associated with the differential 
responses of cells to ascorbate treatment, such as cell culture medium, serum, cell size, catalase 
expression and activity, glutathione peroxidase expression and cell cycle, were investigated using a 
range of cells. The oxidation rate of ascorbate could be significantly affected by cell culture medium 
type and serum, which implicated that the oxidation rate of ascorbate in vivo should be quite different 
from that was under typical in vitro conditions. Cells with smaller cell size, lower expression and 
activities of catalase and glutathione peroxidase and faster proliferation rate seemed to be more 
sensitive to ascorbate treatment. However, at this stage, without a holistic understanding of all 
possible variables, it seemed to be difficult to define a general set of characteristics of susceptible 
cancer cells to ascorbate treatment, or predict the responses of cells to ascorbate treatment. 
 
Compared to the human studies, all the animal studies have demonstrated high anticancer efficacy of 
high-dose ascorbate via IP or IV administration. EL4 cells (mouse lymphoma cell line) were much 
larger than HL-60 cells (human leukaemia cell line), however, the catalase expression and activity 
per cell in an average EL4 cell was only ~ 10% of that in an average HL-60 cell. HL-60 cells also 
had detectable levels of glutathione peroxidase by western blotting, while EL4 cells did not. Although 
EL4 cells cannot represent all mouse cells and HL-60 cells cannot represent all human cells, these 
results implicated that the differential results between the animal and human studies might be partially 
explained by the relevant genetic differences between animals and humans. If the average H2O2 
decomposing activity of all mouse cells is lower than that of all human cells, it may allow higher 
accumulation of H2O2 in mice than in humans when given the same dosage of ascorbate (g/kg of body 
weight), which may result in the inhibition of the growth of human tumour xenografts in mice but not 
the tumours in humans.  
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Our results demonstrated that DHA was also an intermediate of the cytotoxicity of ascorbate. The 
possible mechanism of the DHA-induced cytotoxicity via antagonism of glucose uptake [67]  and 
inhibition of hexokinase activity [116] could be supported with our results that pyruvate but not 
glucose could provide protective effects on the cells that were treated with DHA. It was also supported 
by a study that showed both protein and mRNA expression of M2-type pyruvate kinase were 
quantitatively up-regulated in the xenograft tumours in mice that were treated with IP ascorbate [148], 
which indicated a compensation for lowered glucose uptake.  
 
The possible mechanism of the DHA-induced cytotoxicity via the modulation of the H2O2 
decomposing capacity of cells was supported with the results that increased ROS levels was observed 
in the HL-60 cells that were treated with DHA. It was reviewed that As2O3-induced cytotoxicity might 
be mediated by elevated levels of intracellular H2O2 and a decrease in GSH content could increase its 
effectiveness [149]. Intracellular DHA can be reduced to ascorbate via a pathway that involves the 
consumption of GSH [150, 151]. As the loading of DHA was at millimolar range, it might deplete 
the intracellular GSH contents and allow higher intracellular H2O2 to be accumulated. This could 
explain the synergistic effect of DHA and As2O3 and that the highest ROS levels were observed in 
the cells that were treated with the combination of DHA and As2O3.  
 
In conclusion, both H2O2 and DHA were demonstrated to be the intermediate of the cytotoxicity of 
ascorbate in this chapter. Under typical in vitro conditions, H2O2 can be accumulated in a short period 
of time (e.g. 1 hour), which has more severe cytotoxic effect on cells than DHA. Thus the effect of 
H2O2 could mask the effect of DHA that might be contributed to the cytotoxicity of ascorbate. 
However, in the presence of catalase, which created a more similar situation as the cells would 
encounter in in vivo conditions (i.e. much higher density of cells in which cells could protect each 
other by removing H2O2), DHA was even more toxic than ascorbate. This implicated the DHA-
mediated mechanism may play a more important role in the ascorbate-induced effects in vivo. 
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Chapter 4 
4 A Phase I clinical trial protocol and three cases of intravenous 
administration of high-dose ascorbate as cancer treatment 
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4.1 Background 
In Chapter 2, the simulation of the mathematical model predicted that the increase of intracellular 
H2O2 by IVA treatment in humans based on the sole H2O2-mediated mechanism should be limited, 
which was unlikely to induce cell death in tumours. In Chapter 3, it was demonstrated that the 
effective molecules of ascorbate treatment were both H2O2 and DHA. In order to increase the efficacy 
of IVA, its administration route should be further optimised to allow more H2O2 and DHA to be 
produced and maintained for a sufficient period of time. The optimised (effective and safe) dose of 
IVA should be high enough to provide inhibitory effect on cancer cells while not to induce any severe 
adverse effects on normal cells. The recent Phase I clinical trials of IVA have shown the 
pharmacokinetic profiles of plasma ascorbate during and after treatment [36, 37]. However, the 
plasma concentrations of H2O2 and DHA have not been studied, which may provide the information 
for us to assess which molecule play a more significant role in vivo, and to improve the strategy for 
the use of IVA in the future.   
 
It is not rare that some patients decline conventional cancer therapy after the diagnosis of cancer and 
seek complementary and alternative medicine [4]. IVA is one of the options that is readily available 
[6].Three cancer patients who declined chemotherapy contacted A/Prof Luis Vitetta and expressed 
interest to have IVA. With the concerns of their oncologists, the patients volunteered to take IVA for 
their diseases in the general practice’s place. The progress of cancer and clinical outcome by IVA 
treatment were followed up and the data were passed on to A/Prof Vitetta with the patients’ consent. 
 
4.2 Proposed Phase I clinical trial of high-dose intravenous ascorbate in 
cancer patients 
Based on the published Phase I clinical trials of IVA [36, 152, 153], a new protocol (Table 4-1) was 
proposed and submitted for a grant application. Unfortunately, the application was unsuccessful, and 
as a result the research plan was not progressed due to lack of funding. 
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Table 4-1. A proposed protocol for Phase I clinical trial of IVA. 
Project A phase I clinical study/open label. 
Purpose 1) To evaluate the efficacy and further safety of high-dose ascorbate [1 g/kg body 
weight] administered intravenously twice daily on alternate days for 12 weeks. 
2) To study the pharmacokinetic profiles of the plasma concentrations of H2O2 and 
DHA during and after the treatment. 
Design Allocation: non-randomized;  
Control: active control;  
Endpoint classification: efficacy/safety trial; 
Intervention model: single group assignment;  
Masking: open label;  
Primary purpose: treatment;  
Study duration: 12 weeks. 
Participants 20 Participants; Gender inclusion: males and females. 
Outcomes  Primary: Tumour mass reduction; Tumour markers reduction; No disease 
progression; Inhibitory effect on metastasis. 
Secondary: Safety; Improvement in quality of life and other beneficial effects; 
Pharmacokinetics of plasma H2O2 and DHA. 
Key 
inclusion 
criteria 
Within 1 – 1.5 months of entry on study: 
Participants ≥ 18 years of age at time of entry on study. 
Extent of disease confirmed by oncologist; Documented by computed tomography 
(CT) scan, blood markers and others. 
Participant with a Karnofsky performance status of at least 60; Cognitive ability to 
understand informed consent process and the experimental treatment. 
Declined chemotherapy. 
No immediate reduced life expectancy risks. 
Participants agree to undergo central line placement [i.e. port-a-catheter, central 
venous catheter, percutaneously inserted central catheter line placement]; Patient 
or associated regular caregiver must be willing and able to maintain flush central 
line as directed by study clinician; Study centre would organize the provision of 
periodic site dressing changes as required and requested. 
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Participant safety measures prior to commencement of trial 1) Normal glucose 6-
phosphate dehydrogenase; 2) No current or recent calcium oxalate nephrolithiasis 
with the potential to reduce urinary flow; 3) No pre-existing renal disease; 4) No 
renal insufficiency or renal failure; 5) No paroxysmal nocturnal hemoglobinuria. 
Key 
exclusion  
criteria 
Any clinically relevant abnormal findings which, in the opinion of the 
investigators/clinicians, may put the participant at risk of adverse events because 
of participation in the clinical trial including: 1) Physical examination; 2) Clinical 
chemistry; 3) Haematology; 4) Urinalysis; 5) Vital signs; 6) Electrocardiogram at 
baseline. The use of any nicotine products including: 1) nicotine patches/gum, 2) 
tobacco smoking; Alcohol abuse; The use of any illicit drugs; Unstable angina not 
well managed with medication; History of calcium oxalate stone formation or 
other kidney disease; Pregnancy or nursing of an infant; Diabetes; Any psychiatric 
disorders by history or examination that would prevent completion of the study or 
result in possible adverse events for the participant [i.e. suicide thoughts or 
euthanasia requests]. 
Dosage and 
duration   
1 g/kg body weight of sodium ascorbate IV administered over within 2 – 2.5 
hours, twice a day, on alternate days for 12 weeks. 
Study sites Princess Alexandra Hospital, Brisbane. 
Recruitment Brisbane metropolitan area. 
Ethics 
approvals  
and TGA 
University of Queensland Human Ethics Committee. Princess Alexandra Hospital 
Human Research Ethics Committee. 
TGA notification application on intent to conduct a human clinical trial with a 
high-dose ascorbate preparation administered IV. 
Efficacy of 
treatment 
and 
safety 
Efficacy evaluation using: 1) Response Evaluation Criteria In Solid Tumours 
(RECIST) criteria to determine disease response by CT scan interpretation; 2) 
Blood markers over time frame of 12 weeks. 
Quality of Life evaluation using the Functional Assessment of Cancer Therapy 
(FACT) questionnaire over the time frame of 12 weeks.  
Data 
analysis 
All available data will be treated as for intention-to-treat analyses. All analyses 
will be conducted with R (version 3.1.0, R Development Core Team, 2014). 
TGA: Therapeutic Goods Administration, Australia. 
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4.3 Three cases of intravenous administration of high-dose ascorbate as 
cancer treatment 
The clinical characteristics of the three patients and the progress and outcome data following IVA 
treatment were outlined in Table 4-2, Table 4-3 and Table 4-4 (as current at July 18, 2014). The data 
presented were as complete as provided by the clinicians. As informed to A/Prof Vitetta by the 
oncologists and the general clinicians, the prognoses for two of the three patients before commencing 
IVA were relatively poor. The patient diagnosed with pleural mesothelioma was given at best 9 
months survival with chemotherapy treatment. Whereas the patient diagnosed with leiomyosarcoma 
was not expected to survive a fortnight. The patient diagnosed with undifferentiated uterine sarcoma 
was stable at the time of commencing IVA. During and after the IVA treatments, the three patients 
all appeared to show some beneficial responses that included improved quality of life, palliated 
symptoms, improved ascites status, improved cancer maker status and stabilized cancer progression. 
IVA might also be associated with the patients’ possibly prolonged survival, which was longer than 
expected by their clinicians. During the IVA treatment, the mesothelioma patient’s circulating iron 
was increased while the iron load was reduced, both towards the normal range, indicating an 
improvement of his iron status (Table 4-5). 
 
Of note, the mesothelioma patient had a period of no-progression of tumour during his 1st IVA 
treatment, a significant tumour reduction followed by chemotherapy and a serious regrowth during 
his 2nd IVA treatment (Table 4-2). However, it was not possible to determine whether it was the 2nd 
IVA or the chemotherapy causal for the tumour regrowth because there was a critical time point of 
tumour scanning missing. This should have occurred after the chemotherapy and immediately before 
the 2nd IVA. It was highly unlikely given the clinical data published so far that the tumour regrowth 
was solely attributed to IVA.  
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Table 4-2. Treatment, progress and outcomes of patient 1: pleural mesothelioma, male, age 61. 
Prior to IVA treatment: 
> Diagnosis based on high-resolution CT scan: Clinical history of mesothelioma noted. There was 
significant circumferential and nodular pleural thickening on the right side with reduced volume 
of right lung consistent with neoplastic disease process like mesothelioma.  Findings extended 
along the fissure. There were areas of collapse / consolidation in right lung especially middle and 
lower lobes and these parenchymal changes had increased since the previous CT scan images.    
> Prognosis: At best 9 months survival with chemotherapy treatment. 
> Patients declined chemotherapy.  
2009.10 Began IVA with a low dose increased incrementally over 2 weeks, thereafter for 10 
weeks at a dose of 1 g/kg body weight daily with weekends off. 
> 2010.01-02 No significant disease progression evident on CT scan.  
> IVA well tolerated except for thirst during and post treatment, no severe adverse effect reported. 
2010.02 Began combined Alimta + Carboplatin chemotherapy as the oncologist suggested. 
> 2010.06 Following the completion of chemotherapy regimen, tumour size reduced by 40% 
according to CT scan.  
> The patient’s quality of life improved from poor, prior to chemotherapy, to moderately good, 
post chemotherapy as described in the oncologist’s patient notes. 
2010.06 Began a second regimen of IVA [1 g/kg body weight twice a day on alternate days].  
> 2010.08 Reassessment and progress evaluation showed aggressive regrowth of tumour, based 
on CT scan. This was assessed by the oncologist who reported on his patient notes that the tumour 
had regrown to its original size (prior to the first IVA treatment) quickly post treatment. 
> The second IVA ceased at week 10. 
> Severe adverse effects reported: acute gout requiring pharmacological intervention and at least 
one acute infusion reaction characterised by significant dyspnoea and chest tightness. 
> Patient possibly underwent site specific radiotherapy in Melbourne, and the oncologist reported 
that his quality of life was severely reduced since then. 
> 2012.05 patient died. 
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Table 4-3. Treatment, progress and outcomes of patient 2: primary leiomyosarcoma with liver 
metastasis, female, age 43. 
Prior to IVA treatment: 
> Diagnosis based on CT scan: There were multiple scattered nodules in both lungs most likely 
representing extensive pulmonary metastasis.  Liver was grossly enlarged and showed multiple 
ill-defined hypodense masses suggesting extensive liver metastasis. Gross ascites. Multiple 
lobulated masses were also seen in pelvis and adnexa. Peritoneal deposits were also noted. 
Pathological appearing right groin lymph node. Clinical history of metastatic disease noted.  
> Blood test: CA-125 was 423 U/ mL (High).  
> Ascites: Prior to IVA commencement, approximately 4.5 L of thick and pink coloured fluid was 
drained from the peritoneal cavity under US guidance. A haemorrhagic component was seen on 
the present drainage.  
> Prognosis: Not expected to survive a fortnight. 
> Patient declined chemotherapy. 
2010.07 Began IVA [1 g/kg body weight twice a day on alternate days] for 5 weeks. 
After ~2 weeks of IVA treatment: 
> Night sweats resolved after one week of IVA – improved sleep. 
> Reduction in ascitic fluid volume by ~500 mL/day from the first drainage prior to IVA 
commencement. The ascitic fluid had changed in characteristics, from think and blood stained to 
thin and straw coloured. No haemorrhagic component was seen. 
> Kidney function normal.   
> Quality of life low as assessed and documented in the patient notes by the General Practitioner 
overseeing the IVA administration. 
After ~5 weeks of IVA treatment: 
> Further reduction of ascitic fluid noted ~1000 mL/day.  
> Liver function tests slight improvement. 
> Blood test: CA-125 reduced to 256 U/mL. 
> Quality of life low. 
> IVA well tolerated except for thirst during and post treatment, no severe adverse effect reported. 
> Patient died at week 8. 
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Table 4-4. Treatment, progress and outcomes of patient 3: undifferentiated uterine sarcoma, 
female, age 53. 
Prior to IVA treatment: 
> Treatment: Total Abdominal Hysterectomy (TAH), Bilateral Salpingo-Oophorectomy (BSO), 
partial omentectomy and sampling of pelvic and iliac nodes.  
> Diagnosis: Subsequent investigations with a positron emission tomography (PET) scan showed 
the presence of a metastasis in the right crural lymph gland. Metastatic disease reported after CT 
scan of the lungs with secondaries approximately 7.2 mm in size. 
> Oncologist explained that chemotherapy would NOT extend life expectancy but might delay the 
onset of symptoms. 
> Patient declined chemotherapy. 
> Patient was stable at the time of commencing IVA. 
2010.03 Began IVA with a low dose increased incrementally over 2 weeks, thereafter for 10 
weeks at dose of 1 g/kg body weight daily with weekends off. 
> At the completion of IVA, CT scan showed no progression or metastasis. 
> 2010.08 patient continued well with no symptoms. 
> IVA well tolerated except for thirst during and post treatment, no severe adverse effect reported. 
> The patient was still alive at the census date (July 18, 2014). 
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Table 4-5. Pathology report of the iron status of the mesothelioma patient. 
Iron status  Before IVA treatment 
(09/11/2009) 
After IVA treatment 
(14/12/2009) 
Normal 
range 
Serum iron 3 µmol/L 5 µmol/L 10 - 33 
Transferrin IBC 48 µmol/L 50 µmol/L 45 - 70 
Transferrin saturation 6% 10% 16 - 50 
Serum ferritin assay 478 µg/L 396 µg/L 20 - 320 
Clinician’s comment Iron studies consistent with 
either chronic disease or 
possibly an acute infective or 
inflammatory process. 
Mild elevation of the ferritin, 
which did not necessarily 
indicate true iron loading and 
might be seen in liver disease 
or chronic disease. 
 
Transferrin: a blood plasma protein for iron delivery. Serum iron: the amount of circulating iron that 
is bound to transferrin. Transferrin saturation: the ratio of serum iron and total iron-binding capacity 
(IBC). 
 
4.4 Discussion 
The outcomes of the three patients who received IVA treatment were, in general, consistent with the 
observations reported in the published clinical trials of IVA treatment in cancer patients as reviewed 
in Chapter 1. However, based on the available data, it was not possible for a statistical analysis to be 
performed to evaluate the statistical significance of the effects of IVA and to exclude any possible 
placebo effects. A clinical trial dedicated at investigating the beneficial effects of IVA should be 
conducted in the future. 
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Chapter 5 
5 TGFβ isoforms and receptors mRNA expression in breast 
tumours: prognostic value and clinical implications 
 
 
 
The manuscript incorporated as Chapter 5 is currently under re-review in BMC cancer. Its formatting 
is preserved, except that its specific references are merged into “References” at the end of the thesis. 
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Abstract 
Background: Transforming growth factor beta (TGFβ) signalling is involved in both tumour 
suppression and tumour progression. The mRNA expression levels of the TGFβ isoforms and 
receptors in breast tumours may have prognostic value and clinical implications.  
 
Methods: The mRNA levels of TGFB1, TGFB2, TGFB3, TGFBR1 and TGFBR2 were analysed in 
primary breast tumours and adjacent normal breast tissues, and the associations with tumour 
characteristics and patients’ overall and relapse-free survival were also evaluated, using the public 
gene expression microarray data from The Cancer Genome Atlas (n = 520) and the Gene Expression 
Omnibus (5 datasets) and our quantitative real-time PCR validation data (n = 71). 
 
Results: Significantly higher TGFB1 and TGFB3 mRNA levels and lower TGFBR2 mRNA levels 
were observed in primary tumours compared with their paired normal tissues (P < 0.003). TGFB1 
mRNA expression was significantly lower in triple-negative tumours and in tumours from lymph 
node-negative patients (P < 0.05). TGFB3 mRNA expression was significantly lower in estrogen 
receptor-negative / progesterone receptor-negative / Basal-like / Grade 3 tumours (P < 0.003). High 
TGFB2, TGFB3 and TGFBR2 mRNA levels in tumours were generally associated with better 
prognosis for patients, especially those diagnosed with lymph node-negative diseases (P < 0.05). High 
TGFB1 and TGFBR1 mRNA levels in tumours were associated with poorer clinical outcomes for 
patients diagnosed with small (diameter ≤ 2 cm) tumours (P < 0.05).  
 
Conclusions: The results indicate a reduced responsiveness of tumour cells to TGFβ, a preferential 
up-regulation of TGFB1 in malignant tumours and a preferential up-regulation of TGFB3 in 
premalignant tumours. The results may not only provide prognostic value for patients but also assist 
in classifying tumours according to their potential responses to TGFβ and selecting patients for TGFβ 
signalling pathway targeted therapies. 
 
Keywords: TGFβ, breast cancer, mRNA expression, prognosis  
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5.1 Background 
Transforming growth factor beta (TGFβ) signalling is involved in the maintenance of tissue 
homeostasis and suppression of premalignant tumour cells, however, when the regulations are 
circumvented, TGFβ signalling can be advantageously exploited by the tumour cells to promote 
tumour progression and metastasis [154]. Three isoforms of TGFβ (TGFβ1, TGFβ2 and TGFβ3) all 
function as secreted polypeptides that can modulate the cellular microenvironment [155]. When 
activated, TGFβ binds to and brings together transmembrane TGFβ receptors type I (TβRI) and type 
II (TβRII) to form a ligand-receptor complex that propagates the signal to the nucleus [156]. The 
effects and mode of action of TGFβ are varied and depend on the cellular context [157]. 
 
Extensive efforts have been made to investigate the role of TGFβ signalling in the development and 
progression of cancer and to develop drugs targeting the TGFβ signalling pathway for a number of 
cancer types, including breast cancer [154, 158-160]. The prognostic value of the components of 
TGFβ pathway have also been explored in breast cancer, though conflicting results have been noted 
[161-164]. Much of our knowledge about TGFβ signalling in breast cancer is based on the studies 
characterizing the proteins involved. A few pioneer studies have evaluated the mRNA levels [165, 
166], whereas whether the mRNA levels of the key components of the TGFβ pathway also have 
prognostic value and clinical implications is inconclusive.  
 
Here, we used the public breast cancer gene expression microarray datasets from The Cancer Genome 
Atlas (TCGA) and the Gene Expression Omnibus (GEO) to compare the mRNA expression levels of 
TGFB1, TGFB2, TGFB3, TGFBR1 and TGFBR2 in primary tumours and tumour-adjacent normal 
tissues, and evaluate the associations between the mRNA levels and the clinical, pathological and 
molecular tumour characteristics and the patients’ overall and relapse-free survival. We also validated 
the gene expression profiles on an independent set of breast cancer surgical specimens by reverse-
transcription quantitative real-time polymerase chain reaction (RT-qPCR).  
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5.2 Methods 
5.2.1 Study population and characteristics of breast cancer specimens 
The TCGA breast cancer level 3 mRNA expression Agilent microarray data (Lowess normalized and 
log2-transformed) and the patients’ clinical data were downloaded from the Broad Genome Data 
Analysis Centre Firehose (March 2014 version). The TCGA cohort (Table 5-1) involved 520 
untreated primary breast tumour samples and 59 paired tumour-adjacent normal tissue samples (taken 
from greater than 2 cm away from the tumour) from 520 females (age range 26 - 90 years). The bio-
specimen collection criteria, sample processing, clinical data quality assurance and microarray 
processing had been described by TCGA previously [167]. The pathologic stages, namely, primary 
tumour (T), regional lymph nodes (N) and distant metastases (M) were made binary in this study: 
tumour size was coded as “≤ 2 cm” for T1, “> 2 cm” for T2 and T3, and “Not Available” (NA) for 
T4 and TX; involvement of regional lymph nodes was coded as “negative” for N0, NA for NX and 
“positive” for others; distant metastasis was coded as “positive’ for M1 and “negative’ for others. 
Immunohistochemical data was used for determining estrogen receptor (ER), progesterone receptor 
(PR) and human epidermal growth factor receptor 2 (HER2) statuses. HER2 status was supplemented 
by the results of fluorescence in situ hybridization for the “equivocal” or NA calls. Scores of 
“indeterminate”, “equivocal” or “not performed” were coded as NA. PAM50 subtypes for 513 of the 
tumour samples had been previously assigned [167], and that for the other 7 tumour samples were 
predicted using the 50-gene PAM50 model [168]. 
 
A total of 5 breast cancer microarray datasets from GEO were included in this study (Table 5-1). The 
selection criteria were that the dataset should contain ≥ 200 clinical specimens and there was a 
published paper associated with it. The Hatzis cohort (GSE25066) was mainly composed of HER2-
negative tumour specimens [169]. The Ivshina cohort (GSE4922) was of unselected population [170]. 
The Schmidt (GSE11121) and Wang (GSE2034) cohorts were both composed of the tumour 
specimens from lymph node-negative patients [171, 172]. The Symmans cohort (GSE17705) was 
composed of ER-positive tumour specimens [173].  
 
The RT-qPCR validation cohort was composed of 71 tumour surgical specimens (containing > 50% 
tumour cells) from 71 females (age range 33 - 85 years) diagnosed with breast cancer (Table 5-1). 
Ethical approvals were obtained from the Human Research Ethics Committee at the University of 
Queensland (UQ) and Royal Brisbane & Women’s Hospital before the study was conducted. The 
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tumour specimens were snap frozen after surgery and stored in liquid nitrogen at UQ Centre for 
Clinical Research (the Brisbane Breast Bank) and Wesley hospital, Brisbane, until required for RNA 
extraction.  
 
Table 5-1. Tumour characteristics of the breast cancer specimens. 
Cohorts 
N 
TCGA 
520 
TCGA-sub 
59 
RT-qPCR 
71 
Hatzis 
508 
Ivshina 
249 
Schmidt 
200 
Symmans 
298 
Wang 
286 
 Histological type         
  Ductal 442 (85.0) 51 (86.4) 56 (78.9) - - - - - 
  Lobular 41 (7.9) 3 (5.1) 5 (7.0) - - - - - 
  Mixed and others 36 (6.9) 5 (8.5) 9 (12.7) - - - - - 
Tumour diameter         
  ≤ 20 mm 133 (25.6) 20 (33.9) 39 (54.9) 33 (6.5) 126 (50.6) 112 (56.0) - - 
  > 20 mm 364 (70.0) 38 (64.4) 32 (45.1) 400 (78.7) 123 (49.4) 88 (44.0) - - 
Regional lymph nodes         
  Negative 253 (48.7) 25 (42.4) 34 (47.9) 157 (30.9) 159 (63.9) 200 (100) 175 (58.7) 286 (100) 
  Positive 256 (49.2) 34 (57.6) 36 (50.7) 351 (69.1) 81 (32.5) 0 (0) 112 (37.6) 0 (0) 
Distant metastasis         
  Negative 492 (94.6) 57 (96.6) - - - - - - 
  Positive 14 (2.7) 1 (1.7) - - - - - - 
TNM stage         
  I 89 (17.1) 13 (22.0) - 8 (1.6) - - - - 
  II 290 (55.8) 34 (57.6) - 272 (53.5) - - - - 
  III 110 (21.2) 11 (18.6) - 224 (44.1) - - - - 
  IV 14 (2.7) 1 (1.7) - 0 (0) - - - - 
Tumour grade         
  Grade 1 - - 7 (9.9) 32 (6.3) 68 (27.3) 29 (14.5) - - 
  Grade 2 - - 25 (35.2) 180 (35.4) 126 (50.6) 136 (68.0) - - 
  Grade 3 - - 36 (50.7) 259 (51.0) 55 (22.1) 35 (17.5) - - 
ER status         
  Negative 117 (22.5) 9 (15.3) 18 (25.4) 207 (40.7) 34 (13.7) - 0 (0) 77 (26.9) 
  Positive 396 (76.2) 48 (81.4) 52 (73.2) 299 (58.9) 211 (84.7) - 298 (100) 209 (73.1) 
PR status         
  Negative 176 (33.8) 16 (27.1) 22 (31.0) 258 (50.8) - - - - 
  Positive 336 (64.6) 41 (69.5) 48 (67.6) 243 (47.8) - - - - 
HER2 status         
  Negative 361 (69.4) 48 (81.4) 60 (84.5) 485 (95.5) - - - - 
  Positive 101 (19.4) 10 (16.9) 10 (14.1) 6 (1.2) - - - - 
Triple-negative         
  True 72 (13.8) 7 (11.9) 11 (15.5) - - - - - 
  False 448 (86.2) 52 (89.1) 60 (84.5) - - - - - 
PAM50 subtype         
  Basal-like 96 (18.5) 11 (18.6) - 189 (37.2) - - - - 
  HER2-enriched 58 (11.2) 4 (6.8) - 37 (7.3) - - - - 
  Luminal A 231 (44.4) 32 (54.2) - 160 (31.5) - - - - 
  Luminal B 127 (24.4) 12 (20.3) - 78 (15.4) - - - - 
  Normal-like 8 (1.5) 0 (0) - 44 (8.7) - - - - 
Data are presented as the number of patients in each subgroup with percentage in the parentheses. 
Numbers may not sum to total (N) due to missing data. 
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5.2.2 Processing of GEO datasets 
The gene expression data of the 5 GEO datasets were all based on Affymetrix U133A and U133A&B 
array sets. The data of the probe sets 203084_at (TGFB1), 220406_at (TGFB2), 209747_at (TGFB3), 
206943_at (TGFBR1) and 208944_at (TGFBR2) from each GEO dataset were log2-transformed and 
standardized to mean = 0 and SD = 1. The GEO cohort was then compiled by merging the log2-
transformed and standardized gene expression data and the clinical data from the Hatzis and Ivshina 
cohorts. The Schmidt and Wang cohorts were added to the lymph node-negative subset of the GEO 
cohort, and the Symmans cohort was added to the ER-positive subset of the GEO cohort. The Ivshina 
dataset contained recurrence-free survival data (local, regional or distant), while the other 4 datasets 
contained distant relapse-free survival data. Thus the merged survival data was referred as relapse-
free survival data but with bias to more distant relapse-free survival data. 
 
5.2.3 Reverse-transcription quantitative real-time polymerase chain reaction 
Total RNA was extracted from each specimen using TRIzol reagent (Life Technologies), according 
to the manufacturer’s instructions. RNA concentration, integrity and purity were analysed using 
NanoDrop 1000 Spectrophotometer (Thermo Scientific) and agarose gel electrophoresis. Quality-
checked 500 ng RNA per specimen was reverse transcribed using high capacity RNA-to-cDNA kit 
(Life Technologies) in a final reaction volume of 12 µL containing random hexamer primers. The 
incubation conditions for reverse transcription (RT) were: 37 °C for 60 minutes, 95 °C for 10 minutes 
and hold at 4 °C indefinitely. RT-negative controls (reactions with no reverse transcriptase) of two 
RNA samples were prepared for testing DNA contamination. The cDNA was kept at -20 °C until 
used for quantitative real-time PCR (qPCR).  
 
The qPCR was performed using SYBR Green PCR master mix (Life Technologies) in MicroAmp 
optical 384-well reaction plates (Life Technologies) on an Applied Biosystems 7900HT Fast Real-
Time PCR System. The primers for qPCR were designed using AlleleID 7.6 (PREMIER Biosoft) to 
span at least one exon-exon junction and to cover all the transcript variants found in Entrez Gene 
(Table 5-2). Each qPCR reaction had a total volume of 10 µL that contained 12.5 ng cDNA templates, 
200 nM forward primers, 200 nM reverse primers and 5 µL SYBR Green PCR master mix. The 
thermal cycling conditions were: 95 °C for 10 minutes, followed by 40 cycles of 95 °C for 15 seconds 
and 60 °C for 1 minute, and a dissociation stage. The qPCR reactions containing the same cDNA 
template with the whole set of qPCR primer pairs were run on the same plate to avoid assay variability. 
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Every combination of cDNA template and qPCR primer pairs was tested in triplicate. Each qPCR 
product was verified by dissociation curve analysis, and all the qPCR products of two cDNA 
templates were verified by 2.2% agarose gel electrophoresis that showed single band with correct 
amplicon length and no primer dimmer. There was no positive amplification observed in the qPCR 
reactions using the RT-negative controls as template. The threshold cycle (Ct) was determined by 
setting the threshold to 0.1, in the exponential phase of amplification, in the SDS 2.4 software (Life 
Technologies). Triplicates with median Ct ≤ 30 all had standard deviation (SD) < 0.1, while those 
with median Ct > 30 had relatively increased SD, due to obvious higher variability in templates with 
low transcript copy-number. The median Ct for each triplicate was obtained for further calculations. 
The qPCR efficiencies of all studied genes were similar and close to 100%, i.e. 1 thermal cycle 
(expressed as Ct) corresponds to a 2-fold change.  
 
The 2-∆∆Ct method was used for the qPCR data analysis [174]. GAPDH and HPRT1 were chosen as 
the reference genes for normalization, as they showed smaller SD of Ct values compared with two 
other putative housekeeping genes RNA18S5 and GUSB that were assessed in our pilot study. The 
∆Ct for the gene of interest was calculated by subtracting the average of Ct for GAPDH and HPRT1 
from the Ct for the gene of interest [132]. The relative mRNA expression levels of the genes of interest 
(2-∆Ct) were skewed, thus the normalized and log2-transformed data, i.e. -∆Ct, was used for data 
analysis [174]. 
 
Table 5-2. Characteristics of the primers used for RT-qPCR. 
Gene symbol Targeted transcript variants  Primer sequences (5’ – 3’) Amplicon (bp) 
TGFB1 NM_000660 (F): TCGCCAGAGTGGTTATCTT 148 
  (R): TAGTGAACCCGTTGATGTCC  
TGFB2 NM_001135599, NM_003238 (F): ACACTCAGCACAGCAGGGTCCT 80 
  (R): TTGGGACACGCAGCAAGGAGAAG  
TGFB3 NM_003239 (F): TGAGTGGCTGTTGAGAAGAGA 139 
  (R): ATTGTCCACGCCTTTGAATTTGAT  
TGFBR1 NM_001130916, NM_004612 (F): GCAGAGCTGTGAAGCCTTGAGA 128 
  (R): TGCCTTCCTGTTGACTGAGTTG  
TGFBR2 NM_001024847, NM_003242 (F): ATGACATCTCGCTGTAATGC 163 
  (R): GGATGCCCTGGTGGTTGA  
HPRT1 NM_000194 (F): TGGCGTCGTGATTAGTGATG 160 
  (R): GCCTCCCATCTCCTTCATC  
GAPDH NM_001256799, NM_002046 (F): TCTCTGCTCCTCCTGTTC 112 
  (R): CGACCAAATCCGTTGACT  
(F): forward primer, (R): reverse primer, bp: base pair.  
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5.2.4 Statistical analysis 
Normalized and log2-transformed mRNA expression data of TGFB1, TGFB2, TGFB3, TGFBR1 and 
TGFBR2 was used for all statistical analyses. The Wilcoxon signed-rank test was used to test for 
differences in the mRNA levels between the tumours and the matched normal tissues. The Spearman's 
rank correlation analysis was employed to evaluate the correlations between the mRNA levels of 
pairwise genes. The Wilcoxon rank-sum test and Kruskal-Wallis test were employed to test for 
differences in the mRNA levels grouped by tumour characteristics, namely, tumour diameter, regional 
lymph nodes involvement, distant metastasis, ER status, PR status, HER2 status, triple-negative, 
histological type, TNM stage, tumour grade and PAM50 subtype. Patient’s survival time was 
calculated from the date of diagnosis to the date of event (death or relapse) or censored at the last 
follow-up or last known alive time whichever was longer. The Cox proportional hazards regression 
model was used to evaluate the associations between the mRNA levels and patients’ overall and 
relapse-free survival. To evaluate if the mRNA levels had different associations with the patients’ 
clinical outcomes in the early and late years after the patients were diagnosed with breast cancer, the 
analyses were performed for different periods of follow-up time from 1 to 10 years. The Likelihood-
ratio test was used to assess statistical significance of the calculated Cox regression coefficients (β) 
and hazard ratios (HR), where β = ln(HR). The 95% confidence interval (CI) of HR was calculated 
based on the Wald test. The Log-rank test was used to assess significant differences between the 
Kaplan-Meier estimates. All the statistical analyses were performed using R (version 3.1.0, R Core 
Team, 2014). All the P values presented were two-sided, and P values < 0.05 were considered 
statistically significant unless otherwise stated. 
 
5.3 Results 
The bio-specimens from the TCGA, GEO and RT-qPCR cohorts were all collected from newly 
diagnosed patients with breast tumours that had received no prior treatment, such as chemotherapy 
or radiotherapy. The clinical, pathological and molecular characteristics of the breast cancer 
specimens were summarised in Table 5-1. The population of tumours from the TCGA cohort was not 
significantly different from the TCGA sub-cohort that contained adjacent normal tissues and the RT-
qPCR cohort in terms of the tumour characteristics, with the only exception being “tumour diameter” 
(Fisher’s exact test P = 3.6×10-6), in which the tumours from TCGA were overall larger than the 
tumours from the local tissue banks.  
 
 101 
 
5.3.1 Comparison of the mRNA expression levels between the primary breast 
tumours and the adjacent normal tissues    
Significantly higher TGFB1 and TGFB3 mRNA levels and lower TGFBR2 mRNA levels were 
observed in the primary breast tumours compared with their matched normal tissues (Figure 5-1). 
Higher variance of TGFB2 mRNA levels was observed compared with the other genes. TGFβ1 and 
TGFβ3 are generally considered more alike than either is compared to TGFβ2 in term of functions, 
given that TGFβ1 and TGFβ3 are capable of binding directly to TβRII, while TGFβ2 binds TβRII 
weakly and is dependent upon the co-receptor betaglycan for function [175]. Interesting, positive 
correlations between the mRNA levels of TGFBR2 and the mRNA levels of TGFB1 (Spearman's rho 
= 0.51, P = 5.6×10-5) and TGFB3 (Spearman's rho = 0.42, P = 0.0012) were observed in the tumours 
(n = 59). 
 
 
Figure 5-1. Comparison of the mRNA levels between the primary breast tumours and their 
adjacent normal tissues. 
The mRNA expression levels (log2-transformed and median-centred) of TGFB1, TGFB2, TGFB3, 
TGFBR1 and TGFBR2 were compared between 59 primary breast tumours and their adjacent normal 
tissues from the TCGA cohort using b the Wilcoxon signed-rank test. a The relative median mRNA 
expression levels in cancer versus normal tissues.  
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5.3.2 Associations between the mRNA levels and tumour characteristics 
The associations between the mRNA levels of TGFB1, TGFB2, TGFB3, TGFBR1 and TGFBR2 and 
the tumour characteristics displayed in Table 5-1 were evaluated using Wilcoxon rank-sum test and 
Kruskal-Wallis test. The significant associations that were observed from both of the TCGA and RT-
qPCR cohorts were shown in Figure 5-2. Significantly lower mRNA expression levels of TGFB1 
were observed in the triple-negative tumours and the tumours from regional lymph node-negative 
patients (Figure 5-2A and E). The TGFBR1 mRNA levels were seemly associated with HER2 status 
(Figure 5-2 D). The mRNA expression of TGFB3 was significantly lower in the ER-negative, PR-
negative and triple-negative tumours (Figure 5-2 B, C and F). We also observed that TGFB3 had 
significantly the lowest expression in the Grade 3 tumours (Figure 5-2 G), which agreed with a few 
studies evaluating the mRNA and protein levels of TGFB3 [176, 177]. The consistent results from 
the independent datasets mutually validated themselves.  
 
All the five genes were expressed to variable levels across different PAM50 subtypes, and exhibited 
heterogeneous expression profiles within each PAM50 subtype (Figure 5-3). For example, in the 
Luminal A subtype, some tumours had high expression of all five genes while some had low 
expression of all five genes. Significantly lower expression of TGFB3 was observed in the Basal-like 
tumours, which was in agreement with that the lower expression of TGFB3 was associated with ER, 
PR-negative tumours and that most of the Basal-like tumours were ER, PR-negative. TGFBR2 had 
the highest median expression levels in the Normal-like subtype (Figure 5-3), which was in 
concordance with the result that TGFBR2 was significantly down-regulated in the tumours compared 
with their adjacent normal tissues (Figure 5-1). 
 
 103 
 
 
Figure 5-2. Associations between the mRNA levels and tumour characteristics. 
The mRNA expression levels (log2-transformed and median-centred) of TGFB1, TGFB3 and 
TGFBR1 (labels on y axis) were compared between the breast tumours with different characteristics 
(labels on x axis) from different cohorts (titles on each panel). The number of patients (n) of each 
tumour subgroup was shown under each boxplot. The estimated relative mRNA expression levels in 
the tumour subgroup on the right side in each panel (Positive, False or grade 3, presented as white 
boxplot) versus the one on the left side (Negative, True or grade 2, presented as grey boxplot), 95% 
confidence intervals and P values were calculated from the Wilcoxon rank-sum test. a The data 
presented were standardized, thus no fold change was calculated. b The relevant values were 
calculated for grade 2 and grade 3 tumours. 
 
 104 
 
 
Figure 5-3. Heatmap visualization of the mRNA levels. 
Tumour samples from the TCGA cohort were hierarchically clustered according to the log2-
transformed and standardized mRNA expression levels of TGFB1, TGFB2, TGFB3, TGFBR1 and 
TGFBR2 for each PAM50 subtype in the middle panel, where each row represented a tumour 
specimen and each column represented a gene. The colour represented the mRNA expression levels 
(green: low, red: high). The median mRNA levels of each gene for each PAM50 subtype were shown 
at the bottom, and the P values were calculated from the Kruskal-Wallis test for differences in the 
mRNA levels across the PAM50 subtypes. The tumour diameter (T), lymph node metastasis (N), 
distant metastasis (M), ER PR and HER2 statuses of each specimen were shown in the right-side 
columns, white: positive or > 2 cm, black: negative or ≤ 2 cm, grey: missing data. 
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5.3.3 Associations between the mRNA levels and the patients’ clinical outcome 
The associations between the mRNA levels of TGFB1, TGFB2, TGFB3, TGFBR1 and TGFBR2 in 
the primary breast tumours and the patients’ overall and distant relapse-free survival were evaluated 
in all patients from the TCGA and GEO cohorts and in the patients stratified by tumour diameter, 
regional lymph node and ER statuses (Figure 5-4). We also evaluated if stratifying patients by the 
mRNA expression levels of their tumours would predict patients’ survival (Figure 5-5).  
 
Higher mRNA levels of TGFB2 and TGFB3 in the primary tumours were associated with better 
overall and relapse-free survival respectively, especially for the lymph node-negative patients (Figure 
5-4). In the patients diagnosed with lymph node-negative tumours, the hazard ratio of death for having 
tumours expressing the highest 35% of TGFB2 mRNA levels versus having tumours expressing the 
lowest 35% of TGFB2 mRNA levels for the first 10 years after diagnosis was 0.21 (95% CI: 0.056 – 
0.75) (Figure 5-5 C). Almost no death was recorded for the patients with high expression of TGFB2 
in their tumours for the first 7 years after diagnosis of breast cancer. Compared with the patients 
whose breast tumours were in the lower half of TGFB3 expression, patients in the higher half had 
significantly better relapse-free survival with HR = 0.65, 95% CI: 0.49 – 0.85 (Figure 5-5 E). Higher 
TGFB1 mRNA levels were seemingly associated with poorer prognosis in patients with small 
(diameter ≤ 2 cm) tumours but better prognosis in those with big (diameter > 2 cm) tumours and 
lymph node-positive diseases (Figure 5-5 A and B). 
 
Higher TGFBR1 mRNA levels were associated with poorer overall survival, especially for the 
patients with small (diameter ≤ 2 cm) tumours in the first 3 years (Figure 5-4 A). This finding was 
consistent with de Kruijf et al.’s study evaluating the protein levels of TβRI by immunohistochemistry 
[162]. The authors also reported that high TβRII expression was associated with an unfavourable 
prognosis concerning progression-free survival. Whereas, it was shown in this study that higher 
TGFBR2 mRNA expression was associated with better relapse-free survival for patients with negative 
lymph node status (Figure 5-4 B). This finding was more in agreement with Paiva et al.’s study which 
showed that TβRII down-expression was significantly associated with breast cancer and the absence 
of TβRII was an adverse prognostic factor [163].  
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Figure 5-4. Associations between the mRNA levels and the patients’ clinical outcome. 
(A) The associations between the mRNA levels of TGFB1, TGFB2, TGFB3, TGFBR1 and TGFBR2 
in the primary tumours and patients’ overall survival were evaluated in all patients from the TCGA 
cohort and those stratified by tumour diameter (T), regional lymph node status (N) and ER status 
using the Cox proportional hazards regression model. The hazard ratios of death (y axis, logarithmic 
scale) for a 1-unit increase in the mRNA expression levels (log2-transformed and standardized) of 
the five genes for the follow-up periods from 1 to 10 years (x axis) were shown for each group of 
patients (title on each panel). The shapes were filled black if the corresponding P values for 
likelihood-ratio test were < 0.05. Missing data in the first column of panel “T ≤ 2 cm” were due to 0 
event recorded for the first year. (B) Associations between the mRNA levels and the patients’ relapse-
free survival from the GEO cohort.  
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Figure 5-5. Stratifying patients by mRNA levels for prognosis. 
Patients from the TCGA cohort (A) and GEO cohort (B) were divided into three groups (low, mid 
and high) according to their tumour levels of TGFB1, TGFB2, TGFB3, TGFBR1 or TGFBR2 mRNA. 
To avoid arbitrary grouping, the patients with the lowest / highest 10 - 50% mRNA levels were 
grouped into group “low” / “high” for comparison (y axis). The hazard ratio of event (death for the 
TCGA cohort or relapse for the GEO cohort) for the patients in group “high” compared with the 
patients in group “low” for the different periods of follow-up time from 1 to 10 years (x axis) was 
calculated using the Cox proportional hazards regression model. The corresponding Cox regression 
coefficients (β, β = ln(HR)) with corresponding P values for Log-rank test < 0.05 were shown as 
heatmap (green: low, red: high). The comparison of Kaplan-Meier estimates of survival for the 
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arrowed data points in panels (A) and (B) were shown in panels (C), (D), (E) and (F) accordingly. 
The Kaplan-Meier survival curves were shown up to 10 years of follow-up. The statistical results 
shown in each plot were calculated based on different years of follow-up time as indicated by the 
grey dotted line. The numbers of patients at risk were listed under each time interval. 
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5.4 Discussion 
TGFβ signalling is well known for its involvement in a wide range of different, even opposite cellular 
processes, such as those involved in tumour suppression and tumour progression [157]. Tumour cells 
that have accumulated mutations to circumvent the suppressive effect of TGFβ may not only 
withstand a TGFβ-rich microenvironment but also exploit the TGFβ signalling machinery for 
malignant progression [154]. Thus we may assume that there are generally three types of tumour cells 
in terms of their responses to TGFβ: those that respond to TGFβ and are suppressed (X1), those that 
do not respond to TGFβ (X2) and those that respond to TGFβ but progress (X3).  
 
In breast cancer, mutations are rarely found in the TGFβ family genes [178], which implicates that 
the cellular context rather than the proteins in the TGFβ signalling pathway determines the action of 
TGFβ [157]. Thus the levels of biologically active forms of TGFβ ligands in the microenvironment 
and the protein expression levels of TGFβ receptors may serve as quantitative measures of the 
intensity of signalling input and the responsiveness of cells, respectively. The protein expression 
levels of the TGFβ ligands may be used as the estimates of the levels of their biologically active forms, 
since all the TGFβ isoforms are expressed as latent forms that need to be activated to function [179]. 
The mRNA expression levels may be used as the estimates of the protein expression levels [180].  
 
The TGFBR2 mRNA levels were reduced by around two-thirds in tumours compared with matched 
normal tissues, which was consistent with a study evaluating the protein levels of TβRII [181]. The 
result implicated that the breast tumour cells had developed the ability to reduce their responsiveness 
to TGFβ by down-regulating TGFBR2 expression. Higher TGFB1 mRNA expression levels were 
observed in tumours compared with adjacent normal tissues and in tumours from lymph node-positive 
patients compared with tumours from lymph node-negative patients. It implicated that the malignant 
tumour cells up-regulated TGFB1 expression. The TGFB3 mRNA expression levels were around 50% 
lower in the ER-negative / PR-negative / triple-negative / Basal-like / Grade 3 tumours, which were 
all associated with poor prognosis. As TGFB3 mRNA levels were increased by 84% in tumours 
compared with adjacent normal tissues, the results should be interpreted as that the TGFB3 expression 
was greatly up-regulated in premalignant tumour cells and/or their surrounding cells (the bio-
specimens were usually composed of < 100% tumour cells), rather than TGFB3 expression was down-
regulated in malignant tumour cells. The up-regulated TGFB1 expression in malignant tumour cells 
and the up-regulated TGFB3 expression in premalignant tumour cells were very likely to have 
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different, even opposite effects on the corresponding tumours, which also implicated the specific 
biology of different TGFβ isoforms. 
 
Assuming that we can group breast cancer patients according to the tumour cells’ responses to TGFβ, 
and evaluate the associations between the expression levels of TGFB1, TGFB2, TGFB3, TGFBR1 
and TGFBR2 and the patients’ clinical outcome such as overall and relapse-free survival in each 
group using Cox proportional hazards regression model, then we should expect negative hazard ratios 
for X1 tumours, 0 HRs for X2 tumours and positive HRs for X3 tumours, respectively. Obviously, 
the HRs for different genes should be different. Unfortunately, we are still not able to separate the 
three groups of tumours. However, for a cohort composed of patients with mixed groups of tumours, 
a significant negative HR implicates that there are more patients with X1 tumours, a significant 
positive HR implicates that there are more patients with X3 tumours, and a non-significant HR 
implicates that there are more patients with X2 tumours, the patients are heterogeneous or the 
population is too small. Thus the association between the expression levels and the patients’ clinical 
outcome may serve as an indicator of the proportion of the three types of tumours. The conflicting 
results such as that were reported for the associations between the protein levels of TGFβ1 and TβRII 
and the patients’ clinical outcomes [161-164], were very likely due to that the studied cohorts were 
composed of different proportions of the three types of tumours. 
 
The significant positive associations observed between the tumour levels of TGFB2, TGFB3 and 
TGFBR2 mRNA and the clinical outcomes in the patients diagnosed with lymph node negative 
diseases implicated that the majority of the tumours from those patients still responded to the 
suppressive effect of TGFβ signalling, and the tumours with lower TGFB2, TGFB3 and TGFBR2 
expression were more advantageous in tumour progression. In patients diagnosed with small tumours, 
those with higher TGFBR1 mRNA levels in the tumours had much poorer prognosis for the first 3 
years. High TGFB1 mRNA expression levels also seemed to be associated with poor prognosis in the 
patients with small tumours. One of the rationales for anti-cancer drugs targeting the TGFβ pathway 
is to block the TGFβ signalling for the X3 tumours but not X1 or X2 tumours. Our data implicated 
that in the patients with small breast tumours, there was a high proportion of patients with X3 tumours 
that might be more likely to benefit from the drugs targeting TβRI and TGFβ1.  
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5.5 Conclusion 
In conclusion, the mRNA levels of the TGFβ isoforms and receptors in breast tumours were 
differentially associated with patients’ overall and relapse-free survival in patients stratified by 
different tumour characteristics. Before we can develop techniques to precisely classify breast 
tumours into groups according to their responses to TGFβ, the associations between the mRNA levels 
and the clinical outcomes may not only provide prognostic value for patients but also assist in 
classifying tumours according to their potential responses to TGFβ and selecting patients for the 
TGFβ signalling pathway targeted therapies that are under development [159]. The mechanisms 
underlying the reduced TGFBR2 expression in the tumours and the differentially regulated TGFB1 
and TGFB3 expression by malignant and premalignant tumour cells may also have potential clinical 
implications that need to be further explored. 
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Chapter 6 
6 Conclusion and future directions 
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6.1 Conclusion 
This thesis can be summarized in Figure 6-1. The mathematical model provided a novel in silico tool 
for the estimation of the extracellular and intracellular H2O2 concentrations. The mechanistic study 
demonstrated that the in vitro cytotoxicity of ascorbate to cancer cells was mediated by both H2O2 
and DHA. The simulation of the mathematical model predicted a limited increase of intracellular 
H2O2 concentration in an IVA treatment, which should be insufficient to induce cell death in tumours. 
Although the H2O2-mediated mechanism is the dominant mechanism in a typical in vitro model, its 
contribution to the explanation of the effect of intravenous ascorbate in vivo may not be as high, and 
the DHA-mediated mechanism may play a more important role under in vivo conditions. The study 
on the TGFβ signalling genes suggested that the expression of these genes could be used for the 
prognosis of patients as well as stratifying patients for the TGFβ signalling pathway targeted therapies. 
This thesis improved our understanding of the cytotoxicity of ascorbate, and provided a mathematical 
tool for further research and a promise for developing strategies of identifying the patients where 
TGFβ pathway targeted therapies may improve the efficacy of IVA. 
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Chapter 1 Introduction
> IVA is supported by in vitro and animal studies.
> IVA has limited anticancer efficacy but its beneficial effects are evident.
> Mechanisms and misinterpretation of some published results discussed.
> Hypotheses and aims proposed.
Chapter 3 H2O2- and DHA-mediated mechanisms
> Cytotoxicity of ascorbate and the H2O2-mediated 
mechanism confirmed on a range of cells.
> Oxidation of ascorbate in cell culture media 
demonstrated.
> The associations between the cells’ responses to 
ascorbate and some extracellular, cellular and molecular 
variables were investigated.
> Cytotoxicity of DHA demonstrated and the results 
supported the two proposed mechanisms.
> Synergistic cytotoxicity of DHA and As2O3 on HL-60 
cells demonstrated.
Chapter 4 A proposed IVA protocol and three cases
> A Phase I clinical trial protocol of IVA proposed.
> Beneficial effects of IVA observed.
Chapter 2 Mathematical modelling
> A mathematical model of extracellular and intracellular 
H2O2 concentrations established.
> Values of variables estimated. 
> Method for estimating intracellular H2O2 production rate 
provided.  
> Method for estimating  intracellular H2O2 concentrations 
based on extracellular H2O2 concentrations provided.
> Simulation of the mathematical model and validated 
with experimental data.
> limited increase of intracellular H2O2 by IVA predicted.
Chapter 5 TGFβ mRNA expression in breast tumours
> Associations between tumour TGFB1, TGFB2, TGFB3, 
TGFBR1 and TGFBR2 mRNA levels and tumour 
characteristics / patients’ clinical outcomes analysed.
> Data implicated a reduced responsiveness of the tumour 
cells to TGFβ, a preferential up-regulation of TGFB1 in 
the malignant tumour cells and a preferential up-
regulation of TGFB3 in the premalignant tumour cells.
Chapter 6 Future directions
> Further validation and application of the mathematical 
model proposed.
> Further evaluation of the use of DHA as a adjuvant 
anticancer molecule proposed.
> Clinical trial demonstrating the beneficial effects IVA 
proposed.
> Concept of using personalized medicine to  improve the 
efficacy of IVA proposed.
Key methods used
> Cell culture and treatment.
> Cell viability assay.
> Flow cytometry.
> RT-qPCR.
> Western blotting.
> Programming: Mathematica and R.
 
Figure 6-1. Summary of this thesis in a flow chart. 
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6.2 Future directions 
The mathematical model can be further evaluated by using the experimentally determined cell line-
specific parameters in the simulation and using the experimentally measured extracellular H2O2 
concentrations in the validation. A sensitive and specific detection method of intracellular H2O2, such 
as Hyper (Evrogen) [182], may be used as a means to validate the predicted intracellular H2O2. With 
the precisely determined cell line-specific parameters, the mathematical model may be used in the 
studies where the estimation of the dynamic changes of intracellular H2O2 is desired.  
 
Simulation of the mathematical model predicted a limited increase of intracellular H2O2 concentration 
in a typical IVA treatment, and implicated that the sole use of IVA should be insufficient to induce 
cell death in tumours. Furthermore, the observed and reported beneficial effects of IVA treatment 
alone or in a combination therapy for cancer seem to be more evident than the proposed anticancer 
effect. Thus a properly designed clinical trial should be conducted to thoroughly demonstrate the real 
effect of IVA.  
 
As a natural compound that may be preferentially absorbed by cancer cells and possibly function by 
antagonizing glucose uptake and reducing the cellular H2O2 decomposing capability, DHA may have 
the potential to be used as an adjuvant anticancer molecule in a ROS-mediated treatment of cancer, 
such as As2O3 [149]. Furthermore, DHA should be safe as it is already in the human diet, and can be 
formed during IVA treatment, which has been proven to be safe [36, 64]. Our results have 
demonstrated the synergistic cytotoxicity of DHA and As2O3 on HL-60 cells. Its efficacy in vivo 
should be further investigated using animal models and then in human clinical trials. 
 
Due to the complex nature of cancer, patients diagnosed with the same cancer type may benefit 
differentially from the same treatment [3]. Personalized medicine has the promise of improving the 
efficacy of currently available cancer treatment on selected patients who are more likely to have a 
response [183]. Although more works need to be done to provide evidence for conducting a clinical 
study investigating the efficacy of a combined TGFβ pathway targeted therapy and IVA treatment, 
our study of the TGFβ signalling genes in breast tumours has taken a first step on the path aiming to 
improve the efficacy of IVA for certain tumours with specific bio-makers. Furthermore, the analysis 
platform used in the study may be further extended to investigate other gene makers and cancer types.   
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Supplemental data 
 
MSTO-211 cells could easily form multiple cell layers during cell culture. MSTO-211 cells had been 
used with a range of cancer and normal cells (Table 3-1) to compare their responses to millimolar 
ascorbate (Figure 3-1). When MSTO-211 cells were challenged with 1-hour ascorbate treatment, only 
the cells on the upper surface of the multiple layers were killed, while those at the bottom were still 
alive (Figure S 1). The other cells did not have this feature. Thus the relevant results of MSTO-211 
cells were not suitable for comparison with the results of the other cells. However, due to this specific 
feature, the results of MSTO-211 cells could be used to demonstrate that the cells on the upper surface 
of the multiple layers could protect those underneath them during ascorbate treatment.  
 
 
Figure S 1. Effect of ascorbate on MSTO-211 cells in multiple layers. 
MSTO-211 cells were seeded at a density of 3.0×105 cells/mL in complete RPMI 1640 medium in a 
96-well plate and were allowed to grow multiple layers for 24 hours. The cells were treated with 
ascorbate at different concentrations for 1 hour. Then the cells were washed three times with RPMI 
1640 medium, and cultured in complete RPMI 1640 medium for another 24 hours. Trypan blue was 
used to stain the dead cells. The morphology of MSTO-211 cells that were treated with (A) ultrapure 
water and (B) 19.2 mM ascorbate was photographed 24-hour post-treatment (phase contrast 
microscopy; magnification: 100×; red scale bar: 100 μm).   
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Figure S 2. Linearity and sensitivity of alamarBlue reagent on HL-60 cells. 
HL-60 cells were seeded at a series of cell densities (200 – 2×105 cells/mL) in 100 μL complete RMPI 
1640 medium in a 96-well plate. A volume of 10 μL alamarBlue was added to each well. The plate 
was gently shaken until the medium and alamarBlue agent were well mixed, and then incubated at 37 
˚C in 5% CO2 / 95% air for 3 hours until the measurement at excitation: 544 nm and emission: 590 - 
610 nm. Data represented were the mean ± SD of three repeats. 
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Figure S 3. An example of cell cycle analysis. 
The flow cytometry data for HL-60M cells was gated to allow only single cells to be analysed for the 
PI signal intensity using FACSDiva (Becton Dickinson). 
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Figure S 4. Representative agarose gel electrophoresis of RNA samples. 
The six lanes from the left to the right were the RNA samples of HCC1954 cells that were treated 
with 0, 0.6, 2.4, 4.8, 9.6 and 19.2 mM ascorbate for 1 hour. The RNA samples were collected from 
the cells 24-hour post-treatment using TRIzol. A volume of 2 μL RNA samples (~200 – 1000 ng/µL) 
was mixed with 2 μL 6× loading buffer and 8 μL 1× TAE buffer and loaded on to a 1% TAE agarose 
gel. The electrophoresis was run at 5V/cm for around 60 minutes in 1× TAE buffer. The gel was 
photographed using an ultraviolet gel scanner. The three distinct bright bands from top to bottom in 
each lane were 28S, 18S and 5S ribosomal RNA, respectively. It indicated that the RNA samples 
were of sufficient quality to progress to further tests. 
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Figure S 5. A representative qPCR amplification plot. 
The qPCR data of the mRNA expression of TGFB1, TGFB2, TGFB3, TGFBR1, TGFBR2, GAPDH 
and HPRT1 in 13 breast tumour samples was analysed in SDS 2.4.1 software (Life technologies). The 
green horizontal line was the threshold set for determining the threshold cycles of the target genes. 
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The viability of PC-3 cells (prostate cancer cell line) reduced to zero after exposure to 30 mM 
ascorbate for 8 hours, and reduced to ~20% after exposure to 3 mM ascorbate treatment for the same 
period of time (Figure S 6 A). No cell viability was detected after longer post-treatment time, 
indicating the remaining ~20% viable cells were undergoing cell death (Figure S 6 A). In comparison, 
the cells at higher density all survived the 8-hour 3 mM ascorbate treatment (Figure S 6  B), 
confirming that the cells at higher cell density should experience lower cytotoxicity (Figure 2-7). 
When catalase was added in these ascorbate treatments, the cells were completely protected from 
being killed by ascorbate in the first 8 hours, however, in the 26-hour treatments, significantly lower 
cell viability was observed in the cells treated with 30 and 60 mM ascorbate (Figure S 6). NaCl was 
used as a reference for the effect of Na+, which had not observable effect on the cell growth. The 
results of cell viability assay had been confirmed with the viable cell count using Trypan blue under 
the microscope.  
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Figure S 6. Effect of sodium ascorbate and sodium chloride with or without catalase on PC-3 
cells. 
Viability of PC-3 cells at densities of (A) 5.0×104 cells/mL and (B) 1.0×105 cells/mL after exposure 
to sodium ascorbate and NaCl with or without 640 U/mL catalase (CAT) for various periods of time. 
The cells were seeded at densities of (A) 5.0×104 cells/mL and (B) 1.0×105 cells/mL in complete 
RPMI 1640 medium and cultured for 24 hours. Catalase was always added before the ascorbate and 
NaCl treatment. For the 8h treatment, the cells were exposed to the treatment for 8 hours and followed 
by three times washing using RPMI 1640 medium. For the 8h treatment + 18h in fresh RPMI, the 
cells were exposed to the treatment for 8 hours and followed by three times washing and cultured for 
another 18 hours in complete RPMI 1640 medium. For the 8h treatment + 38h in fresh RPMI, the 
cells were exposed to the treatment for 8 hours and followed by three times washing and cultured for 
another 38 hours in complete RPMI 1640 medium. For the 26h treatment, the cells were exposed to 
the treatment for 26 hours and followed by three times washing. Then the cell viability was 
determined by alamarBlue. P values were obtained from t-test.  
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Figure S 7. No effect of physiological ascorbate on mesothelioma cells. 
NCI-H2052 and NCI-H2452 cells were seeded at a density of 3.0×104 cells/mL in RPMI1640 medium 
supplemented with 10% FBS and 1× PSG. After 24 hours, the cells were treated with sodium 
ascorbate (final concentration 0 – 200 µM) for 43 hours. Then the cells were washed with RPMI 1640 
medium twice and cultured in complete RPMI 1640 medium for another 24 hours before the cell 
viability was determined using alamarBlue assay. Data represented were the mean ± SD of four 
repeats. 
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Figure S 8. Standard curve of sodium dehydroascorbate concentrations. 
The absorbance at 450 and 544 nm of sodium dehydroascorbate at a series of concentrations in 
ultrapure distilled water was plotted. The absorbance was linearly correlated with the concentration 
of sodium dehydroascorbate with an R2 of 0.9999. Data presented were the mean ± SD of two repeats. 
The SDs were too small to be displayed. 
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Figure S 9. Effect of serum on the cytotoxicity of ascorbate. 
The cells in logarithmic growth phase were seeded at a density of 8.0×104 cells/mL in 96-well plates 
and cultured in their recommended media with 10% FBS and 1× PSG. After 24 hours, the cell culture 
media were changed to RPMI 1640 medium supplemented with or without 10% FBS and D-PBS. 
The cells were exposed to ascorbate at a serial concentrations for 1 hour. After the treatment, the cells 
were washed twice and cultured for an additional 24 hours in complete RPMI 1640 medium. The cell 
viability was determined by alamarBlue. Data presented were the mean ± SD of six repeats.  
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DHA exhibited dose-dependent cytotoxic effect on MCF7 cells in the presence of catalase (Figure S 
10). Overall lower cell viability was observed in the cells cultured in Glucose-, FBS- medium. No 
significant difference in the viability was observed between the cells cultured in the Glucose+, FBS+ 
medium and those cultured in the Glucose-, FBS+ medium. This seemed reasonable as FBS also 
contained some glucose, and the Km for glucose transports was at the low millimolar range.  
 
 
Figure S 10. Effect of dehydroascorbate on MCF7 cells. 
MCF7 cells were seeded at a density of 5.0×104 cells/mL in glucose-free RPMI 1640 medium and 
that supplemented with 10% FBS and/or 11 mM glucose. The cells were treated with DHA at a series 
of concentrations in the presence of 500 U/mL catalase for 20 hours. The cells were then washed 
twice and the cell viability was determined by alamarBlue. Data presented were the mean ± SD of 
two repeats. 
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Figure S 11. Inhibitory effect of catalase on the cytotoxicity of hydrogen peroxide. 
HL-60 cells (2.0×105 cells/mL) in complete RPMI1640 medium were treated with 200 μM H2O2 in 
the presence of catalase or HL-60 cell lysate (amount equivalent to 0 – 200 ng protein per mL). The 
catalase used in the treatment had 4 U/μg protein catalase activity. The HL-60 cell lysate was made 
by multiple freeze and thaw in dry ice and 37 °C water bath, and had ~0.37 mU/μg protein catalase 
activity (Figure 3-6). After 2-hour treatment, large amount of catalase (500 U/mL) was added to 
remove the remaining H2O2, and the cells were returned to the incubator for additional 20 hours before 
the alamarBlue cell viability assay was performed.  
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Figure S 12. No effect of pharmacologic ascorbate on the mRNA expression of catalase and 
TGFβ in four breast cancer cell lines. 
The breast cancer cells (1.0×105 cells/mL) were treated with ascorbate (0, 0.6 and 2.4 mM) for 1 hour 
in complete RMPI 1640 medium. After the treatment, the cells were washed three times with RMPI 
1640 medium and then cultured in complete RMPI 1640 medium for another 24 hours before mRNA 
extraction using TRIzol. The mRNA expression levels of TGFB1, TGFB2, TGFB3 and CAT were 
measured by RT-qPCR. The relative mRNA expression of the genes (∆Ct) were calculated by 
subtracting the average Ct of GAPDH and GUSB from the Ct of the genes of interest. Data presented 
were the mean ± SD of three repeats. No significant change was observed in the mRNA expression 
levels between the treatments and controls. 
 
 
